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1.1 THE ADVENT OF PEPTOIDS 
The concept of peptidomimetics deeps its roots mainly in the 
work of Ariëns between the 70s and 80s.1 He was intrigued by the 
possibility to translate bioactive peptides into correspondingly active 
small non-peptide compounds.  
Peptides play a central role in biological systems; 
nevertheless, they suffer from metabolic lability and systemic 
transport problems. Ariëns foresaw that bridging the gap between 
peptides  and  non-peptides could have opened new and interesting  
outlooks  in  the field  of  drug  design.1a Indeed, he suggested some 
perspectives in design of compounds mimicking the biological 
activity of natural peptides but structurally diverse from them, and he 
designated such analogues with the term peptoids.  
 This definition was then borrowed by Horwell et al. for 
describing the analogues of cholecystokinin-(30-33) as probes for 
central nervous system cholecystokinin receptors, so it was still 
referring to a vast class of compounds biologically resembling natural 
peptides.  
It was just in 1992 that the term peptoids gained a narrow 
sense, when Bartlett and co-workers addressed it to a specific family 
of oligomers of N-substituted glycines.2 They are based on an 
unnatural repetitive unit that, respect to the parent peptide, swaps 
the amide hydrogen atom for the α-carbon side chain, making the 
peptoid backbone achiral (Figure 1.1). 
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Figure 1. 1. Generic structures of peptide (1.1) and peptoid (1.2). 
Even though peptides and peptoids are structural isomers, 
the echo of such difference is impressive.  
Being related to peptides, they are compatible with biological 
environments, but the abiotic character of these molecules can 
confer protection from proteolytic degradation and allow high cellular 
uptake, offering a wide variety of biological applications. 
Peptoids can exist in a much bigger conformational state 
with respect to peptides, since they can adopt low energy 
conformations with either cis and trans amide bonds, as depicted in 
the Ramachandran-type plots.2 Furthermore, the lack of amide 
hydrogens removes intramolecular hydrogen bond networks and the 
stabilization of secondary structures as in peptides.2 All those 
peculiar features make the peptoid main chain extremely flexible. 
Another important attribute to take into account for the 
development of new structures alternative to natural compounds is 
the synthetic route for preparing them. The synthesis should be easy, 
scalable, automatable and versatile, allowing the introduction of a 
wide variety of functional groups to build large libraries of analogues 
to test. Peptoids’ chemistry offers this advantage as well since their 
first introduction.  
Bartlett and co-workers first prepared the monomer in 
solution, then achieved the fast oligomerization on solid-phase.2 In 
the same year, Zuckermann et al. introduced a completely 
automated solid-phase method for the synthesis of peptoids, general 
 4 
and versatile to incorporate different side-chain substituents.3 This 
relies on the two-step-assembly of the monomer unit directly on 
solid-phase from two submonomers; bromoacetic acid and the 
desired primary amine (Scheme 1.1). Iterating the cycles of 
coupling/amination, the peptoid chain grows on solid-phase, to be 
detached when the desired length is reached.   
 
Scheme 1. 1. General synthetic scheme for the solid-phase assembly of peptoids. 
The introduction of submonomer solid-phase peptoids 
synthesis allowed for the rapid diffusion and deep investigation of 
this class of peptides mimics. After more than twenty years since 
their development, peptoids are still a hot topic in many fields. With 
such versatile and efficient tool in our hands, we can count on 
exciting leads for drug design as well as for engineering 
biocompatible materials. 
1.2 CONFORMATIONAL CONTROL 
One of the very first properties of the newborn peptoids 
studied by researchers was their folding into secondary structures.  
Due to the flexibility of the backbone, peptoids are not 
structurally well organized and defined. The advantage is that they 
can be forced into helical, loop and turn motifs in a controlled fashion. 
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The proper choice of the side chains to incorporate into the 
peptoid sequence restricts the backbone conformations and 
achieves control on the secondary structure.  
For example, molecular mechanics calculations on the 
octamer of (S)-N-(1-phenylethyl) glycine (1.3, Figure 1.2) suggested 
that the introduction of bulky chiral side chains causes steric 
interactions and charge-charge repulsion with backbone carbonyls, 
which are the driving force for peptoid helical secondary structure.4 
As polyproline type I helix, peptoid helix has all cis-amide bonds, a 
right-handed screw sense, and three residues per turn (Figure 1.2).4  
 
Figure 1. 2. Octamer of (S)-N-(1-phenylethyl) glycine (1.3) and its molecular mechanic 
model showing the predicted helical conformation. The N terminus is free and the C 
terminus is amidated. 
Later on, studies on several peptoid oligomers containing 
chemically diverse side chains, performed by circular dichroism (CD) 
spectroscopy, NMR spectroscopy, and X-ray crystallography, 
attempted to highlight the rules of predictability for helix 
conformations. The results of those efforts point out the importance 
of different parameters, such as; the content of aromatic and aliphatic 
residues,5 the peptoidic chain length,5a-c the chirality of the side 
chains,5a, 5b, 5d and the electronic and steric features of the groups 
appended to the backbone.6  
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  When all chiral, aromatic side chains are present in the 
peptoid, this can stabilize the helical structure even as short as a 
pentamer.5a, 5b Hexameric oligomers, on the other hand, require at 
least 50% chiral, aromatic residues for the formation of the helix,5c 
but this percentage is intended to fall with the increasing of chain 
length beyond 12-15 residues.5a, 5c, 5d Surprisingly, a N-(1-
cyclohexylethyl) glycine pentamer showed a helix with cis amide 
bonds at solid state, as revealed by X-ray crystallography.5d  
However, its weak CD spectrum indicated a less ordered and stable 
helical fold, in agreement with the results previously reported.   
The use of chiral side chains can afford a preferred 
handedness in peptoid helices, and the corresponding enantiomers 
can invert the screw-sense.5a, 5b, 5d Nevertheless, the content of 33% 
achiral residues in a dodecamer peptoid did not disrupt the helical 
profile; hence, the chirality can be propagated even in the presence 
of achiral units.5a    
In addition, carbonyl oxygen-carbonyl amide and carbonyl-
aromatic nπ* interactions are hypothesized to play a role in 
peptoids folding promoting the isomerization between the cis and 
trans geometry of the amide bonds.6a The first one requires an orbital 
overlap that can be satisfied just in trans-amide, whereas the other 
one stabilizes the cis-amide (A and B, Figure 1.3). 
It has been demonstrated that a careful selection of the side 
chains can tune the nπ* interactions and so the geometry of the 
amide bonds. 1H-NMR examination on a series of compounds 
incorporating different N-side chains and various functional groups-
capped C-terminal carbonyl proved that nπ*Am interactions can 
be enhanced by N-cyclohexyl chains and C-terminal methyl esters.6a 
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Figure 1. 3. Three-dimensional representations of nπ*Am (A) and nπ*Ar 
interactions (B). 
The strength of such interaction can stabilize and increase 
the content of trans-amide rotamers in solution. Likewise, N-aryl side 
chains exerts control over peptoid bond geometry and enforce the 
trans conformation due to repulsive interactions between the 
aromatic ring and the amide oxygen in the cis geometry.6b, 6c 
Computational studies on N-(phenyl) glycine hexamer (1.4, Figure 
1.4) showed the formation of extended helices, containing repeating 
trans amide bonds and resembling the polyproline type II helix.6b      
 
Figure 1. 4. Hexamer of N-(phenyl) glycine (1.4) and its molecular mechanic model 
showing the predicted helical conformation. 
Amide rotamer equilibria can be influenced and shifted 
towards trans conformations also by N-hydroxy7 and N-alkoxy8 side 
chains. The ability to induce a high extent of order derives from the 
oxygen atom that, directly bound to the amide nitrogen, exerts steric 
and stereoelectronic effects directing the side chain away from the 
amide oxygen.  
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Further studies on the relationship between monomer 
sequence and secondary structures led to the discovery of an 
interesting new three-dimensional architecture, the threated loop 
(Figure 1.5).9 The nonamer of N-(S)-(1-phenylethyl) glycine, unlike 
its analogues ranging from 6- to 15-mer that displayed the expected 
helical conformation, showed an unusual folded unit triggered by 
multiple intramolecular hydrogen bonds between the terminal NH2+ 
group and the backbone carbonyl groups of residues 5, 7 and  9. The 
bonding with the ninth unit, together with the interaction between the 
capping amide group and the carbonyl from residue 2, are 
fundamental to close the loop. The non-covalent interactions 
inducing the threated loop have a precise disposition that explains 
why such conformation is unique and peculiar for the nonamer 
peptoid. 
 
Figure 1. 5. Solution structure of the nonamer of N-(S)-(1-phenylethyl) glycine 
showing the peptoid threated loop. The dashed green lines denote hydrogen-bonding 
interactions. 
The design of novel peptoid structural motifs always requires 
innovative tools since, unlike peptides, the peptoid backbone lacks 
almost completely of hydrogen-bonding donors, fundamental in the 
stabilization of several secondary structures.  
Cyclization of linear peptoids is also an effective strategy to 
increase structural rigidity and so their conformational order.10 
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It has been recently demonstrated that linear peptoids of 
different chain length and composition, incorporating exclusively N-
alkyl side chains, can efficiently undergo head-to-tail condensation 
reaction in the presence of the common coupling agents, to form 
macrocyclic compounds ranging from 4- to 20-mer.10 As for peptide 
chemistry, this is a tool to further enforce peptoids biostability, 
resulting more resistant to proteolysis lacking of free N and C 
termini.11 Cyclopeptoids showed higher conformational order with 
respect to their linear counterparts; hence, the macrocyclization 
reaction resulted to be a covalent constrain that, in the hexamer and 
octamer macrocycles (A and B, Figure 1.6), led to a folding 
resembling peptide β-turn, as revealed by their crystal structures. 
This result is of outmost importance in the development of bioactive 
peptidomimetics. Macrocyclic structures are indeed recurring in 
many natural and pharmaceutical compounds and cyclic peptides 
have improved stability and pharmacokinetics compared to their 
linear precursors.12 However, peptides macrocyclization reaction 
may proceed in low yield, to due the preferred trans geometry of the 
peptide bond.13 On the other hand, peptoids can easily interconvert 
between the cis and trans conformations of the amide bond, being 
susceptible to turn structures and assisting smoothly rapid 
macrocyclization. Indeed, as showed in Figure 1.6, each cyclic 
peptoid contains a mixture of cis and trans amide bonds, 
accommodating two consecutive cis amides that reside in the 
correspondence of the tight turn regions.      
In addition, it has been shown that the incorporation of two 
trans amide-inducing N-aryl side chains into a cyclic peptoid 
hexamer, at the positions (i and i + 3), showed to mimic the same 
conformation pattern (-cis-cis-trans-cis-cis-trans-)cyclic found in the 
hexamer of Figure 1.6A.6b 
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Figure 1. 6. X-ray crystal structure of cyclic peptoid hexamer (A) and octamer (B) 
backbone. Side chains are omitted for clarity.   
As expected, the N-aryl side chains displayed the trans 
geometry, whereas cis amides were preferred along the turn regions. 
Similarly, many other cyclic hexapeptoids, comprising different 
typology of side chains, yielded crystal structures with the same 
sequence of amide bond conformations cctcct.14  These studies 
provide some criteria of predictability of the backbone structural 
architecture. Indeed, blind-structure predictions correctly suggested 
the cis/trans pattern also for a bigger-size cyclic peptoid.15 The 
crystal structure of the nonamer composed of (S)-N-(1-phenylethyl) 
glycine units exhibited a cccctccct motif, with several significant 
deviations from amide planarity.  
A further degree of constrain is achieved in peptoid 
backbone with macrocyclization of short oligomers. For example, 
tetrameric cyclic peptoids present a typical ctct core geometry and 
the comparison of the amide backbone structure reveal a similar 
overall rectangular shape.14, 16 This peculiar structure is retained also 
in solution, as showed by NMR analysis, and it confirms the strength 
of the added constrain and the high degree of conformation order in 
small-size peptoid ring.17   
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Additional stabilization of peptoid structures and generation 
of high-ordered conformations is accomplished by metal 
coordination.18  
In the specific case of cyclic peptoids, our group 
demonstrated the binding affinity of hexameric and octameric 
oligomers towards Li+, Na+, K+, Sr2+, and Gd3+.17, 19 
The cyclic hexamers of N-benzyloxyethyl glycine and N-
methoxyethyl glycine (1.5 and 1.6, Figure 1.7) showed 
conformational disorder in solution as result of several conformers 
slowly equilibrating on the NMR time scale.17, 19b  
 
Figure 1. 7. Structures of cyclic hexapeptoids of N-benzyloxyethyl glycine (1.5) and 
N-methoxyethyl glycine (1.6).  
In both cases, upon addition of sodium picrate, the 
coalescence of the NMR signals demonstrated the formation of a 
new chemical species in solution with an S6-symmetry axis. 
Interestingly, the cyclic hexamer 1.5 yielded needle-like crystals as a 
2:3 complex with strontium picrate.17 The analysis showed unique 
all-trans amides because of the ion coordination (Figure 1.8). 
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Figure 1. 8. Top view (A) and side view (B) of X-ray crystal structure of 
1.52*[Sr(Picr)2]3. 
Cyclopeptoid 1.6 was instead crystallized both in the free 
and Na+-complexed forms.19d A direct comparison of the two crystal 
structures was possible. The typical cctcct amide bonds pattern 
arose in the free form (A, Figure 1.9), while the sodium complex 
showed a different peptoid backbone conformation with all-trans 
amide geometries (B, Figure 1.9).  
 
Figure 1. 9. Columnar arrangement of the cyclic hexapeptoid N-
methoxyethyl glycine (1.6) in the free (A) and sodium coordinated form (B).   
It is worth to note that in the presence of the cation, 1.6 
formed a 1D coordination polymer, preserving the columnar 
arrangement of the free form.14 
 The examples showed herein prove that the toolbox for 
controlling the folding of the “rebel” peptoidic backbone is 
progressively expanding. The theoretical calculations to predict the 
structural conformations of peptoids are becoming extremely precise 
and the discoveries achieved so far highlight the tricks for 
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accomplishing the desired secondary structures and high-ordered 
conformations. The degree of control that we gained over peptoids 
is of utmost importance to make such foldamers unique and valuable 
peptidomimetics.    
1.3 THE IMPORTANCE OF PEPTOIDS: PROPERTIES 
AND APPLICATIONS 
The pace of progress since peptoids discovery is 
breathtaking. The rational criteria for the de novo design of stable 
structured peptoids and a better understanding of their properties 
expanded their potential biological applications as biomimetic 
materials. 
The metal binding ability, for example, was crucial for 
generating cation transport systems,19a potential MRI probes,19c and 
efficient phase transfer catalysts.19b, 20  
Peptoids folding into helix have been applied as antimicrobial 
compounds21 as well as biomimetic catalysts.22 
Helical peptoid oligomers were demonstrated to act as 
enantioselective catalyst when an achiral catalytic center is attached 
to it. The helical scaffold, with its intrinsic screw-sense, provide the 
asymmetric environment that transfer the chiral information to the 
substrate.  
Maayan et al. tried oxidative transformations of 1-
phenylethanol with right- and left-handed helices on which TEMPO 
(2,2,6,6-tetramethylpiperidine-1-oxyl) was placed as a catalyst 
(Figure 1.10).22a The oligomer length and the position of TEMPO 
was varied in order to find the parameters for the best catalytic 
activity. 
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This idea was further extended to create cooperative 
catalytic systems.22b  
 
Figure 1. 10. Monomeric units used in the design of catalytic peptoids 
These are featured by a transition metal catalyst and an 
organocatalyst in proximity to each other, creating a confined 
catalytic pocket. Phenanthroline-copper and TEMPO were installed 
onto the peptoid-helix scaffold, allowing for the oxidation of primary 
alcohols in 0.1% loading (Figure 1.11).  
 
Figure 1. 11. Intramolecular cooperative catalytic system. 
Antimicrobial peptoids recall the main features of natural 
antimicrobial peptides (AMPs). These are usually amphipathic 
secondary structures, such as α-helical, β-hairpin, extended, or loop 
structures). The cationic region serves to discriminate between the 
bacterial negatively charged cell membranes and the mammalian 
neutral ones, whereas the hydrophobic portion should mediate the 
mechanism of interaction and lysis of bacteria. Following those 
features, a library of linear peptoids of different chain length and 
charge, achieved by the introduction of N-(4-aminobutyl) and N-(2-
carboxyethyl) side chains (1.7 and 1.8, Figure 1.12), was 
synthesized and evaluated against Gram-negative and Gram-
positive bacterial strains.21b 
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Figure 1. 12. Peptoid monomer charged side chains structures. 
Remarkably, a stronger helical structure and an increased 
hydrophobicity led to greater hemolytic activity. On the other hand, 
good antibiotic activity was displayed with overall cationic charge of 
3+ at least and moderated hydrophobicity.  
Cyclic peptoids, recapitulating the features of natural AMPs, 
were also synthesized in order to evaluate their antimicrobial activity 
and selectivity.23 The activity against Gram-negative and Gram-
positive bacteria increased with the presence of charged amino 
groups and, comparing cyclic peptoids with their linear precursors, 
macrocyclization resulted to enhance microbial activity. Furthermore, 
these peptoids showed a high selectivity without affecting human 
erythrocytes.   
The results obtained were a clear evidence that macrocyclic 
peptoids are promising candidate for the development of novel 
antimicrobial compound. The interest of the researchers in such field 
is due to the higher resistance of bacterial pathogens to conventional 
antibiotic. Hence, more amphiphilic cyclic peptoids were synthesized 
and tested against the methicillin-resistant Staphylococcus aureus 
(MRSA).24 The compounds showed potent antimicrobial activity and 
non-hemolytic activity, and may act through a pore formation 
mechanism on the bacterial cell surface, as showed by scanning 
electron microscopy (SEM) images of untreated S. Aureus and cell 
treated with different concentration of cyclic peptoids. Such 
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mechanism of action, in which MRSA is a primary target, has recently 
been demonstrated.25 SEM images elucidated that treatment with 
antimicrobial peptoids induces membrane pore formation but such 
activity is attenuated when osmoprotective polymers (polyethylene 
glycol) are added. 
One of the very first properties of peptoids to have been 
explored was molecular recognition. Zuckermann and co-workers 
evaluated the affinity binding of peptoid dimers and trimers to G-
protein-coupled receptors.26 The importance to inhibit protein-protein 
interaction is the potential application of peptoid as pharmaceutical 
agent or chemical tool to shed light on the mechanism of 
biomolecular interaction. 
Recently, linear and cyclic peptoids were prepared to study 
their inhibitory activity towards amyloid-β (Aβ), involved in the onset 
of Alzheimer disease.27 They were designed inspired to the binding 
motif of the apolipoprotein E (ApoE) that interacts with Aβ, 
introducing on the nitrogen atom the aminoacidic side chains found 
in that sequence. In vivo experiments are in course to evaluate their 
ability to block the interactions between ApoE and Aβ and to 
compare the pharmacokinetics properties of cyclic peptoids with 
respect to their linear counterparts. The comparison between the 
macrocyclic and linear compounds related to their properties as 
protein ligands will give new elements to discuss about which one 
can be consider a drug lead.  
In this context, Kodadek published a comparison of linear 
and macrocyclic compound libraries as a source of protein ligands, 
highlighting the advantage of macrocyclization, especially for the 
cyclic hexamers over their linear counterparts.28  
The properties and applications presented herein are just 
few of the many that peptoids exhibit.29 However, those examples 
 17 
aim to point out the versatility of such class of compounds, which can 
be finely tuned to achieve the desired behavior. Peptoids are just a 
powerful weapon in the hand of the scientists who understand their 
unlimited potentials in the vast scenario of chemistry.  
1.4 AIM OF THE THESIS 
Peptoid chemistry is a source of inspiration itself. The control 
we can exert on the structures of such compounds pushes us to go 
further on in the exploration of new architectures trying to find out if 
there is a limit to our imagination.  
The aim of my PhD thesis is to contribute to such research 
and to enrich the realm of peptoids with novel compounds and new 
insight into their behavior and properties investigating potential 
applications.  
Chapter 2 describes the synthesis of extended cyclic 
arylopeptoids. The idea is to stretch the peptoid backbone by 
inserting a benzylic unit. The result is the development of compounds 
with cavities, tested as cationic transporters to elucidate how the ring 
size and the introduction of aromatic units could influence the ion 
affinity and transportation mechanisms. 
Chapter 3 concerns the synthesis of two cyclic hexapeptoids 
designed for the complexation of gadolinium ion. Our attempt is to 
enhance the affinity for the lanthanide and to study the relaxation 
properties of the complex, in order to develop effective and safe 
contrast agents. 
Chapter 4 shows the generation of the first example of 
cyclopeptoid-based iminosugar click-clusters with unprecedented 
valences. Starting from the synthesis of the cyclopeptoid central 
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scaffold, I describe the route to high molecular weight compounds, 
tested as inhibitors of a class of glycosidases.   
Chapter 5 is focused on the crystal engineer. A library of 
hexameric cyclopeptoids has been synthesized to study the role of 
the side chains in the solid state self-assembly and to disclose which 
interactions are fundamental for the packing of these molecules. 
   The fil rouge through the thesis is the synthesis of linear 
and cyclic peptoids. Once prepared, the destiny of those compounds 
was completely different. They entered in diverse fields of chemistry 
and added a small piece of knowledge with their unique properties. 
Such heterogeneity gave me the chance to deeply understand the 
variety of potential applications of cyclopeptoids and to appreciate 
the tools I had in my hands. 












Sight, hearing, taste, smell, touch and dreaming are the five 
(plus one) senses that make us just us.  
Behind our perception of the entire world around, there is a 
complex sensory system coordinated by an even more intricate 
nervous system. Excitation and electrical signal production in 
neurons are physiological processes that involve the flow of ions 
across the insulating cell membranes.30 The continuous 
transportation of ions into and out of cells is thus critical for many of 
life’s processes.31  
The elaborate design of the cytoplasmic membrane provides 
6transport devices that were highly refined during the course of 
evolution.30, 32 Nature made them up to overcome the energy barrier 
the membrane presents to ion crossing.31 Outside the membrane, 
ions are stabilized by polar water molecule, but they lose such 
hydration energy when crossing the lipid bilayer getting into the oily 
environment inside the membrane.31 
Pore, channels and carriers mediate fast traffic of ions 
stabilizing the dehydrated species and acting in lipid bilayers.33  
Ion transporters exhibit selectivity not only for certain 
charged species but also for the membranes in which they function.32 
Such evolved system ensures the effectivity of the proper cellular 
activities, e.g., maintenance of biological homeostasis (essential for 
differentiation, proliferations and apoptosis of cells), electric signal 
transmission and energy conversion. 34  
The general molecular understanding of the variety of ion 
transporters and the elucidation of their mechanism of action could 
 21 
lead to the fundamental “structure-activity” relationship. This is a 
powerful tool in the hands of chemists and molecular biologists, 
because it allows them to tailor the functions of ion transporters and 
to access such a structural diversity to overtake the biological 
limitations.  
The challenge is to look up at Nature and try to mimic the 
perfect gears that move the carousel of life.  
2.1.1 Ion Transporters At Work 
High-resolution crystal structures and functional experiments 
on ion transporters have helped the investigation on a structural and 
functional level.  
Studies on chloride channel families (ClC),35 cation-selective 
channels such as gramicidin,36 bacterial K+ channel called KcsA from 
Streptomyces lividans,37 and K+ carriers such as valinomycine,38 
elucidated their architectures, shapes and organization within the cell 
membrane.   
Natural ion channels are both peptidic channel and large 
protein complexes, whereas carriers are typically cyclic polypeptide.  
To mediate the flow of ions across the membrane, ion 
channels create a passageway spanning the thickness of the 
membrane bilayer, which is about 4 nm, or creating aqueous cavities 
in the middle of the transmembrane portion of the channel (Figure 
2.1).30-31 They open a pore through the lipid bilayer that has the 
important property of the selective permeability; its size dictates the 
maximum size of ions allowed to pass through its length. Ion 
channels conduct specific ions at high rates (>106 ions per second) 
and finally conduction is turned on and off by a gating mechanism, 
that is a simple pore opening/closing, regulated by an external 
stimulus such as ligand binding or membrane voltage. 
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Figure 2.1. Overall architecture of ion channels. (A) KcsA K+ channel has a wide 
water-filled pore in the middle of the transmembrane portion of the channel and a 
selectivity filter K+ ions (green spheres). (B) ClC has ha double funnel-shaped 
structure leading to a narrow pore that selectivity filters the anions (red spheres). (C) 
Gramidicine is a pentadecapeptide with a β-helix secondary structure that arranges in 
a head-to-head helical dimer forming tubular channels for the passage of alkali metals 
(blue spheres). 
Natural ion carriers regulate ions traffic on the basis of 
transport mechanisms which differ from ion channels for kinetic 
criteria.30 They are often described as “molecular ferryboat” (Figure 
2.2).32  
Figure 2.2. Schematic transport mechanism of ion carriers. The ion carrier and its 
cargo (green sphere) move together through the membrane. 
In this analogy, the membrane can be seen as the river and 
the two aqueous phases, intracellular and extracellular media, as the 
opposite shores.39 Firstly, the carrier binds to a specific ion, 
selectively and reversibly, forming a metal ion complex that is lipid 
soluble. Therefore, they move together, allowing the ion to pass 
through the hydrophobic region of the bilayer. When the complex 
arrives at the other membrane interface, the ion is released and the 
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ionophore crosses again the membrane. The rate of passage of ions 
is of 104 ions per second, thus much slower than through open 
channels. 38-39  
The above-mentioned systems are the two broad 
mechanisms for transmembrane transport of ions. 
Nevertheless, the chemical details beyond the designation 
of the channel-forming mechanism remain unclear and more insights 
are needed to shed light on how the ion or substrate reaches the 
binding sites within transmembrane domains.  
Knowing the structure of an ion channel or an ion carrier, 
however, is the starting point to understand the principles of selective 
ion transport in terms of the architecture and detailed chemistry of 
the ion conduction pathway. 
It is now clear that the essential and basic ability of 
membrane-spanning and amphiphilicity are needed.40 Amphiphilic 
structures present a hydrophobic region moiety, for solubility in the 
bilayer environment and branching interactions with the membrane, 
plus charged head groups in the metal-coordinating midsection.41 
Such inner surface should present weak regions of electron density, 
such as hard oxygen containing ethers and esters or aromatic groups 
to capture and transport small cations, or hydrogen bond donor 
groups to stabilize anions. 
Ion transport through membranes is definitely a 
supramolecular function.42 Hydrogen bonding, hydrophobic 
interactions, ion pairing, π,π-interactions and cation–π interactions 
are the five standard non-covalent interactions of supramolecular 
chemistry for stabilizing the self-assembly of functional architectures 
and the flow of ions. As such, the transporter has to be preorganized 
in order to attain the perfect complementarity with a certain guest. 
The binding process will be selective and effective if the match 
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between the binding site and the size of the ion is achieved and its 
preferred coordination geometry is respected.  
With these features in mind, it is possible to provide a 
structural and functional paradigm that shows the basic design 
criteria for artificial ion transporters.   
2.1.2 Mimicking Nature And Beyond: Synthetic Ion 
Transporters  
The design of Nature-inspired synthetic ion transporters that 
reproduce natural motifs is of utmost importance for their contribution 
in the fields of both biomedicine and technology. Non-natural 
antibacterial and anticancer,32 catalyst 43 and sensors,44 are just 
some of the many applications such systems could find in the vast 
scenario of scientific research. Furthermore, developing synthetic ion 
transporters would mean generating chemical models to probe 
different aspects of ionophores and to gain a greater understanding 
of the chemical mechanism of transporters functions. 
Extensive research has been devoted to mimic natural 
ionophores and thereby design and prepare synthetic compounds 
that have comparable properties exhibiting channel or carrier 
behavior. 
Nature stimulated the creativity of chemists, who went well 
beyond the observation of reality. Following their imagination, they 
produced an arsenal of artificial ion transporters featured by 
modification of naturally occurring motifs from proteins and peptides 
or totally new structures.45 Ranging from steroid-based to 
calix[4]arene-based ionophores, passing through sugar-based or 
crown ethers ionophores  and metal-organic transmembrane 
nanopores, numerous examples of synthetic systems forming 
artificial ion transporters are reported in the literature (Figure 2.3). 
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Although the impressive expansion of structural diversity, it 
is remarkable that all of these compounds, differing in their chemical 
structure, show quite similar ionophoric behaviors. Indeed, their 
common feature is the ensemble of supramolecular interactions, 
which is at the basis of ion transport. Furthermore, beside this 
standard “chemical code”, there are more “exotic” interactions, such 
as anion-π and halogen bonding interactions,46 which expand the 
landscape of synthetic transport system. 
The major contribution of such intriguing and exciting 
investigation is the conceptual innovation and the motivation to 
realize more and highly creative examples for broadening the realm 
of ion transportation systems.  
The introduction of new types of transporters, exhibiting 
refined motifs and fascinating architectures, was a real source of 
inspiration to us. We took on the challenge to give our contribution to 
such topic and a possible breakthrough on the design of new 
synthetic transport system. 
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Figure 2.3. Recent synthetic transport systems: self-assembled cyclopeptide 
nanotube 2.1, dimeric steroid derivatives 2.2 and 2.3, cone-shaped calixarenes 2.4–
2.7, cyclic oligosaccharides named CyPLOS 2.8–2.10, crown ether oligomers 2.11 




2.2     AIM OF THE WORK: SYNTHESIS AND ION 
TRANSPORT ACTIVITY OF EXTENDED CYCLIC 
ARYLOPEPTOIDS. 
2.2.1 Introduction 
Peptoids have been broadly applied to complex metal ions. 
17, 19c, 48 Upon coordination, they are usually able to form well-defined 
folded architectures. The conformation triggered by the ion 
complexation defines their specific properties and activities.  
Our group showed that cyclopeptoids can be tested for 
cation transport activity (2.14-2.17, Figure 2.4). 19a 
Macrolactamization restricts peptoids conformations, so that 
they result quite preorganized as required for ion complexation. The 
carbonyl ligands are the binding sites in the cyclopeptoids cavity, 
whose dimension can be varied to accommodate ions of different 
size.  
 
Figure 2.4. Cyclopeptoids tested for cation transport activity.  
The flexible eighteen-membered N-benzyloxyethyl 
macrocycle 2.15 showed to strongly bind small cations such as Li+, 
Na+ and K+, whereas the expanded cyclopeptoids 2.16 and 2.17 
preferred larger cations from the first group alkali metals. In 
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particular, 2.15 transported Na+ with high selectivity, and the octamer 
macrocycle 2.16 showed Cs+> Rb+> K+ selectivity, both acting as 
unimolecular ion carriers. The extreme macrocycles 2.14 and 2.17, 
either too small or too floppy, were both inactive. 
Encouraged by those results and inspired by the family of 
synthetic macrocycles of N-alkylated para-cyclophanamides (2.18, 
Figure 2.5), that have been shown to act as selective hosts, we 
decided to develop a new group of cyclopeptoids that incorporates 
aromatic units into the peptoidic backbone.  
 
Figure 2.5. N-alkylated para-cyclophanamides.  
In the design of the reported macrocycles, the methoxyethyl 
side chain was chosen for its ability to increase the amphiphilicity of 
the molecule and optimize its water/lipid partition. 
As result of our efforts, here it is reported the synthesis of 
two cyclic oligomeric N-substituted aminomethyl benzylamides: the 
cyclotrimeric oligoamide 2.19 and cyclotetrameric 2.20 (Figure 2.6). 
The N-alkylated para-aminomethyl benzylamides fall in the 
class of “arylopeptoids”, extensively studied by the group of 
Hjelmgaard and Faure who synthesized and characterized linear and 
cyclic ortho- meta- and para- N-alkylated aminomethyl 
benzamides.49-33 They demonstrated that the amide group of the 
arylopeptoid backbone may exist as a cis/trans mixture which may 




Figure 2.6. Cyclic oligomeric N-substituted aminomethyl benzylamides 2.19 and 2.20. 
The cis-trans isomerism facilitated the head-to-tail 
macrocyclization for the ortho- and meta- derivatives but not the 
para-series of the trimeric arylopeptoids (2.21 and 2.22, Figure 
2.7).49b The aromatic core skeleton may represent a rigidified motif 
that, combined with the para-substitution pattern, hampered the 
macrocyclization reaction.    
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Figure 2.7. para-Series of properly N-substituted arylopeptoids. 
With this in mind, we thought to extend the backbone with a 
methylene unit that may give much more freedom to the carbon 
skeleton, so facilitating the termini condensation and the generation 
of new and interesting structures. Indeed, they provide a hydrophobic 
core and large internal cavities, easily sizeable by means of the 
synthetic protocol, which may be examined from the host-guest 
chemistry viewpoint. The guest recognition may become effective 
through non-covalent interactions at the binding site via the n 
carbonyl lone pairs and aromatic π cloud. The binding behavior of 
the macrocycles may arise through an induced-fit mechanism 
originating from the intrinsic flexible character of the peptoid 
backbone.   
Figure 2.8 displays possible conformations of 
cyclooligomers 2.19 and 2.20 in the presence of the sodium cation. 
The structural analysis shows that the 24-membered ring 2.19 has a 
C3-symmetry and perfectly encircle the sodium cation through cation-
π stabilizing interaction, whereas the 32-membered ring 2.20 seems 
too big to comfortably accommodate it. 
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Figure 2.8. Structures showing the Na+ complex of compounds 2.19 (A: side view; B: 
top view) and 2.20 (side view) in their trans peptoid bond conformations. For 
simplicity’s sake, the N-linked side chain is reported as –CH3. Hydrogen atoms have 
been omitted for clarity. Atom type: C gray, N blue, O red, Na magenta. (Chem 3D 
plus output). 
The backbone structure of arylopeptoids still retains the 
favorable characteristic of peptoids:  they are accessible through the 
“submonomer” approach.49c  
Nevertheless, arylopeptoids synthesis results more 
demanding with respect to the peptoid counterpart. The benzyl group 
is much less reactive than the bromoacetate, the substitution 
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reaction is substrate depending and the growing aromatic chain 
suffer from poor solubility.49a, 49d  
For those reasons, there is plenty of synthetic methods in the 
literature, both on solid phase as well as in solution, highly refined 
and tuned according to the specific substrates applied.49a, 49c-e, 50  
2.2.2 Results And Discussions 
We have developed a new and facile synthetic approach to 
construct the first N-substituted aminomethyl benzylamide 
oligomers, in order to have ample variety of chemical structures. 
Our first attempt was to study the feasibility of solid-phase 
synthesis. We chose the 2-chlorotrityl resin as solid support and p-
bromomethyl benzylic acid as building block, applying the standard 
conditions of the submonomer approach.2 The instability of the 
building block under basic conditions and the sterically hindered solid 
support led to a complex mixture of products as revealed by HPLC 
analysis. Having excluded the use of such method, we thought to 
bring together the advantages of the solution and solid-phase 
synthesis. 
The method we optimized could be described as a 
“submonomer” approach in solution followed by a monomer solid-
phase synthesis. Indeed, the displacement reaction was realized in 
solution, whereas the subsequent acylation on the less reactive 
secondary amide and growth of the oligoamide chain were 
performed on solid-phase. 
We started the synthesis of the Fmoc-protected arylopeptoid 
building-block with the radical bromination of the commercially 
available p-tolylacetic acid in presence of NBS (Scheme 2.1). Such 
procedure was inspired by the one reported for the m-isomer 51 to 
avoid the use of the toxic Br2 described for the bromination of the p-
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tolylacetic acid.52 The esterification of the free carboxyl group of the 
4-(bromomethyl)phenylacetate (2.24) was carried out following a 
well-known methylation procedure 53 to give the protected methyl 
ester (2.25). The methyl 4-(bromomethyl)phenylacetate was then 
subjected to the amination reaction in the presence of an excess 
methoxyethylamine. Excess amine and a very slow addition of the 
substrate to its solution are mandatory to prevent polyalkylation of 
methoxyethylamine.  
 
Scheme 2.1: Synthesis of monomer 2.27. Reagents and conditions. (a) N-
bromosuccinimide, benzoyl peroxide (40%); CCl4 (b) methanol, chlorotrimethylsilane 
(97%); (c) methoxyethylamine, DMF (98%); (d) i) LiOH.H2O, 1,4-dioxane; ii) NaHCO3, 
Fmoc-Cl, 44% yield. 
The subsequent hydrolysis of the methyl 2-(4-((2-
methoxyethylamino)methyl)phenyl) acetate (2.26), in the presence 
of lithium hydroxide, was followed by the protection of its free amino 
group as 9-fluorenylmethoxycarbonyl (Fmoc) derivative. 
The overall yield of the monomer 2.27, ready for the solid-
phase oligomerization, was 17%.  
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The Fmoc protected 2.27 was then oligomerized on the 2-
chlorotrityl chloride resin (Scheme 2.2).  
 
Scheme 2.2: Synthesis of trimer and tetramer N-substituted aminomethyl 
benzylamides 2.32 and 2.33, respectively. Reagents and conditions. (a) i) 2.27 (0.67 
equiv., 0.2 M), DIPEA (4.0 equiv.), CH2Cl2, 90 min.; ii) DCM/MeOH/DIPEA (17:2:1), 
15 min.; (b) Piperidine/DMF (1:4) (2 x 1 min, 2 x 5 min); (c) 2.27 (3.0 equiv, 0.3 M), 
HATU (3.0 equiv.), DIPEA (6.0 equiv.), DMF, 1 h; (d) HFIP/DCM (1:4) solution (2 x 30 
min). Overall yields of the crude residues 2.32 and 2.33: 60%. 
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Loading onto the resin was realized in the presence of 
DIPEA and the subsequent capping, in order to terminate the excess 
of reactive positions, was performed using a mixture of 
DCM/MeOH/DIPEA (17:2:1). The elongation of the desired 
arylopeptoid chain was accomplished by iterative deprotection-
coupling cycles. The detachment of the Fmoc- protective group was 
carried out with piperidine (25% in dry DMF) and the free amine was 
then coupled with the HATU-activated monomer 2.27 in the presence 
of DIPEA as the base. The yields per coupling were excellent (>99%, 
based on the chloranil test) and gave the linear trimeric and 
tetrameric N-substituted aminomethyl benzylamides 2.32 and 2.33 
respectively, once detached from the acid labile resin with 
hexafluoroisopropanol (HFIP) (20% in dry DCM).  
The crude intermediates 2.32 and 2.33 were cyclized in high 
dilution conditions (2.0.10-3 M) with the assistance of HATU and 
DIPEA (Scheme 2.3), affording the expected targets 2.19 and 2.20 
in good yields (>90%, RP-HPLC analysis). This exciting result 
suggests that the addition of an extra- methylene unit into the 
arylopeptoid backbone strongly favours the direct macrocyclization. 
 
Scheme 2.3: Synthesis of macrocyclic arylopeptoids 2.19 and 2.20. Reagents and 
conditions. (a) 2.32 and 2.33 (1.0 equiv., 2.0.10-3 M), HATU (4.0 equiv.), DIPEA (6.0 
equiv.), DMF, 24 h. Overall yields of 2.19 and 2.20: 25% and 16% respectively.  
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The complexity of the r.t. 1H-NMR spectra recorded for both 
the cyclic “benzylopeptoids” demonstrated the slow exchange of 
multiple conformations on the NMR time scale. This result was 
expected due to the relative flexibility of the backbone skeleton and 
the cis-trans isomerism of the amide bonds. However, our attempt 
was to understand whether a preferred conformation could emerge 
in solution decreasing the acquisition temperature at 268 K. Again, 
1H-NMR spectra with broad signals indicated the presence of several 
conformers in equilibrium at NMR time scale. The cyclotrimer 2.19 
was further analyzed via 1H-NMR recording the spectrum at 263 K. 
Also in this case no discernible pattern was observed. This outcome 
is in contrast with the one obtained by the group of Faure and 
Hjelmgaard for the meta- and orto- cyclotrimers carrying ethyl side 
chains.49b This result suggests that 2.19 is much more flexible and 
has much more conformational freedom in solution thanks to the 
extra methylene unit and the para- substitution.    
Furthermore, differently from the parents peptoids,14, 17, 19-20 
the N-substituted aminomethyl benzylamide cyclic trimer 2.19 and 
tetramer 2.20 did not yield any ordered conformation in the presence 
of cationic guests.  
The ion transport activities of the benzylopeptoids 2.19 and 
2.20 were evaluated by the group of Prof. Tecilla at the University of 
Trieste. The ionophoric activities of compound 2.19 and 2.20 and the 
determination of their anion/cation selectivity were investigated by 
means of the HPTS assay.54 HPTS is the 8-Hydroxypyrene-1,3,6-
Trisulfonic Acid, a sensory fluorescent dye with a pKa ~7.3, primarily 
used as a pH indicator in the near-neutral range. Its working 
mechanism is one excitation maximum at 405 nm decreasing with 
pH and another one at 450 nm increasing with increasing pH. When 
the fluorescent dye is entrapped in vesicles, of large unilamellar 
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liposomes (100 nm diameter) with a 95:5 egg phosphatidylcholine 
(EYPC) and egg phosphatidylglycerol (EYPG) lipid composition 
prepared in HEPES buffer at pH 7.0 containing 100 mM NaCl, it can 
detect the downfall of 0.6 units transmembrane pH gradient by 
external addition of NaOH and so the ability of synthetic ion 
transporters to dissipate it (HEPES = 4-(2-hydroxyethyl)piperazine-
1-ethanesulfonic acid). Indeed, if a base is applied in the 
extravesicular compartment, the synthetic ion transporter can 
mediate the increase of intravesicular pH by facilitating either proton 
efflux or OH- influx. To compensate the charge translocation, there 
will be either a cation influx or an anion efflux depending on the 
cases. The four possible overall processes are H+/Na+ antiport, OH–
/Cl– antiport, H+/Cl– symport and Na+/OH– symport. Hence, the 
increase in HPTS emission with time after the ion transporter addition 
can help detecting the preferred ion exchange process. The 
ionophoric activity of the cyclic peptoids is reported in Figure 2.9.  
Figure 2.9a shows that compound 2.19 promotes the pH 
gradient collapse across the phospholipid membrane and its activity 
increases by increasing the ionophore concentration. On the 
contrary, 2.20 is inactive and the kinetic trace recorded at 2% 
concentration of peptoid is almost superimposed to that obtained in 
the absence of any ionophore (control). Figure 2.9b reports the first-
order rate constants (kobs, s-1) for the transport process whose kinetic 
traces were recorded for different concentrations of 2.19. Such linear 
behaviour indicates that the species responsible for the transport 
process is monomeric.  
Furthermore, by changing the cation and the anion present 
in solution,55 the HPTS assay revealed ion selectivity. 
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Figure 2.9. a) Normalized fluorescence change in HPTS emission as a function of 
time after base pulse to 95:5 EYPC/EYPG vesicles containing 2.19, 2.20 and without 
additives (control) at 25 °C. b) Dependence of the observed rate constant for the 
transport process (kobs, s
-1) vs concentration of compound 19. The concentration of 
peptoids is indicated in the Figure and is given in percent with respect to the total 
concentration of lipids (0.17 mM). 
In particular, for cation selectivity the liposome suspension 
was prepared as described above but using 100 mM MCl (M= Li+, 
Na+, K+, Rb+, Cs+) as added salt and the corresponding MOH base 
for the pH pulse. Figure 2.10a reports the variation of the observed 
rate constants for the transport process (kobs, s-1) as function of the 
concentration of peptoid 2.19 obtained in the experiments with the 
different cations. For all the cations investigated a unified transport 
mechanism was envisioned, since all the kinetic profiles are linear. 
The same rate of transport was revealed for Na+, K+, Rb+. However, 
the selectivity is low and only slightly more efficiently than Li+ and 
Cs+. On the contrary, compound 2.20 did not show any activity 
regardless the cation present in solution. Anion selectivity of 
compound 2.19 was also investigated. Figure 2.10b shows the result 
obtained in the presence of 3% concentration of compound 2.19 and 
using 100 mM NaX (X= Cl-, Br-, I-, ClO4-) as added salt and NaOH 
base for the pH pulse. Also in this case the selectivity observed is 
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low. Halides are better transported that perchlorate and, among 
halides, the more lipophilic iodide is the faster anion transported. 
  
Figure 2.10: a) Cation selectivity: dependence of the observed rate constant 
for the transport process (kobs, s
-1) vs concentration of compound 2.19 in the HPTS 
assay using 100 mM MCl (M= Li+, Na+, K+, Rb+, Cs+) as added salt and the 
corresponding MOH base for the pH pulse. b) Anion selectivity: normalized 
fluorescence change in HPTS emission as a function of time after base pulse with 
NaOH to 95:5 EYPC/EYPG liposomes containing compound 19 (3%) and using 100 
mM NaX (X= Cl-, Br-, I-, ClO4
-) as added salt. The concentration of peptoid is given in 
percent with respect to the total concentration of lipids (0.17 mM). 
The outcome of the experiments performed clearly indicates 
that the two examined macrocycles have different ion transport 
activities. The cyclic peptoid 2.19 is able to transport cations across 
a phospholipid membrane in response to a pH gradient, whereas 
2.20 does not show any transport ability. Such different behaviour 
can be explained on the basis of the different macrocycles’ size that 
strongly influences the cation capture/transport. In addition to this, 
the observation that the active species involved in the transport is a 
monomer, enforces the hypothesis of a carrier mechanism, in 
analogy to that demonstrated for related glycine base α-
cyclopeptoids.19a Nevertheless, the cyclic arylopeptoids show lower 
selectivity and activity with respect to the parent cyclopeptoids.  A 
possible explanation relies in the lower number of efficient cation-
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binding carbonyl groups (6 in the α-cyclopeptoid versus 3 in 2.19) 
and a more rigid, less adaptive structure. Thus, the arylopeptoid is 
not able to “wrap” around the cation and the binding is weaker and 
less size specific. Despite of that, the slight selectivity of compound 
2.19 towards the mid-size alkaline cations (Na+, K+, Rb+) respect to 
the smaller Li+ and the larger Cs+ may be the starting point for 
optimization of the system in the next future. Finally, the observed 
selectivity among anions with the more lipophilic iodide better 
transported suggests that the cation is translocated across the 
membrane together with its counteranion in a symport carrier 
mechanism in which MX is exchanged with MOH thus resulting in the 
observed pH gradient discharge. 
2.3    CONCLUSION 
A new class of arylopeptoids has been designed, 
synthesized and characterized in order to explore their binding 
properties towards the first group alkali metal and their ion transport 
activities. The reported structures, based on the N-
aminomethylphenylacetyl spacer, have an extended carbon skeleton 
with respect to the parent arylopeptoids described in the literature so 
far. The para-substituted cyclic trimer and tetramer have been 
efficiently synthesized by means of a mixed in-solution/ on-solid 
phase synthetic approach. The difficult alkylation steps of the primary 
amine were conveniently carried out in solution using 4-
(bromomethyl)phenylacetate and, upon amine Fmoc-protection, the 
desired building block was isolated and oligomerized on 2-chlorotrytil 
chloride resin. This methodology afforded the linear precursor of the 
target compounds in an efficient manner. Finally, they underwent 
macrocyclization in high dilution conditions, leading to the cyclic 
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arylopeptoids. This studies show that the extra methylene units in the 
aromatic carbon skeleton provide a certain degree of conformational 
freedom, facilitating the termini condensation despite the para-
substitution pattern and the rigid aromatic units. 
The 1H-NMR spectra recorded either at room temperature as 
well as at 268K and 263K, showed the absence of well-defined 
conformations in solutions.  
The cyclic trimer and tetramer extended arylopeptoids were 
finally subjected to ion transport studies, demonstrating not only a 
dependence on the size and the charge of the cavity, but also on the 
flexibility of the structure. The cyclic tetramer inner cavity is too large 
to selective accommodate any ion, whereas the cyclic trimer is 
slightly active towards the mid-size alkaline cations (Na+, K+, Rb+), 
preferably transported with the iodide counterion, showing a symport 
carrier mechanism. 
The results of our efforts contributed to the realm of synthetic 
ion transporters with two new structures, accessible through a 
versatile synthetic methodology. Despite their modest ionophoric 
activity, they lead to important hints for a better understanding of the 








































Cyclic Hexapeptoids As Potential MRI 
Probes: Design, Synthesis And 







The medical need to explore deep inside the human body 
from the outside led to enormous advances in clinical diagnosis. 
Increasing research activities are providing new opportunities for 
visualization and characterization of soft, hydrated tissues to 
discriminate between healthy and diseased ones.  
A very large contribution to the field is from magnetic 
resonance imaging (MRI) that, since its introduction in the early 
1980s, has been growing very fast.56  Its deep tissue penetration and 
ability to acquire high-resolution images in any plane, without 
exposing the patient to ionizing radiation as in X-Ray analysis, made 
it a routinely used diagnostic tool in hospitals worldwide. The 
detection and evaluation of biochemical, biomechanical, or structural 
pathological changes in tissue is a revolutionary tool for early 
diagnosis and interventions that can considerably slow or reverse the 
progression of the disease.57 
Over the years, MRI has achieved a number of successes to 
become the technique of choice for the study of several diseases, in 
particular tumors.58  
The brain can be deeply scanned for the detection of 
intracranial tumors, structural vascular anomalies (aneurysms and 
vascular malformations) and ischemia or heart attacks, white matter 
lesions in the brain such as the plaques found in multiple sclerosis or 
Alzheimer's disease and congenital diseases.56, 59  Other areas of the 
body can also be imaged by the optimal choice of MRI parameters. 
MRI can be applied to the facial bone, the structures below the face, 
the neck and the cervical spine.56  Furthermore, it is an extremely 
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effective technique for evaluating the musculoskeletal system and 
pelvic anatomy (e.g. the uterus).56-57 Finally, the use of MRI has also 
been extended to the diagnosis of chest and intra-abdominal 
disease, limited in the past because peristaltic motion significantly 
degraded the quality of images.56, 60   
The intensive investigation in this research area hardly 
changed and broadened the spectrum of clinical MRI examinations 
during the last decade.  
In his paper from 1983, three years after MRI emerged, 
Richard Henderson wrote “NMR (in former times this is how they 
referred to MRI) is a significant new imaging modality, the importance 
of which is only beginning to be realized”.61  
Now, his words sound more like a prediction of the actual 
broad applications of MRI. 
3.1.1 Description Of MRI 
The experimental foundations of MRI lay on the NMR 
spectroscopy basis.60c, 61-62  
Since its discovery in 1942, NMR has been used for 
elucidating the structure of organic molecules, but just in 1971 its 
medical value was realized.61  
NMR application to produce medical images was obtained 
tuning it on hydrogen nuclei resonances, since the human body is 
75% water molecules and its distribution is known to be altered by 
many pathological states.62 Indeed, the strength of the MRI signal 
depends primarily on the density of the protons in the tissue; the 
greater the density, the stronger the signal. Furthermore, signal 
intensity in MRI stems from two parameters defined in the basic 
principles of NMR that are the relaxation times T1 and T2. They 
describe the time for the net macroscopic magnetization of proton 
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spins to relax back to its equilibrium value in the longitudinal Z axis 
and transverse XY plane respectively, after a radio-frequency pulse 
has been applied. T1 and T2 are strongly influenced by the viscosity 
or rigidity of a tissue. Hence, there can be dramatic differences in 
relaxation times between the tissues and so a major contrast 
between them, giving a high or low signal that results in a bright or 
dark image. For example, pathology is usually associated with both 
prolonged T1 and T2.61 In general, signal tends to increase with the 
decrease of T1 and so with the increasing of the longitudinal 
relaxation rate of water protons in the tissue, because the steady-
state magnetization along the Z axis is greater yielding brighter 
images.60b, 60c On the other hand, they decrease with the decrease of 
T2, and so with the increasing of the transverse rate, since this 
diminishes its availability for detection, appearing as darker 
images.60b, 60c Moreover, pulse sequences can emphasize changes 
either in T1 or in T2, in order to manipulate the MRI response and so 
the imaging. The former are referred to as T1-weighted, and the other 
as T2-weighted scans.60b  
Finally, also the apparatus needed for MRI is inspired to the 
technology developed for NMR spectroscopy.61-62 Indeed, MRI 
system requires a magnet for applying the static magnetic field, large 
enough for accepting the human body, a radio-frequency coil to 
generate the pulse and detect the free induction decay signal and 
finally a computer to process it. This applies the Fourier 
transformation to yield a one-dimensional projection of signal 
amplitude and then a series of such projections can be reconstructed 
into two-dimensional images of NMR signal intensity.61 
3.1.2 Contrast Agents For MRI: Gd3+ Complexes 
Under normal conditions, MRI provides impressive images 
that reproduce anatomy in high resolution. Nevertheless, in order to 
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indicate the status of organ function or physiological information, a 
greater image contrast is required.60c To further enhance it, a 
contrast agent (CA) can be administered to patients prior to 
scanning.60c, 63 
Contrast agents are a new class of pharmaceuticals 
comprising complexes of paramagnetic transition and lanthanide 
metal ions.60c, 61-63 Their mode of action is to increase the relaxation 
rate of water proton spins in the immediate surroundings of the tissue 
in which they localize, via dipolar interactions and in dependence on 
their concentration. The result is a change in signal intensity so 
enhancing the image contrast. This is the only effect that can be 
observed, because CAs are not directly visualized in the image.  
Depending on the nature of the contrast agents as well as 
the applied magnetic field, they are able to decrease both T1 and T2 
to different extents.60b CAs can thus be classified into two general 
categories; positive, those that predominantly reduce T1, and 
negative, those that only mostly affect T2.64 The choice of the proper 
CA is generally oriented towards the positives, in order to obtain an 
intense signal in short times, since the percentage change in 
longitudinal relaxation rate in tissue is much greater than that in the 
transverse.60b, 64  
Ranging from Fe3+ oxide nanoparticles to metal complexes 
of Mn2+, Eu2+ and Gd3+, many different types of CA have been 
investigated.  
Gadolinium based contrast agents have been found to be the 
most useful ones. Due to its seven unpaired electrons combined with 
the ability of decreasing T1 and T2 by roughly similar amounts, that 
allows the best visualization mapping T1-weighted images, Gd3+ ions 
induce the largest effect in signal enhancement.60b, 63 Furthermore, 
there is another important electronic reason that explains such well 
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performing behavior. Gd3+ has a symmetric ground state electronic 
structure and couples a large magnetic moment with a long electron 
spin relaxation time. A much slower electronic relaxation rate makes 
Gd3+ electrons more closely in tune with water proton frequency, so 
that they can feel much better the effect of ions that gives rise to 
relaxivity.60b, 65  
Despite all the advantages of Gd3+ application in MRI, this 
cannot be injected as free ion, due to its high toxicity even at low 
doses (10-20 µmol Kg-1).64 Indeed, having a size approximating Ca2+ 
but with a higher charge, it can favorably displace endogenous 
calcium ion and block its binding sites, leading to inhibition of 
peptides and enzymes functions and disruption of Ca2+-required 
signaling.60b, 63, 65-66   
For the exposed reasons, Gd3+-based contrast agents have 
to be finely designed and developed in order to meet stability, non-
toxicity and specific tissue localization requirements. The efforts for 
reaching those targets and making such CA of effective diagnostic 
value produced an active research area that joined together 
chemical, physical, and biological sciences and brought them into 
diagnostic medicine.  
Nowadays, it is known that it is necessary to use ion organic 
ligands that tightly bind a single gadolinium ion forming very stable 
chelates with the lanthanide.64, 66 If the proper ligands are chosen, 
they remain chelated to the metal ion that is kind of buried in a 
molecular cage with no chance to bind to donor groups in proteins 
and enzymes.60b Hence, the complex can be viewed as an inert 
species that acts as an intact drug molecule.60b 
The most stable complexes have been developed exploiting 
the high affinity shown by Gd3+ towards cyclic or linear 
polyaminocarboxylate ligands, in which nitrogen and oxygen donor 
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atoms are the binding sites that coordinate the metal center.63-64 
Figure 3.1 shows the six complexes approved as CAs for clinical 
use. Gd-DTPA (Magnevist® 3.1, Figure 3.1) was the first MRI-CA to 
have been commercially available and opened the way to the design 
and synthesis of several derivatives.63-64 
 
Figure 3.1. Gd3+-based MRI contrast agents currently used in the clinical practice.  
The cyclic analogue of DTPA ligand is DOTA, whose Gd3+ 
complex was commercialized as Dotarem® (3.2, Figure 3.1) right 
after the diffusion of Magnevist®. 
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Later, two new neutral complexes became soon available; 
Gd-DTPA-BMA (Omniscan®, GE Health, USA) and Gd-HPDO3A 
(Prohance®, Bracco Imaging, Italy) (3.3 and 3.4, Figure 3.1).  
The feature that joins 3.1-3.4 is their high hydrophilicity that 
blocks the access to the cells.60b After administration via 
intravascular injection, these compounds equilibrate quickly between 
plasma and interstitial spaces (spaces between cells) across the 
walls of capillaries, to be finally excreted from the kidney with half-
lives of about 1.6 h. 63  
With the aim of altering the pharmacokinetics and the 
biodistribution of these CAs, designed as specifically targeted 
agents, an aromatic substituent was introduced on the carbon 
backbone of the DTPA ligand, so generating two new derivatives; 
Gd-EOB-DTPA (Eovist, Schering AG, Germany) and Gd-BOPTA 
(Multihance®, Bracco Imaging, Italy) (3.5 and 3.6, Figure 3.1).64 
Those are able to target the hepatobiliary system and act as a liver 
imaging agent for the indication and evaluation of hepatic lesions.63 
A common feature to all of these commercially available Gd-
based MRI-contrast agents is the choice of ligands, that consist of 8 
donor atoms.63, 66 Such design allows the chelate to leave an open 
coordination site just for one water molecule that will directly interact 
with the 9-coordinate gadolinium ion in the inner-sphere.63, 66 In the 
second sphere, there will be the water molecules hydrogen-bonded 
to the ligand, while all the others comprise the outer sphere and the 
solvent, called bulk water. The fast exchange between the inner-
sphere water molecule and the bulk water affect the relaxation 
process of all protons present in the region in which the CA 
distributes and contributes to increase the observed longitudinal 
relaxation rate. 
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The advantageous electronic features that make Gd3+ the 
metal of choice for the synthesis and application of MRI-CA are 
complemented by another property, ideal for fast water exchange; 
the ionic radius.63 Being in the middle of the 4f row of the periodic 
table, it can easily fluctuate between higher coordination numbers 
(9), typical for the early lanthanides, and lower coordination numbers 
(8), as for the late lanthanides. Moreover, the hindrance of the 
chosen ligand can also influence the water exchange and so the 
relaxation process.  
Detailed studies on the ligand features led to the design and 
synthesis of a number of them, able to wrap around Gd3+ yielding 
kinetically and thermodynamically stable chelates in vivo that induce 
dramatic variation of the water proton relaxation rates, thus providing 
innovative probes for MRI applications.  
3.2 AIM OF THE WORK: GADOLINIUM-BINDING 
CYCLIC HEXAPEPTOIDS: SYNTHESIS AND 
RELAXOMETRIC PROPERTIES. 
3.2.1 Introduction 
The chemistry of Gadolinium complexes is a rapidly growing 
field of research, motivated by the extraordinary fascinating 
properties of these compounds as potential contrast agents for MRI 
investigations. This interest has led to the synthesis of several 
example of Gd3+ complexes characterized by the presence of a 
variety of functionalized scaffolds or nanoparticles.58c Ranging from 
dendrimers,67 polymers,68 and supramolecular aggregates,69 to 
peptides,58a, 58e, 70 peptidomimetics,19c, 71 lipids,58d sugars72 and 
proteins,73 all of them containing stabilized Gd3+ ions, multiple 
environments have been studied to find optimization of the relaxivity 
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and unique applications in medical diagnosis. More specifically, the 
last ones were mainly conjugated to Gd3+ chelates, comprising 
polyaminopolycarboxylate ligands, as vectors to deliver the contrast 
agent to the targeting sites, so increasing their specificity.  
Based on the original DOTA and DTPA frameworks for 
chelation, and on the natural Ca-binding proteins that commonly 
present a loop made by 12 amino acids bearing side chains with 
oxygen donors, innovative systems have emerged as effective Gd3+ 
ligands. 
A huge work with peptides has prompted interesting 
structures able to stably encapsulate the ion and dramatically 
increase relaxivity.  
Interesting examples are the de novo designed gadolinium 
metallopeptides 3.7 and 3.8 showed in Figure 3.2. 
 
Figure 3.2. 3.7A. Sequence of P3W, with Gd-binding site highlighted in blue;70b 3.7B. 
Folded structure of metallopeptide with Gd-chelate embedded within the binding 
moiety;70b 3.8. Schematic representation of the cyclodecapeptide PA. Only the side 
chains of the aspartic and glutamic acids have been represented.70a 
3.7 (Figure 3.2) is the 33-mer peptide called P3W, featured 
by a helix-turn-helix structure; α-helicity is found to increase the Gd3+ 
binding.70b 
3.8 (Figure 3.2) is a new cyclodecapeptide that acts as a 
tetrapodal ligand. It incorporates two prolylglycine sequences as β-
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turn inducers and two aspartic acids and glutamic acids with acidic 
carboxyl side chains for cation complexation. The ligand is 
preorganized, with the four carboxyl groups oriented on the upper 
face to coordinate the Gd3+ ions. 
Peptides have been most widely used for building effective 
MRI contrast agents. However, they suffer from enzymatic 
degradation by protease and peptidase activity, hence being poorly 
biostable and bioavailable in vivo. 
To overcome this problem, recently peptidomimetics have 
gained interest in such research field due to their higher stability with 
respect to their parent peptides.74    
Peptoids are slowly emerging as supporting ligands in the 
complexation of Gd3+, and the few examples in the literature show 
that they can either act as transporter systems71a or target specific 
moiety,71b either as chelating agents.19c 
Our group contributed to the development of peptoid-based 
MRI probes introducing the gadolinium-binding cyclic hexapeptoid 
3.9 showed in Figure 3.3.19c  
The molecular design chosen for the ligand was dictated by 
several factors that we thought could positively influence the 
complexation of Gd3+. 
Cyclic peptoids demonstrated to be preorganized and 
flexible enough to selective complex different metal ions depending 
on the size of their cavity. Hexameric structures showed the highest 
affinity towards Na+ cation,17, 19a, 19b, 19d therefore, considering the 
comparable ionic radii of sodium (1.02 Ǻ) and gadolinium (0.94 Ǻ), 
we envisioned a stable Gd-coordination by the proposed cyclic 
hexapeptoid. Furthermore, water soluble and polar carboxylic acid 
side chains were incorporated into the peptoid backbone given their 
well-known Gd3+ complexing ability. 
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The strong enhancement of water proton longitudinal 
relaxation upon Gd3+ coordination by 3.9, revealed its useful 
properties as contrast agent and its potential application in MRI. 
Such chelate also represents the first example of water soluble Gd-
coordinating hexadentated cyclopeptoid.  
 
Figure 3.3. Structure of cyclic hexapeptoid with six carboxyl side chains. 
Fascinated and encouraged by those results, we designed 
two more cyclic hexapeptoids (3.10 and 3.11, Figure 3.4), differing 
in the chemical composition of the side chains and the backbone.  
Our aim was to study how the decoration of the carbon 
backbone core could affect the Gd-binding abilities and the 
longitudinal relaxation rate of water protons.  
In the design of both compounds 3.10 and 3.11, we decided 
to keep three carboxyl functionalities and to alternate them with three 
methoxyethyl amine and three proline residues respectively. The 
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ether-bearing arms alter the polarity and the content of oxygen in the 
ligand 3.10 so, given the high Gd3+ oxophilicity, they could influence 
the complexation process. The proline units in the ligand 3.11, on the 
other hand, were thought to favor the chelate formation with Gd3+, 
due to the enanced selectivity, observed for cyclopeptoids containing 
proline units,19d to coordinate Na+ cation.  
The outcome of the following experiments will tell us the role 
exerted by the side chains, also providing a deeper understanding of 
the overall complexation process.  
With the aim of expanding the vast platform of peptoids and 
giving new insights into their not-so-far explored applications as MRI-
probes, we successfully synthesized cyclic hexapeptoids 3.10  and 
3.11.   
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3.2.2 Results And Discussion 
Cyclic peptoids 3.10 and 3.11 were synthesized on solid-
phase through two different methods. The synthetic strategy applied 
for 3.10  was the mixed “submonomer/monomer” approach, whereas 
3.11 was obtained via the monomeric one. 
The common feature was the introduction of three carboxyl 
arms, accomplished by the coupling of the N-
fluorenylmethoxycarbonyl,N’-carboxymethyl-β-alanine t-butyl ester  
building block 3.15. 
This was easily synthesized in solution through two different 
synthetic procedures. 
Our first attempt was to reproduce a well-known method that 
we previously used in the synthesis of 3.9 (Figure 3.3). As shown in 
the Scheme 3.1, this consisted in two main steps.  
 
Scheme 3. 1. Synthesis of N-fluorenylmethoxycarbonyl,N’-carboxymethyl-β-alanine t-
butyl ester 3.15. Regents and conditions; (a) DIPEA, dry DMF, 18 h, r.t.; (b) i) LiOH, 
H2O/1,4‐dioxane (1:1), 0 °C, 3h; ii) NaHCO3 , Fmoc‐Cl, r.t., 18 h, 57%, three steps.  
First, we performed the N-alkylation of the β-alanine t-butyl 
ester hydrochloride 3.13 with ethyl bromoacetate 3.12 in the 
presence of DIPEA. Then, compound 3.14 underwent the one-pot 
hydrolysis of the ethyl ester and protection of the amino group with 
9-fluorenylmethoxycarbonyl chloride (Fmoc-Cl) to yield the desired 
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building-block 3.15. This was incorporated on solid-phase after flash 
chromatography purification on silica gel. 
The need of a second procedure was due to the mismatch 
of this method with the scale-up of the building-block 3.15. When 10 
g of β-alanine t-butyl ester hydrochloride 3.13 were used, the step of 
hydrolysis dramatically failed, as revealed by 1H-NMR that still 
showed the ethyl group pattern. Hence, we thought to protect the 
carboxylic acid as methyl ester, which requires milder conditions for 
removal. 
The development of the new synthetic strategy started with 
the study of a known facile method for the N-alkylation of various 
glycines via aza-Michael addition with acrylate derivatives75. This is 
reported as an effective route to the alkylation of several amino acids 
and, in our case, avoided the use of the expensive β-alanine t-butyl 
ester hydrochloride 3.13.  
Scheme 3.2 shows the synthetic procedure for the scale-up 
to 5.0 g of N-fluorenylmethoxycarbonyl,N’-carboxymethyl-β-alanine 
t-butyl ester  building block 3.15. 
Starting with the glycine methyl ester hydrochloride 3.16, this 
was first treated with sodium carbonate in a mixture of H2O/brine in 
order to obtain the methyl glycinate 3.17. That was a very delicate 
step, since 3.17 is relatively volatile. Indeed, this was extracted with 
DCM that was then just in part evaporated under controlled pressure. 
1H-NMR signals integration provided the amount of product obtained, 
so it could undergo the next step. Methyl glycinate 3.17 was added 
to t-butyl acrylate 3.18 in the aza-Michael reaction, and then 3.19 
was efficiently demethylated and protected on the amino group as 
Fmoc-derivative. The modified procedure for the synthesis of N-
fluorenylmethoxycarbonyl,N’-carboxymethyl-β-alanine t-butyl ester 
3.15 perfectly suited the needs for the scale-up. 3.15 was purified by 
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flash chromatography on silica gel and then used for the solid phase 
synthesis of the two oligomers 3.10 and 3.11.     
 
Scheme 3. 2. Scale-up synthesis of N-fluorenylmethoxycarbonyl,N’-carboxymethyl-β-
alanine t-butyl ester 3.15. Regents and conditions; (a) Na2CO3 8% in H2O/brine; (b) 
MeOH, o.n, 50°C; (c) i) LiOH, H2O/1,4‐dioxane (1:1), 0 °C, 3h; ii) NaHCO3 , Fmoc‐Cl, 
r.t., 18 h, 46%, three steps. 
The on-resin oligomerization was accomplished through a 
mixed “submonomer/monomer” and a “monomer” approach, giving 
the linear N-t-butoxycarbonylethyl/N-methoxyethyl glycine oligomer 
3.20 and N-t-butoxycarbonylethyl/N-prolyl glycine oligomer 3.21 
(Figure 3.5).  
The overall oligomerization process on solid-phase is 
illustrated in Scheme 3.3.  
The building-block 3.15 was loaded on the solid support 2-
chlorotrityl chloride resin 3.22, and the unreacted sites were capped 
with a solution of DCM/MeOH/DIPEA to avoid the growth of shorter 
oligomers. The Fmoc protecting group was removed under basic 
conditions, and the coupling of the free amine was accomplished in 
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Figure 3. 5. Linear precursors 3.20 and 3.21. 
the presence of DIC for the bromoacetic acid or 
HATU/DIPEA for the proline residue, with average coupling yields 
>98%.  
In the submonomeric approach the subsequent step was the 
displacement with methoxyethylamine, hence the formation of the N-
alkylated glycine on solid-phase (left side of Scheme 3.3). On the 
other hand, the monomeric approach required the deprotection of the 
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amine group to set it free for the next coupling (right side of Scheme 
3.3). This allowed us to install the building-block 3.15 in both the 
growing chains through the assistance of HATU. The cycles of 
deprotection/coupling/amination/coupling (submonomeric approach) 
and deprotection/coupling (monomeric approach) were reiterated 
until the desired length of the peptoids was reached (n = 3). The 
linear peptoids 3.20 and 3.21 were then cleaved from the resin under 
acidic conditions and utilized in the next step without further 
purification.  
3.20 and 3.21 were efficiently cyclized under high dilution 
conditions (3.0.10-3 M) in the presence of HATU to give the protected 
cyclic peptoids 3.24 and 3.25 (Figure 3.6) in good yields (purity 
>85%, RP-HPLC analysis). The cyclic hexapeptoid 3.24 was purified 
by flash chromatography on demetallated silica gel, in order to avoid 
undesired complexations with the cations present in the common 
silica gel, whereas 3.25 was purified by C18 semi-preparative RP-
HPLC. 
The protected  cyclic  precursors  were  then  liberated  by  
the  t-butyl  groups  with  trifluoroacetic  acid  and  m-cresol,  as  
cation  scavenger,  to  afford  the  target  compounds  3.10  and  3.11.  
The complexity of the r.t. 1H-NMR spectrum recorded for the 
cyclic precursors 3.24 and 3.25 and the target compounds 3.10 and 
3.11 demonstrated the slow equilibrium of multiple conformations on 
the NMR time scale. Spectroscopic studies were performed in order 
to establish their Na+ cation propensities (as a prelude to the studies 
on their Gd-binding properties). 
The addition of an excess amount of sodium picrate to 
solution of 3.24, 3.25, 3.10 and 3.11, induced the formation of 
complexes with remarkably simplified 1H-NMR spectra. 
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Scheme 3. 3. Solid-phase synthesis of 3.20 and 3.21. Reagents and conditions; (a) i) 
DIPEA in dry DCM, 1.5 h; ii) DCM/MeOH/DIPEA (17:2:1), 15 min; iii) Piperidine 20% 
in DMF; (b) i) bromoacetic acid/DIC (10:11 equiv.) in dry DMF, 40 min; ii) 
methoxyethylamine (10 equiv.) in dry DMF, 30 min; (c) i) Fmoc-Pro-OH/HATU/DIPEA 
(4:4:8 equiv.) in dry DMF, 1 h Pro2, 2 h Pro4 and Pro6; ii) Piperidine 20% in DMF; (d) 
i) 3.15/HATU/DIPEA (4:4:8 equiv.) in dry DMF, 1 h; ii) Piperidine 20% in DMF; (e) 
HFIP 20% in dry DCM (2 x 30 min). 
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Figure 3. 6. Structures of cyclic precursors 3.24 and 3.25. 
Figure 3.7 and 3.8 show a comparison between the free 
forms and the Na-complexes of 3.24 and 3.10 respectively, through 
their 1H-NMR spectra.  
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Figure 3. 7. 1H-NMR spectra of free 3.24 (a) (CD3CN/CDCl3 9:1 solution, [24]=4.0 mM, 
400.13 MHz) and (b) in the presence of 6.0 eq. of sodium picrate. Residual solvent 
peaks are labelled with *. 
 
Figure 3. 8. 1H-NMR spectra of free 3.10 (a) (CD3CN/CDCl3 9:1 solution, [10]=4.0 mM, 
400.13 MHz) and (b) in the presence of 6.0 eq. of sodium picrate. Residual solvent 
peaks are labelled with *. 
The same information is given in Figure 3.9 and 3.10 for 3.25 
and 3.11 respectively. In particular, it was evident the formation of 3-
fold symmetric species for all the complexes. 
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Figure 3. 9. 1H-NMR spectra of free 3.25 (a) (CD3CN/CDCl3 9:1 solution, [25]=4.0 mM, 
400.13 MHz) and (b) in the presence of 6.0 eq. of sodium picrate. Residual solvent 
peaks are labelled with *. 
 
 
Figure 3. 10. 1H-NMR spectra of free 3.11 (a) (CD3CN/CDCl3 9:1 solution, [11]=4.0 
mM, 400.13 MHz) and (b) in the presence of 6.0 eq. of sodium picrate. Residual 
solvent peaks are labelled with *. 
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The next steps were the formation of Gd3+ chelates and the 
characterization of their possible relaxometric properties, performed 
by Dott. Gianolio at the University of Turin.  
Structural and dynamic information on the Gd3+ complexes 
can be obtained from relaxometric studies on their aqueous 
solutions. Such investigation consists in the measurement of water 
proton relaxation times, since those depend on the interaction of 
water molecules in the inner and outer coordination sphere of the 
paramagnetic Gd3+ complexes. For these reason, the observed 
relaxation enhancement of the bulk water protons is directly 
correlated to structural and dynamic properties of the Gd3+ 
complexes.   
To start this study, first it was evaluated the complex 
formation through the relaxometric titration of a given quantity of 
ligand with increasing amounts of GdCl3. 
Surprisingly, the cyclic peptoid 3.11 did not show 
complexation ability towards Gd3+. This result was unexpected and 
disappointing and made us doubting also about the properties of the 
cyclic peptoid 3.10. Luckily, this resulted to effectively chelate the 
Gd3+ ion. Hence, it was possible to follow the formation of the 
complex by measuring the observed relaxation rate (R1obs=1/T1obs) at 
20 MHz (Proton Larmor Frequency) and 25°C, of solutions of ligand 
3.10 as a function of increasing concentrations of added GdCl3 
(Figure 3.11).  A straight line is obtained which slope is the relaxivity 
(r1p) of the readily formed Gd-3.10 complex (equation 1): 
R1obs = R1W + r1p [Gd‐CP]                        (1) 
Where R1W is the diamagnetic contribution of pure water (0.38).   
 66 
 
Figure 3. 11. Relaxometric titration of ligand 3.10 with Gd3+ ion (20 MHz, 25°C, neutral 
pH). 
After the ligand saturation point, when the added Gd3+is in 
excess with respect to the ligand, the slope of the line changes to 
follow the relaxivity of the free Gd3+ aqua ion (r1p=12.98 mM-1s-1 at 20 
MHz and 25°C). From this experiment, relaxivity value of 27.2 mM-
1s-1 was determined for Gd-3.10. Such parameter is proportional to 
the efficiency of the paramagnetic complex acting as relaxation 
agent. The extracted value is significantly higher than those reported 
for the commercially available Gd3+ complexes, that range between 
4 and 6 mM-1s-1.   
The next experiment was performed in order to estimate the 
stability constant for the Gd-3.10 complex. This consisted in a 
relaxometric procedure measuring the observed relaxation rate of 
Gd-3.10 solution, upon addition of increasing concentration of EDTA. 
EDTA is a Gd3+ ligand with a known Kf (5.01×1017) and competes 
with 3.10 for the complexation. Indeed, there was a decrease in the 
observed relaxation rate due to the transfer of the Gd3+ ion from 
ligand 3.10 to EDTA ligand (Figure 3.12). By knowing the stability 
constant of Gd-EDTA and the relaxivities of the Gd-complexes (Gd-
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3.10 and Gd-EDTA) it is possible to fit these  experimental  data  in  
order  to  extract  the  value  of  the  unknown  Kf  for Gd-3.10. The 
value found was 3.65×1014±1.04×1014. 
 
Figure 3.12. Variation of the observed longitudinal relaxation rate of solutions of Gd‐
3.10 (0.954  mM) as  a  function  of  the  addition  of increasing concentrations of 
EDTA. Measures were carried out at 25°C, 20 MHz and neutral pH. 
Furthermore, we measured how the relaxivity changed when 
a magnetic field, varying over a range corresponding to proton 
Larmor frequencies, was applied. Reporting the relaxivity values as 
a function of the proton Larmor frequencies on a logarithmic scale, 
we obtained a profile called NMRD (nuclear magnetic relaxation 
dispersion) (Figure 3.13).  
Table 3.1 shows all the parameters involved in the relaxation 
processes, and they were extracted by fitting of the experimental 
data with the equations that describe the paramagnetic relaxation 
theory; the Solomon-Bloembergen-Morgan equations. The values of 
the parameters involved in the electronic relaxation (Δ2 and τν) are 
very similar to those reported for the Gd3+ complexes. 
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Figure 3. 13. 1/T1 NMRD profiles of Gd‐10, recorded at 25 °C in PBS buffer (pH  7.4). 
The data refer to 1 mM concentration of the paramagnetic complex. 
The value of the reorientational correlation time (τR) depend 
on the volumetric and dimensional features of the chelates; the 
bigger the system, the slower the reorientation. Increased relaxivity 
in the magnetic fields in the range of 20-60 MHz are caused by 
slowed reorientational motion.  
Finally, the values obtained for q and qass account for the 
coordination of water in the chelate. Three molecules are directly 
coordinated to the Gd3+ ion in the inner sphere and fifteen in the 
second sphere, proximal to the ion through hydrogen bonds.  
It is worth noting that Gd-3.10 showed the same value of q 
and the other determinants of the observed relaxivities of 
cyclopeptoid 3.9 (Figure 3.3).19c Our aim was to highlight the role of 
the side chains in the formation of the chelate, and giving a better 




 Δ2 (s-2)b τνc τRd τme (s) qf qassg 
Gd-10 2.7x1019 22.5 22.6 1x10-8 3 15 
Table 3.1. Main relaxometric parameters derived from fitting of NMRD profiles 
reported in Figure 3.13. [a]   
[a]  On  carrying  out  the  fitting  procedure,  some  parameters  were  fixed  to  
reasonable values; rGd-H (distance between Gd and protons of the inner sphere water 
molecule)=3.1 Å; a (distance of minimum approach of solvent water molecules to Gd 
ion)=3.8 Å; D (solvent diffusion coefficient)=2.2x10-5cm2s-1. [b] Squared mean 
transient zero-field splitting (ZFS) energy. [c] Correlation time for the collision-related 
modulation of the ZFS Hamiltonian.  [d] Reorientational correlation time.  [e] Exchange 
life-time of the coordinated water molecule (fixed). [f] Number of inner sphere water 
molecules.  [g] Number of second sphere water molecules. 
The results obtained are extremely exciting, suggesting that 
the two ligands, 3.9 and 3.10, coordinate the metal in a similar way. 
Hence, we can state that the arms of cyclopeptoid do not seem to be 
involved in the binding process, since they are not part of the 
coordination sphere of Gd3+. The six oxygen atoms from the six 
endocyclic carbonyl groups are the ones thought to capture the 
oxophilic Gd3+ in a TTP geometry (tricapped trigonal prismatic) that 
leaves three binding site for three molecules of water, which 
complete the 9-coordination.  
The rationale behind Gd3+ complexation from cyclic peptoids 
herein proposed is also in line with the result obtained for the 
compound 3.11: the need of all the oxygen donors from the inner 
cavity implies a huge flexibility of the peptoidic backbone, so they 
could catch Gd3+ ion respecting its preferred coordination geometry. 
It has been demonstrated that cyclic peptoids comprising 
proline residues are more constrained than the others are, since 
proline favours the cis geometry of the amide bond, reducing the 
conformational freedom typical of the peptoids. The degree of 
preorganization induced by proline residues in the cyclic peptoids 
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could advantage the coordination of Na+ ion, but it is evident that this 
is not the case of Gd3+. The structure of 3.11 is too rigid to attain the 
conformation ideal for Gd3+ chelation.    
3.3    CONCLUSION 
Intrigued by the several properties and applications of 
cyclopeptoids, we proposed two new structures, 3.10 and 3.11, for 
the production of next generation MRI contrast agents.  
Studying an almost unexplored field for peptoids, we 
envisioned the chelation of Gd3+ via such innovative ligands, in order 
to enhance the relaxation rate of water protons and hence the MRI 
signal.   
Experiments on the Gd3+ binding affinity and relaxometric 
properties of the complexes not only revealed their behavior and 
potential application in the clinical practice, but also shed light on the 
factors playing in the chelation process. 
The high activity showed by 3.10 was comparable to the 
result obtained for the compound 3.9, which differs in the chemical 
composition of the side chains. On the other hand, the more rigid 
3.11 did not display Gd3+ coordination. It seems that a crucial factor 
in the formation of the metallocyclopeptoid in the presence of Gd3+ is 
the flexibility of the backbone.  
The research and development of safe and specific contrast 
media is always increasing, with the ultimate goal of enhancing the 
power of MRI even further, getting rid of painful, invasive procedures 




























Synthesis And Inhibitory Activity 
Evaluation Of The First Example Of 
Cyclopeptoid-Based Iminosugar Click-
Clusters 




Glycoconjugates play fundamental roles in the cell 
physiology and are pivotal metabolites in health and disease states. 
76 For that reason, the enzymes involved in the biosynthesis and 
degradation of glycosidic bonds have gained increasing attention.77  
Intracellular glycosyltransferases and glycosidases, act in a 
very precise and controlled fashion, with specificity directed towards 
each of the different sugar linkages and functions depending on their 
intracellular compartmentalization.76a, 77-78  
Once glycosylation patterns are altered, the normal 
expression, metabolism and functions of the organisms can be 
permanently altered.76a, 77 Lysosomal storage diseases (LSDs),78a 
type II diabetes,76a bacterial and viral infections,76a immune 
responses76a as well as metastasis of tumor cells76a, 77-78 are all 
related to structure modifications of the carbohydrates of 
glycoconjugates and so to the activity of defective glycosidases.   
A proper control of glycosidases activities could be a way to 
restore their normal catalytic behavior and so could represent a 
potential treatment of carbohydrate-related diseases.76a, 77 This could 
be achieved by the application of small agents able to bind at 
glycosidases catalytic site and act as glycosidases inhibitors.  
4.1.1 Glycosidases Inhibitors 
X-ray crystal structures of carbohydrates-glycosidases 
complexes provided mechanistic insights into glycosidic bond 
hydrolysis.76b, 79 Crystallographic studies indicated the existence of a 
short-lived transition state possessing substantial oxocarbenium 
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character (Figure 4.1).79b, 80 Under these conditions, the substrate is 
distorted from its typical chair conformation and the anomeric carbon 
possesses trigonal character.  
 
Figure 4. 1. Transition state of enzymatic hydrolysis of glycosidases. 
A good glycosidases inhibitor shows the highest affinity for 
the enzyme and, according to Pauling postulate, this is likely to mimic 
the structure of the transition state.81  
This hint led to the generation of therapeutically valuable 
inhibitors, designed incorporating one or more features, such as 
charge or geometry, which resemble the ones from the transition 
state.  
Alongside with chemically synthesized sugar mimics, many 
natural occurring products have been isolated, inhibiting 
glycosidases and sometimes showing therapeutic potential.76a, 77, 80 
Nojirimycin (NJ, 4.1, Figure 4.2) was the first natural sugar mimic to 
have been isolated from Streptomyces strains in 1966.82 NJ is an 
iminosugar, also called azasugar, a cyclic sugar where a nitrogen 
atom has replaced the ring oxygen atom. Its structural studies led to 
the synthesis of the derivative deoxynojirimycin (DNJ, 4.2, Figure 
4.2), later shown to occur naturally.83 
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Figure 4. 2. Structures of iminosugars NJ (4.1) and DNJ (4.2) 
As a result, iminosugars were further investigated for the 
treatment of carbohydrates-related diseases. The structures of NJ 
and DNJ served as templates for the design and synthesis of 
different glycoside derivatives as promising candidates in 
glycosidases inhibition.  
A growing number of natural and unnatural analogues of 
these compounds have been reported and some of them emerged 
on the market as powerful drugs. Glyset®, the  N-hydroxyethyl-1-
deoxynojirimycin (4.3, Figure 4.3), is in use for the treatment of type 
II diabetes.84 Zavesca®, the analog possessing an N-butyl group 
(4.4, Figure 4.3), has already been approved to tackle the symptoms 
of type I Gaucher disease85  and is under evaluation in clinical trials 
for cystic fibrosis.86 
 
Figure 4. 3. Structures of Glyset (4.3), and Zavesca (4.4). 
Gaucher disease is the most severe lysosomal-storage 
disorder (LSD) and it is caused by a deficiency of glucosylceramide 
β-glucosidase, also called β-glucocerebrosidase, (GCase), the 
enzyme responsible for glucosylceramide (GlcCer) hydrolysis to 
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release ceramide and glucose.87 The mutant GCase results in a 
misfolded structure, which does not pass the “quality control” 
mechanism of the endoplasmic reticulum, being partially or 
completely disrupted in there. This mechanism leads to an 
accumulation of undegraded (GlcCer) in lysosomes, leading to 
symptoms such as bone pains, skeletal lesions, anemia, liver or 
spleen damage.88  
Aware of the onset of Gaucher disease, scientists developed 
three different therapeutic approaches in the last twenty years.  
The first successful treatment was the enzyme replacement 
therapy (ERT), consisting in the administration of a recombinant form 
of GCase.89 However, the drawbacks of ERT are the high cost and 
the availability just for non-neurophatic type 1-Gaucher disease. 
Recently, two novel strategies arose in this field: the substrate 
reduction therapy (SRT) and the pharmacological chaperone therapy 
(PCT).90 In SRT, inhibitors of GlcCer synthase reduce the synthesis 
of glycosphingolipids to decrease their influx into the lysosomes. 
Zavesca® (4.4, Figure 4.3) is an implementation of this therapy 
being the first oral treatment for a lysosomal disease. Despite its 
efficacy, large doses are required, which led to side effects, such as 
abdominal pain, and its use is recommended only for adults with 
type1 Gaucher disease. In this context, PCT emerged as a promising 
therapeutic option. The concept at the basis of PCT is that 
competitive GCse inhibitors are capable to restore the catalytic 
activity of the defective enzymes. When binding the active site, they 
alter or stabilize the three-dimensional architecture of misfolded 
mutant enzymes and so induce their proper conformation. This 
prevents their degradation in the ER and allows trafficking to 
lysosomes, where GCse will exert their normal activity. Hence, PCT 
benefits of specificity, targeting directly the cause of LSDs, and of a 
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small-molecule-based approach, that implies oral bioavailability and 
the potential to cross the blood-brain-barrier. 
Cystic fibrosis is not a LDS but rather a genetic disease. 
However, it is related to a mutant protein, the Phe508del-cystic 
fibrosis transmembrane conductance regulator (CFTR), degraded by 
the ER quality control. The result is a reduced chloride and sodium 
transport across membranes that in the lungs generates dehydration 
and abnormal formation of thick mucus.91 N-Bu DNJ is among those 
small molecules demonstrated to act as CFTR correctors by 
overcoming the processing defect of the mutant protein, hence of 
interest in pharmacological therapy as alternative to heart or lung 
transplantation, which to date is the only cure available for CF.86, 92  
4.1.2 Multivalent Effect 
Despite many efforts, to date just few rational design criteria 
are available for improving the chaperon activity of a potent PC and 
no clue is known for the design of CFTR correctors as well. 
Consequently, more studies must be done in order to achieve 
sufficient levels of residual cellular activity enhancement and shed 
light on the mechanism of action of PC and iminosugar-based CFTR 
correctors. 
Since 1999, an intense research activity on iminosugar 
derivatives has enriched the field of glycoscience thanks to the group 
of Prof. Compain.93  Compain and coworkers are investigating new 
therapeutic approaches for Gaucher disease as well as for cystic 
fibrosis.  
With the aim of identifying new CFTR correctors94 and 
overcoming the obstacles to therapeutic application of 
pharmacological chaperones, getting closer to species displaying 
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enhanced activity, Compain’s group recently investigated the 
potential of multivalency.95  
Multivalency is a common concept in glycoscience, since 
many recognition events are mediated by the interaction between a 
receptor and a matching ligand present in multiple copies on a 
central scaffold. For example, multimeric carbohydrate-binding 
proteins, such as lectins, show affinity enhancement on a valence-
corrected basis, when matching with multivalent ligands. This binding 
mechanism is known as clustering and the consequent binding 
potency enhancement is the multivalent effect.96 
At first glance, this approach might look odd applied to 
glycosidases, since these enzymes usually possess a single 
substrate-binding site. Indeed, the effect of multivalency on 
glycosidases inhibition does not involve clustering but rather 
statistical rebinding. This mechanism can be explained in terms of a 
bunch of keys opening one lock.95 The “bunch” of iminosugars 
provides a high local ligand concentration that should favor the 
recapture mechanism by the glycosidase. An additional sliding 
mechanism of iminosugar in the enzyme active site guarantees an 
increasing of the life-time of the multivalent ligand–enzyme complex, 
thereby leading to higher binding affinities. 
It is worth noting that the biological activity of the multivalent 
ligand depends not only on the moiety that binds the receptor, but 
also on the scaffold.95 This is relevant since it influences the overall 
architecture of the multivalent system, defining its shape, orientation, 
flexibility, size, and valency; hence its mechanism of action.  
To understand which structural features could have a 
significant effect on the biological activity and so how to design 
synthetic multivalent ligands, our group has entered the field of 
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glycoscience examining the role of several scaffolds on the 
multivalent effect. 
4.2 AIM OF THE WORK: SYNTHESIS OF THE 
FIRST EXAMPLE OF IMINOSUGAR-
CYCLOPEPTOID CLICK-CLUSTERS 
4.2.1. Introduction 
Enzyme inhibition is an emerging approach in the treatment 
of carbohydrate-related diseases and multivalency is gaining 
growing interest for enhancing the inhibition potency of weak or 
poorly selective inhibitors.  
In parallel, the synthetic methodology for generating 
multivalent inhibitors is also rapidly expanding. The most valuable 
approach is the use of click-chemistry that allows a facile and rapid 
functionalization of the central scaffold with the selected ligand. The 
clicking bioconjugation technique has enabled the preparation of 
several multivalent inhibitors, subsequently submitted to the 
biological evaluation of their activity.  
The proof-of-concept of multivalent effect from multivalent 
inhibitors has been demonstrated, ranging from modest to high 
values depending on the scaffold features.  
Figure 4.4 shows the structures of iminosugar clusters that 
gave the best results and inspired our work.  
The dodecavalent DNJ cluster 4.5, based on a compact 
spherical fullerene C60 building block, led for the first time to strong 
affinity enhancements of the inhibitory potency for Jack bean α-
mannosidase, approximately 2150-fold relative to the corresponding 
monomer.97 Right afterwards, β-cyclodextrin-based DNJ clusters 
were evaluated against Jack bean α-mannosidase.98 Increasing 
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either the valency (21) either the linker alkyl chain length (C9) 
enabled to reach the highest multivalent effect, as found for 4.8, 
which had 9900-fold enhancement compared to the monovalent 
iminsugars. Tetravalent click-clusters based on porphyrin (4.9)99 and 
calix[4]arene (4.10 and 4.11) with the same linker length (C3) and 
ligand motif (DNJ) were also studied.108 Their comparison provided 
the opportunity to evaluate the binding properties of multivalent 
systems with different scaffolds but identical valency and linker 
length.  
In this context, the results obtained pointed out the 
importance of the spatial ligand orientation and the rigidity of the 
central scaffold, given the higher multivalent effect obtained with the 
rigid porphirine core (800-fold enhancement relative to the 
corresponding monomer against 20-fold and 267-fold for 4.10 and 
4.11 respectively). 
Regarding the study of multivalency on CFTR correction 
activity enhancement, significant results were obtained for the 
trivalent iminosugars 4.12 and 4.13, providing the first evidence of 
multivalent effect as therapeutic potential in cystic fibrosis.94 The 
compound with the longest spacer arm (C9) demonstrated to have 
an EC50 value of 0.5 µM, hence to be up to 1000-fold stronger than 
the monovalent model (EC50 = 458 µM) and 225-fold more potent 
than the clinical candidate N-Bu DNJ (EC50 = 112 µM). Being a 
submicromolar CFTR corrector, it points out that a lower valency 
highly enhances the CFTR correction activity.  
With these features in mind, we envisioned a new class of 
iminosugar clusters showing ascending valences and diverse spatial 
ligand orientation. It is worth to note that such systems should also 
possess the properties desired for biological application.  
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Hence, our attention was directed to cyclic peptoids, which 
appeared as the optimal scaffolds for the design and synthesis of 
innovative iminosugar clusters with improved performances.  
Peptoids are easy to prepare and benefit of enhanced 
proteolytic stability and cellular up-take over the parent peptides.2 
Due to these advantages, they have been widely applied for the 
synthesis of molecules of biological interest, also entering the field of 
glycoscience as candidates for new therapeutics.100 However, just 
few example of cyclic peptoids have been reported in such context 
and no iminosugar-cyclopeptoid cluster has ever been described 
before.101   
Our aim is to further explore the application of cyclic peptoids 
for building potentially bioactive glycoconjugates, and to evaluate the 
role of the scaffold architecture on multivalent effect, highlighting the 
structure-activity relationship and unveiling the secret for reaching 
the highest multivalent effect.  
Hence, herein we report the first example of cyclopeptoid-




Figure 4. 4. Structures of iminosugar clusters active towards Jack bean α-





4.2.2. Results and Discussions 
The assembly of the multivalent glycoconjugates was 
performed by using a convergent approach. This involved the 
attachment of azido-functionalized carbohydrates DNJ onto the 
cyclic peptoid scaffolds through copper(I)-catalyzed azide-alkyne 
cycloaddition reaction (CuAAC).102 The choice of DNJ as peripheral 
ligand is due to its own inhibitory activity and therapeutic value; the 
majority of the glycoclusters reported in the literature is indeed 
decorated with DNJ binding motifs. This also means that conjugating 
the same carbohydrate probes to the cyclic peptoids could allow a 
comparison with the other systems already described.  
The synthesis started with the assembly of the cyclic 
peptoids. These were designed with appended propargyl groups, 
which make them “clickable” to undergo the click chemistry with the 
azido-DNJ derivatives.103  
The library of the scaffolds synthesized is showed in Figure 
4.5.  
The linear precursors were obtained by the efficient solid 
phase sub-monomer approach elaborated by Zuckerman et al. for 
the preparation of peptoids.2 This method allowed for the rapid 
synthesis of various oligomers of valences ranging from two up to 
sixteen. Scheme 4.1 shows the synthetic strategy, relying on the use 
of 2-chlorotrityl chloride resin as solid support on which the peptoid 
chain was elongated. In the first step, bromoacetic acid (4.25) was 
loaded onto a 2-CTC (4.26) through an ester linkage. Each monomer 
was then built directly on the resin through a two-step sequence that 
was iteratively repeated until the desired oligomer length was 
reached. Amination with suitable primary amines displaced the 
bromine and installed the desired N-alkyl side chain. We introduced 
N-propargyl amines for the synthesis of the scaffolds all 
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propargylated (4.17-4.24, Figure 4.5) and N-propargyl amines 
alternated with N-methoxyehtyl amines for the divalent one (4.16, 
Figure 4.5). Once on solid phase, the free amine was coupled with 
bromoacetic acid with the assistance of N,N-diisopropylcarbodiimide 
(DIC). The reactions of amination and acylation were carried out in 
the presence of an excess of reagents (10 equivalents) and 
accomplished in 30 and 40 min respectively. The success of each 
coupling step was confirmed via the colorimetric analysis of chloranil 
test and the growing of the peptoidic chain was monitored by means 
of HPLC-ESI of the crude products upon mini-cleavage. After the 
completion of the synthesis, the oligomers were cleaved from the 




Figure 4. 5. Library of cyclopeptoid scaffolds 4.16-4.24. 
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Scheme 4. 1. Sub-monomer approach for the synthesis of precursors of cyclopeptoids 
4.16-4.24: (a) DIPEA, in dry DCM, 1.5h; (b) propargylamine or methoxyethyl amine 
when needed (10 equiv) in dry DMF, 30 min; (c) bromoacetic acid/DIC (10:11 equiv.) 
in dry DMF, 40 min; (d) HFIP 20% in dry DCM (2 x 30 min).  
N-substituted glycine oligomers comprising 4 to 16 
monomers were synthesized manually in high to good yield and 
crude purity, estimated by analytical reversed-phase HPLC, to range 
from 95% to 60% largely depending upon oligomer length (Figure 
4.6, Table 4.1). The preparation of longer structured molecules 
logically presents some synthetic challenges.104 The coupling 
efficiency tends to decrease slightly at the increasing of the chain 
length due to conformational and solubility issues. 
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Peptoid oligomer Oligomer length Purity % 
4.30 6 >95 
4.31 4 >95 
4.32 5 >95 
4.33 6 >95 
4.34 8 82 
4.35 10 72 
4.36 12 70 
4.37 14 65 
4.38 16 60 
Table 4. 1. Purity of crude products 4.30-4.38 determined by analytical RP-
HPLC. 
However, the submonomer approach is a useful and 
powerful method to overcome such drawbacks and to access longer 
oligomers in good purity.2  
Without further purifications, all linear products underwent 
head-to-tail cyclization in solution. Under high dilution conditions (3.0 
× 10−3 M) and in the presence of the efficient coupling agent HATU, 
macrocyclization proceeded smoothly to give the cyclic compounds 
4.16-4.24. Furthermore, a syringe pump105 was used to slowly add 
the linear peptoide precursor and so avoiding the side reactions of 
dimerization or cyclodimerization that may accompany the 
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cyclization of peptoids. After purification, compounds 4.16-4.24 were 
recovered in 31%, 35%, 20%, 31%, 32%, 12%, 10%, 8%, 5% overall 
yield respectively.  
 
Figure 4. 6. Analytical HPLC traces of crude peptoid synthesis products: trace A, 12-
mer 4.36; trace B, 14-mer 4.37; and trace C, 16-mer 4.38. Traces A and B are 
vertically offset for clarity. 
All the cyclic oligomers, except the tetramer 4.17, showed 
complex room temperature 1H-NMR spectra, suggesting the 
contemporary presence of several conformers in slow exchange on 
the NMR time scale. Cyclotetrapeptoid 4.17 provided simplified NMR 
spectra with two independent resonance peak patterns both in the 
1H- and in the 13C-NMR spectra. This result invokes the presence of 
a center of symmetry in the molecule and a ctct amide sequence as 
indicated by the values Δδ of diastereotopic intra-annular proton 
doublets: Δδ (a) 1.67 ppm, (b) 0.07 ppm, respectively (Figure 4.7). 
Such well-defined shape and the rigid conformation of the amide 
backbone structure are in agreement with the other 
cyclotetrapeptoids described in the literature.14, 16-17 
Furthermore, it is worth to note that the big size rings are so 
flexible that from 4- to 16-mer cyclopeptoids, 1H-NMR peaks broaden 
 88 
progressively. Hence, the spectra from 10- to 16-mer cyclopeptoids 
yielded three broad patterns belonging to the alkynyl protons, around 
2.5 ppm, and the methylene units, either from the side chains either 
from the backbone, that overlap in the region between 4.6 and 4.0 
ppm (Figure 4.8 and 4.9).  
 
Figure 4. 7. 1H-NMR for compound 4.17.  
 
Figure 4. 8. Zoom in 1H-NMR spectrum of: (A) compound 4.35 (400 MHz, CDCl3) 






Figure 4. 9. Partial 1H-NMR spectrum of (A) compound 4.37 (600 MHz, CD3CN) and 
(B) 4.38 (600 MHz, CD3CN). * Residual solvent peak for CD3CN, X for H2O. 
With the platform of clickable cyclic peptoids in our hands, 
we were ready to perform the functionalization with N-alkyl 
derivatives of DNJ.  
This last synthetic stage and the evaluation of the inhibitory 
activity were carried out in collaboration with the group of Prof. 
Compain at the University of Strasbourg.    
I have been visiting his laboratory in Strasbourg for a short 
period, to take part in the preparation of the azide-armed N-hexyl and 
N-nonyl DNJ ligands and the DNJ-clusters based on compounds 
4.19. 
The synthetic strategy applied was the one recently 
developed and optimized by Compain and coworkers.94, 98, 106 The 
first step was the synthesis of the peracetylated azide-armed N-hexyl 
and N-nonyl DNJ derivatives 4.43a and 4.43b from the preformed 
4.41 (Scheme 4.2).97 First, the azidobromoalkanes 4.40 were 
obtained through the nucleophilic substitution with sodium azide on 







Scheme 4. 2. Synthesis of N-alkyl DNJ 4.43a and 4.43b. Reagents and 
conditions: (a) NaN3, DMSO, overnight; (b) K2CO3, CH3CN, MW, 150°C; 
(c) i. BCl3, CH2Cl2, -60°C to 0°C; ii. Ac2O, pyridine, DMAP cat. 
The crude compounds were purified on flash 
chromatography, to remove the undesired dialkylation side products, 
and the pure azidobromoalkanes were thus dissolved in acetonitrile 
with the iminosugars 4.41. The resulting solution was heated in a 
microwave reactor at 150°C for 4 h, giving the expected products 
4.42 in yields up to 81%. The microwave-assisted alkylation of the 
rather unreactive endocyclic amine 4.41 is a huge improvement with 
respect to the method previously reported and allows for much better 
yields.98a The way to the synthesis of the peracetylated iminosugars 
required the selective cleavage of the benzyl protecting groups 
affording the azidopiperidinols, which were readily peracetylated to 
provide compounds 4.43. 
At this stage of synthesis, we were ready to perform the 
multiconjugaton reaction that enabled the attachment of 
peracetylated azido iminosugars 4.43 onto polyalkyne scaffolds 4.16 
and 4.19-4.21107 by microwave-assisted CuAAC reaction (Scheme 
4.3). The desired DNJ clusters 4.44 and 4.46-4.48 were obtained in 
good to high yield, ranging from 69% to 95%.  
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Scheme 4. 3. Synthesis of DNJ clusters 4.45 and 4.49-4.51. Reagents and conditions: 
(a) CuSO4 * 5H2O cat., sodium ascorbate, DMF/H2O (5:1), MW, 80 °C, 3 h; (b) 
Amberlite IRA 400 (OH–), MeOH/H2O (1:1), 40 °C. Overall yields from compounds 
4.16 and 4.19-4.21: 4.45a 73%; 4.45b 94%; 4.49a 95%; 4.49b 83%; 4.50a 69%; 4.50b 
80%; 4.51a 70%; 4.51b 80%. 
1H-NMR spectra recorded at room temperature for such 
compounds showed interesting pieces of information on their 
conformation in solution. The hexavalent and decavalent clusters 
4.46 and 4.48 yielded complex NMR patterns, as a result of the 
simultaneous presence of several conformers in solution slowly 
equilibrating on the NMR time scale. This outcome is in agreement 
with the conformational disorder highlighted for the scaffolds and for 
other cyclic peptoids described in the literature. On the other hand, 
the octavalent clusters 4.47 showed simplified 1H-NMR spectra. A 
possible explanation could be the chelation of Na+ upon the CuAAC 
reaction in the presence of sodium ascorbate. Interestingly, the 
divalent clusters 4.44 presented just a partial conformational 
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disorder, as a sign of a predominant conformation in solution and the 
minor presence of exchanging conformers. Upon addition of excess 
of sodium picrate to 4.44a and 4.46a, the 1H-NMR spectra showed 
the coalescence of signals, indicating that the metal chelation 
triggered the formation of a sodium complex with a 2-fold and 6-fold 
symmetry respectively (Figure 4.10 and 4.11).     
 
Figure 4. 10. i) Partial 1H-NMR spectrum (400 MHz, CD3CN/CDCl3 9:1) of compound 
4.44a; ii) Partial 1H-NMR spectrum (400 MHz, CD3CN/CDCl3 9:1) of compound 4.44a 
with sodium picrate (11 equiv). * Residual solvent peak for CDCl3. •, X and   are 
assigned to protons a or b or c. 
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Figure 4. 11. i) Partial 1H-NMR spectrum (400 MHz, CD3CN/CDCl3 9:1) of compound 
4.46a; ii) Partial 1H-NMR spectrum (400 MHz, CD3CN/CDCl3 9:1) of compound 4.46a 
with sodium picrate (11 equiv). * Residual solvent peak for CDCl3. • and X are assigned 
to protons a or b. 
Products 4.44 and 4.46-4.48 underwent the subsequent O-
deacetylation on an anion exchange Amberlite IRA-400 (OH−) resin, 
to afford the final deprotected iminosugar clusters 4.45 and 4.49-4.51 
in quantitative yield (Scheme 4.3). 
The eight cyclopeptoid-based iminosugar click-clusters 
underwent biological evaluation to address the importance of the 
scaffold architecture on multivalent effect for correcting protein-
folding disorders such as Gaucher disease and cystic fibrosis.  
The divalent compounds 4.45 were shipped to Dr. C. Norez 
lab where they were tested as CFTR correctors. Indeed, it has been 
demonstrated that the highest activity enhancement can be obtained 
with systems of lower valency.94 Concentration-dependent correction 
by multivalent iminosugars was determined treating CFKM4 cells for 
2 h with 100 µM of compounds. Then, Phe508del-CFTR activity was 
assessed  with  the  iodide  effluxes  technique  in  the presence  of  
a stimulating cocktail of CFTR activators made of forskoline  (10 μM)  
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plus  genistein  (30 μM). The responses yielded the EC50 values 
reported in Table 4.2, together with the EC50 values for N-Bu DNJ 
(4.4, Figure 4.3), as a reference compound with regard to its 
therapeutic potential and their monovalent analogues, included as 
model controls (4.52, Figure 4.12). 
 
Figure 4. 12. Model control of monovalent iminosugars. 
Entry Iminosugar Valency Spacer 
lenght 
EC50 [µM] 
1 4.494 1 - 112 
2 4.45a 2 C6 91 
3 4.45b 2 C9 82 
4 4.52a94 1 C6 12 
5 4.52b94 1 C9 458 
Table 4. 2. Corrector efficiency for multivalent iminosugars and their monovalent 
analogues. 
The divalent iminosugars (entries 2 and 3) were comparable 
to the clinical candidate N-Bu DNJ (entry 1) and the different alkyl 
spacer lengths C6 and C9 had no significant impact on EC50 values. 
Furthermore, the C6-armed divalent iminosugar 4.45a resulted 
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weaker than the corresponding monovalent model (entry 4) whereas, 
the compound with the longest spacer arm (C9) 4.45b, was slightly 
more efficient than its monovalent counterpart (entry 5). Even though 
the CFTR-correction gained with the trivalent iminosugar 4.12a 
(Figure 4.4) are still the strongest, cyclopeptoid-based iminosugar 
click-clusters are anyway a step forward in the field of therapeutic 
treatment for cystic fibrosis. Indeed, they demonstrate that 
multivalency is an effective tool for enhancing CFTR-correction 
activity and such scaffolds are a valuable platform of compounds to 
explore the role of key structural parameters, such as valency, ligand 
topology, and alkyl spacer length, on the biological activity for the 
identification of molecules capable of rescue of functional CFTR in 
cystic fibrosis. New insights, more hints and a better understanding 
of the concept of multivalent design will come after the preparation 
and biological evaluation of the tetra and pentavalent iminosugar 
click-clusters based on cyclopeptoids 4.17 and 4.18 (Figure 4.5). 
To further study the inhibitory multivalent effect of DNJ 
clusters to defective glycosidases of therapeutic interest, compounds 
4.49-4.51 (Scheme 4.3) were subjected to inhibition assay by Prof. 
C. Tarnus in her lab in Mulhouse.107 
Jack bean α-mannosidase was the enzyme against which  
the best multivalent effects in glycosidase inhibition were collected 
so far. Hence, to add one more piece to such intriguing puzzle, the 
hexa-, octa- and decavalent iminosugars were tested as inhibitors of 
such peculiar enzyme. Table 4.3 reports the values of the constant 
inhibition Ki, which reflects the inhibitory activity of the multivalent 
cluster, the relative inhibition potency rp, which defines the inhibitory 
activity of the multivalent cluster with respect to the analogue 
monovalent model, so giving an idea of the enhancement of the 
inhibitory activity obtained, and the relative inhibition potency per 
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number of iminosugar units rp/n, which mathematically estabilishes 
the multivalent effect as a normalized parameter. The related 
monovalent controls  4.52 are also shown in the table for 
comparative purposes. 







1 4.49a 6 C6 65 ± 24  4.9 0.8 
2 4.49b 6 C9 11 ± 1   17 2.8 
3 4.50a 8 C6 21 ± 2  15 1.9 
4 4.50b 8 C9 8 ± 3  23 2.9 
5 4.51a 10 C6 15 ± 10 21 2.1 
6 4.51b 10 C9 5 ± 1  38 3.8 
7 4.52a 1 C6 322 - - 
8 4.52b 1 C9 188  - - 
Table 4. 3. Relative inhibition potency, multivalent effect and inhibitory activity (Ki, μM) 
against jack bean α-mannosidase of cyclopeptoid-based clusters 4.49-4.51 and their 
monovalent control models 4.52.  
A careful analysis of the data reported in the table reveals 
that all the cyclopeptoids tested show a significant multivalent effect 
(rp/n > 1), a part from the hexavalent ligand bearing the C6 alkyl 
spacer (entry 1). Furthermore, also in this case, the C9 alkyl-armed 
DNJ clusters resulted in a higher inhibition potency, with the best 
performance being obtained with the decavalent ligand and the C9 
linker (entry 6, rp/n = 3.8). Despite the encouraging activities found 
for such compounds, they are still less potent than the clusters based 
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on β-cyclodextrins. Recalling the inhibitory potency and the 
multivalent effect found for the two heptavalent β-CD 4.6a and 4.6b 
(Figure 4.4), the value of Ki was 7.7 and 0.36 μM, which leads to a 
rp/n of 6.0 and 75 respectively.98a Hence, cyclopeptoid-based 
iminosugar click-clusters 4.49-4.51 were 2- to 31-fold less potent 
than their analogues with the same alkyl spacer but different inner 
core. A possible explanation to those results could rely in the different 
ligand spatial orientation as consequence of the structural features 
of the central scaffold. Indeed, it has been demonstrated that the 
rigidity of the scaffold is beneficial in achieving higher multivalent 
effects.97, 99 Our multivalent systems could be not rigid enough to 
raise the inhibitory potencies due to the intrinsic flexibility of the 
cyclopeptoid backbone. However, even though they are not the best 
α-mannosidase  inhibitors, the evaluation of their activities further 
highlights the role of the scaffold architecture on binding affinity 
enhancements. In addition, this outcome clearly points out that an 
increase both in the valency and in the linker length favours the 
inhibition potencies of cyclopeptoid-based iminosugar clusters. This 
hint, together with the improved biostability and bioavailability of 
cyclic peptoids, their easy synthesis, the simple functionalization by 
CuAAC reactions and the facile access to scaffolds with increased 
valency, indicates that they are a valuable and promising tool for the 
construction of multivalent ligands with improved performances. 
Their advantages pushed us to further investigate the application of 
such new systems into the α-mannosidase inhibition. Hence, we 
developed the second generation of cyclopeptoid-based iminosugar 
click-clusters. 
The six cyclopeptoids 4.19-4.24 (Figure 4.5) incorporating 
six to sixteen propargyl side chains were chosen as the central 
scaffolds. The alkynyl termini underwent CuAAC reaction in the 
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presence of the azido-armed tripode 4.53 that enabled to expand the 
valency by three and to create elegant and branched molecular 
structures (Scheme 4.4). Once again, DNJ iminosugars were 
chosen as peripheral ligands, attached through a C9 alkyl linker, 
since the clusters comprising these structural elements showed the 
largest inhibitory multivalent effects.  
18- to 48-valent DNJ clusters 4.60-4.65 were obtained in two 
steps. First, the microwave assisted derivatization of the propargyl 
side chains with the trivalent ligands afforded peracetylated DNJ 
clusters 4.54-4.59 in 32 to 77% yields. Then, the O-deacetylation 
with basic anion exchange resin gave the final deprotected 
cyclopeptoid-iminosugar conjugates in good yield. 
The second generation of cyclopeptoids iminosugar click-
clusters were ready to be evaluated as inhibitors of Jack bean α-
mannosidase, the glycosidase with the largest responses to 
multivalent inhibitor presentation to date. 
Table 4.4 shows the corresponding inhibition constants (Ki) 
as well as relative inhibition potency (rp) and the multivalent effect 
(rp/n) of multivalent ligands 4.60-4.65. For comparative purposes, 
4.52b was included as structurally related monovalent control.  
Comparing the inhibitory multivalent effect of the decavalent 
cluster 4.51b (entry 6, Table 4.3), the last component of the first 
generation synthesized, with the value found for the 18-valent cluster 
4.60 (entry 2, Table 4.4), the first member of the second generation 
of iminosugar ligands, an increase of one order of magnitude was 
gained (rp/n from 3.8 to 74). Hence, the addition of eight DNJ units 
to the cyclopeptoid core was beneficial for dramatic improvement in 
binding enhancements.  
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Scheme 4. 4. Synthesis of DNJ clusters 4.60-4.65. Reagents and conditions: (a) 
CuSO4 * 5H2O cat., sodium ascorbate, DMF/H2O (5:1), MW, 80 °C or 90°C, 3 h; 4.54 
75%; 4.55 73%; 4.56 53%; 4.57 70%; 4.58 77%; 4.59 32%; (b) Amberlite IRA 400 
(OH–), MeOH/H2O (1:1), 40 °C. Overall yields from compounds 4.19-4.24: 4.60 66%; 
4.61 56%; 4.62 53%; 4.63 40%; 4.64 62%; 4.65 28%. 
However, for a better understanding of the multivalent effect, 
two more compounds were synthesized. 
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 To determine the minimum number of DNJ units to generate 
a significant binding enhancement, a 14-valent iminosugar 4.67 was 
prepared (Scheme 4.5). 
To evaluate the influence of the cyclic nature of the peptoid 
scaffold on the multivalent effect, cluster 4.70, the acyclic analogue 
of 4.63, was synthesized by clicking the tripode 4.53 on the linear 
peptoid 4.68 previously obtained on solid-phase (Scheme 4.6).  
Switching from a cyclic to a linear peptoid scaffold resulted 
detrimental to α-mannosidase inhibition, as reflected by rp/n values 
reduced by one order of magnitude (entry 6, Table 4.4). 
Concerning the evaluation of 4.67 binding potency, this 
revealed that an increment of just four DNJ units, from 10 to 14 in 
4.51b and 4.67 respectively, led the multivalent effect to raise of two 
orders of magnitude (entry 7, Table 4.3 and entry 1 Table 4.4). It is 
interesting to note that, from 14- to 18-valent iminosugar, there is a 
slight decrease of inhibitory activity. This result is probably to address 
to the ligand special orientation presented by the 14- and 6-mer 
cyclopeptoid. However, it was noteworthy to follow an outstand 
increase of rp/n moving from 18- to 36-valent iminosugars (4.60-
4.63, entries 2-5 Table 4.4). 4.63 led to a remarkable relative 
inhibition potency, ca. 171000-fold stronger than the one displayed 
by the corresponding monovalent analogue 4.52b (entry 9, Table 
4.4). Comparing such value with the multivalent effect showed by 21-
valent β-cyclodextrin (4.8, Figure 4.4, rp/n = 610), we can state to 
have reached a new record with the highest inhibitory activity ever 
reported in the field of glycosidases inhibition. This result also means 
that the multivalent effect has touched a plateau, since no 
enhancement of inhibitory potency is observed further increasing the 
valency to 42 and 46 (compounds 4.64 and 4.65, entries 7 and 8).       
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Entry Iminosugar Valency Ki [μM] rp 
 
rp/n  
































9 4.52b 1 188  - - 
Table 4. 4. Relative inhibition potency, multivalent effect and inhibitory activity (Ki, μM) 
against jack bean α-mannosidase of cyclopeptoid-based clusters 4.60-4.65, 4.67, 4.70 
and their monovalent control model 4.52b. 
Collecting all the multivalent effect values registered for the 
first and the second generation of cyclopeptoid-based iminosugar 
click-clusters and plotting them versus the valency of the 
corresponding compounds, it is interesting to highlight an 
exponential increase of rp/n that goes to the top with the 36-valent 




Scheme 4. 5. Synthesis of DNJ cluster 4.67. Reagents and conditions: (a) 
CuSO4 * 5H2O cat., sodium ascorbate, DMF/H2O (5:1), MW, 80 °C, 3 h; 4.66 
53%; (b) Amberlite IRA 400 (OH–), MeOH/H2O (1:1), 40 °C. Overall yield 
from compound 4.23: 4.67 45% 
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Scheme 4. 6. Synthesis of DNJ cluster 4.70. Reagents and conditions: (a) 
CuSO4 * 5H2O cat., sodium ascorbate, DMF/H2O (5:1), MW, 80 °C, 3 h; 4.69 
88%; (b) Amberlite IRA 400 (OH–), MeOH/H2O (1:1), 40 °C. Overall yield 
from compound 4.68: 4.70 88% 
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Figure 4. 13. Relative inhibition potency/DNJ units vs. valency of 
cyclopeptoid (CP) based iminosugar click-clusters. 
 
The achievement of a plateau in the multivalent effect broke 
a new record in Jack Bean α-mannosidase inhibition. Nevertheless, 
the operating binding mode of such multivalent ligands still remains 
unclear. To shed light on their mode of action in order to construct a 
rule for developing new and powerful inhibitors, we studied the 
interactions of Jack Bean α-mannosidase and the 36-valent cluster 
4.63, for which the highest multivalent effects are reported.  
Jack Bean α-mannosidase is a high-molecular-weight 
metalloenzyme (LH)2 of 230 kDa.  It can be defined as a homodimer 
comprising two heterodimeric subunits (LH for Light and Heavy 
chains) of around 49 (L) and 66 kDa (H). Recently, it has been 
suggested that each subunit has a binding site, being catalytically 
active in the dimeric structure. 
Since several binding modes can be possible with the 
multivalent iminosugars, electron microscopy (EM) with negative 
staining was performed by Dr. Birck at the Structural Biology 
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Platform, IGBMC in Illkirch  (France) to obtain high-resolution images 
of the enzyme alone and in the presence of 4.63, hence providing 
receptor/ligand interactions on nanometric scale.  
 
Figure 4. 14. EM pictures of Jack Bean α-mannosidase (A) and Jack Bean α-
mannosidase interacting with 4.63 (B) - scale bars = 50 nm. 
Figure 4.14A shows an image of mannosidase alone. The 
green frame contains clear clusters of ~10x20 nm matching the size 
of two Jack Bean α-mannosidase molecules in a 2x(LH)2 complex. 
The enzyme, incubated with the multivalent cluster at a concentration 
in the same range than the one used for the inhibition assays (5 
µg/ml), produced several disparate arrangements. In Figure 4.14B 
different assemblies can be seen, such as some in the red frame of 
size ~ 20x20 that may correspond to the interaction of one inhibitor 
with two tetramers (LH)2.  
Analytical Ultracentrifugation Sedimentation Velocity (AUC-
SV) experiments performed by Dr. A. Podjarny at the Institut de 
Génétique et de Biologie Moléculaire et Cellulaire in Illkirch (France) 
confirmed this hypothesis. AUS-SV measures the rate of movement 
of solutes in high centrifugal fields, and enables the quantitative 
analysis of macromolecules in solution to define the size, shape and 
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interactions of macromolecules. One common application of this 
method is to determine the sedimentation coefficient distribution c(s) 
of macromolecules. Since it is related to the buoyant molar mass M, 
the unequivocal deterrnination of M is possible from sedimentation 
velocity experiments. Figure 4.15 shows the sedimentation 
coefficient distribution plot for Jack Bean α-mannosidase (in 
magenta) and for the Jack Bean α-mannosidase:4.63 complex (in 
blue). Peaks in the distribution belong to certain oligomers and may 
identify their molecular mass. For Jack Bean α-mannosidase alone 
(magenta curve), the main species sedimented at 9.3 S 
corresponding to the tetramer (LH)2 with a molar mass estimate of 
210 kDa. A minor peak at 13.4 S also appears in the c(s) plot, 
indicating species with a molar mass estimate of 377 kDa which may 
correspond to the association of two Jack Bean α-mannosidase 
molecules in a 2x(LH)2 complex. The blue curve indicates the binding 
of Jack Bean α-mannosidase to 4.63 and shows the broadening of 
sedimentation coefficient distribution. This exhibites maxima at about 
14 S suggesting the reversible formation of a 2:1 




Figure 4. 15. AUC-SV experiments: sedimentation coefficient distribution plot for Jack 
Bean α-mannosidase (in magenta) and for the Jack Bean α-mannosidase-4.63 
complex (in blue).  
Finally, a third method was applied to get complete insight 
into the binding mode of multivalent iminosugars.  
Dr. N-T. Nguyen-Huynh at the Laboratoire de Spectrométrie 
de Masse des Interactions et des Systèmes (University of 
Strasbourg) performed electrospray mass spectrometry (ESI-MS) on 
the native enzyme before (Figure 4.16A) and after the addition of 
the inhibitor 4.63 (MW = 17,4 kDa) (Figure 4.13B). In both cases 
there were identified three different multi-charged ions patterns. 
Figure 4.16A reveals the molecular mass of the primal heterodimer 
LH (MW = 121.3 kDa), the tetramer (LH)2 (MW = 242.3 kDa) and the 
association of two tetramers (LH)2 (MW = 484.9 kDa), respectively. 
Figure 4.16B shows two enzyme:inhibitor complex with two different 
stoichiometries; 1:1 (MW = 259.9 kDa) and 2:1 (MW = 501.9 kDa).  
 
Figure 4. 16. Native ESI-MS spectra for (A) Jack Bean α-mannosidase and (b) Jack 
Bean α-mannosidase interacting with 4.63. Multi-charged ions patterns are labelled 
with the corresponding enzyme and enzyme-inhibitor complexes. 
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The experiments performed on Jack Bean α-mannosidase 
and the multivalent iminosugar 4.63 gave a series of complementary 
pieces of information that we put together to finally have an overall 
picture of the mechanism behind multivalent inhibition. The 36-valent 
cyclopeptoid-based iminosugar click-cluster provides the optimal 
number of ligands and allows for the ideal spatial orientation of the 
iminosugar moieties to bind a first molecule of Jack Bean α-
mannosidase and then cross-link a second one allowing for the 
stabilization of a 2:1 tetramer (LH)2-inhibitor chelate complex (Figure 
4.17). Reversible active-site specific interactions with the 
iminosugars but also protein-protein interactions between two 
tetramers interplay in the formation of the enzyme-inhibitor complex. 
It is worth to note that the architectural features of the scaffold, such 
as its size, valency and flexibility, revealed to be crucial in shifting the 
equilibrium of the different species in solution towards the formation 
of the complex.  
 
Figure 4. 17. Cartoon representation of the equilibrium between the free forms of the 







4.3    CONCLUSION 
A library of propargylated cyclopeptoids 4.16-4.24 (Figure 
4.5) has been synthesized on solid-phase via the submonomer 
approach. This powerful method allowed for an easy access to 
longer chains (12- to 16-mer) that underwent the macrocyclization 
reaction to afford the largest cyclopeptoids size ever described.  
The platform of cyclopeptoids was then decorated with 
hexyl- and nonyl-azide armed DNJ ligands via the efficient CuAAC 
reaction, to yield the first example of cyclopeptoid-based iminosugar 
click-clusters. 
The first generation of such compounds presented 2 to ten 
copies of the DNJ iminosugar ligands, installed on the 6- to 10-mer 
cyclopeptoid scaffolds. The divalent compound was tested as CFTR 
corrector, resulting as powerful as the structures previously reported. 
The 6- to 10-valent compounds were evaluated as inhibitor of Jack 
Bean α-mannosidase. Despite the considerable multivalent effect 
registered, they resulted weak inhibitors of the enzyme studied. 
However, they highlighted the importance of the high valency and 
the longer C9 alkyl spacer as structural element to enhance the 
binding potency. 
The second generation of cyclopeptoid-based iminosugar 
click-clusters was synthesized incorporating a DNJ tripode with nonyl 
spacer arms on 6- to 16-mer scaffolds, accessing valency never 
reached before. The 36-valent cluster showed the best multivalent 
effect and broke the record previously won by 21-valent β-
cyclodextrine.  
Experiments of EM, AUC-SV and ESI-MS revealed its 
mechanism of action. The flexible and long-armed DNJ cluster is 
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able to accommodate two mannosidase molecules and bridge four 
active-sites to form very tight sandwich-type complexes. 
The importance of this outcome is providing a rational behind 
the binding of the multivalent inhibitors and an explanation to the 
multivalent effect. This claims the key architectural features for 
designing and developing new structures able to rise the inhibition 

































The Role Of Side Chains In The Solid-






Since the advent of peptoids, researchers started to play 
around with their structures and to explore the enormous structural 
diversity exploiting the malleability of the backbone. 
Many complementary methodologies are employed in the 
structural characterization of peptoids, most of all circular dichroism 
spectrophotometry (CD), NMR spectroscopy and X-ray 
crystallography.108 However, due to the cis/trans isomerism of the 
peptoid bonds,2 a peptoid made of n monomers gives rise to 2n-1 
equilibrating configurational isomers in solution, or 22 if the N-
terminal amino group is capped and acetylated.109 Hence, it is 
extremely difficult to go through their NMR spectra,110 which appear 
of tough interpretation even if a covalent constrain as 
macrolactamization is applied.10, 16-17, 19, 49b  
For that reason, crystallization of peptoids is highly 
auspicable, in order to freeze a preferred conformation and to attain 
their structural characterization. In this respect, X-ray crystallography 
ranks over the other “devices of curiosity”. 
5.1.1. Solid State Assembly Of Cyclic Peptoids 
As stated in the paragraph 1.3, cyclopeptoids have shown to 
be extremely interesting for the various properties displayed and their 
potential applications.  
The elucidation of their structure is fundamental to gain a 
deep understanding of the structure-activity relationship, in order to 
get more hints for the de novo design of folded and active 
compounds. X-ray crystallography is of first aid in reaching this 
target, which is also central in the crystal-engineering field.  
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Very recently, our group presented a survey on the solid-
state assembly of cyclic peptoids with the aim to recapitulate their 
main features, hence to shed light on the interactions that interplay 
in their arrangement.14 Eighteen compounds, both homo- and 
heterooligomers, have been studied and classified depending on 
their ring size, ranging from 3- to 10-mers.  
It is remarkable that the side chains have a primary role in 
defining the solid-state arrangement of the cyclopeptoids. Indeed, 
the removal of the amide proton implies the exclusion of NH…OC 
hydrogen bonding from the structural interactions and renders the 
backbone conformation almost identical within the same-size-ring 
family. It means that there is a recurrent sequence of geometry of the 
amide bonds (Table 5.1), and this was also confirmed in the crystal 
structures of small cyclopeptoids synthesized later on.16 
Furthermore, it is worth to note that hexameric cyclopeptoids pass 
from a cctcct to an all-trans configuration upon metal complexation.17, 
19d  
Weak but extended interactions, such as inter-annular 
CH…OC hy and CH…π for compounds including pi systems (aromatic 
side chains, triple bonds and so on…) chains, vicariate the stronger 
NH…OC interactions. 












Table 5. 1. Pattern of cis (c) and trans (t) amide bonds configuration in the crystal 
structures of cyclic peptoids.  
     CH…OC hydrogen bonds involve the methylene hydrogen 
from one molecule’s peptoid backbone and the carbonyl oxygen from 
another neighboring molecule. Such interactions support side-by-
side and face-to-face arrangement that provides a columnar 
assembly of the macrocyclic compounds. For example, cyclotetra-N-
benzyloxyethyl glycine (5.1, Figure 5.1) forms columns thanks to the 
interaction between two methylene hydrogen atoms and two trans 
carbonyl oxygen atoms (A, Figure 5.1).17  
Benzyloxyethyl side chains, extending horizontally with 
respect to the plane occupied by the cyclopeptoid, contribute to the 
overall assembly. CHar…O and CH2…pi interactions stabilize the 
staking of the macrocycles, while CH2…OC and CHar…pi bonding 
provide side-by-side intertubular contacts. 
A comparison of 5.1 (Figure 5.1) with cyclotetrasarcosyl17 
5.2 (Figure 5.2) clearly highlights the importance of side chains and 
how they can influence the assembly. Indeed, while benzyloxyethyl 
side chains promotes a columnar arrangement, methyl side chains 
hampers such disposition of the macrocycles. 
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Figure 5. 1. Cyclotetra-N-benzyloxyethyl glycine (5.1) and its tubular assembly (A). 
Benzyloxyethyl side chains are omitted for clarity. 
Crystal structure of 5.2 shows weak CH…OC hydrogen 
bonding involving the methyl hydrogen atoms from the side chains 
and the oxygen of the carbonyl groups (A, Figure 5.2). Such 
interactions bring the two molecules perpendicularly to each other 
and so determine a T-shape arrangement. T-shape arrangement 
often occurs with methyl and benzyl side chains, which can compete 
with CH…OC inter-annular hydrogen bonds.  
On the other hand, methoxyethyl side chains showed to 
promote a different arrangement, acting as pillars in the cyclohexa-
N-methoxyethyl glycine (1.6, Figure 1.7).19d The long side chains, 
protruding vertically with respect to the plane defined by the 
macrocycle, provide the CH2…OC interactions with the backbone 
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carbonyl groups and with the other side chains that guarantee the 
columnar arrangement.  
 
 
Figure 5. 2. Cyclotetrasarcosyl (5.2) and the T-shaped arrangement of two adjacent 
molecules in the crystal structure (A). 
Methoxyethyl side chains promote the same assembly also 
in the cyclic octamer 5.3 (Figure 5.3), by means of CHar…OC 
hydrogen bonding and CH3…pi interactions with the aromatic ring 
from the benzylic groups (A, Figure 5.3).10   
 
Figure 5. 3. Side view of crystal packing of cyclo-(Npm-Nme)4 (5.3) and the tubular 
arrangement (A). 
Propargyl side chains have demonstrated to act as 
pillars as well, stabilizing the columnar architecture. The cyclic 
octamer 5.4 (Figure 5.4) stacks by means of CH…pi 
interactions (A, Figure 5.4) and methoxyehtyl side chains 
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provide additional interactions binding cyclopeptoids 
molecules side-by-side.111  Figure 5.4B is the top view of the 
crystal packing and shows the inner cavity in which water 
molecules are located. They do not have any structural role, 
since dehydrated crystals yielded the same arrangement via 
single crystal to single crystal transformation. Just empty 
hollows were left once water had gone.    
 
Figure 5. 4. Cyclo-(Npa-Nme-Nph-Nph)2 (5.4) and its tubular assembly (A). The view 
from the top shows water moleculers into the hollow (B).  
Those last examples not only make clear the function of side 
chains but also the influence of the ring size. Bigger the macrocycle, 
higher is the probability to set a columnar arrangement. Smaller 
rings, on the other hand, favor T-shape interactions. Finally, it is quite 
usual to find the crystallization solvent included in the structure. 
Sometimes this has a structural role and contribute to the asset of 
the solid state, not so often this is uninfluential and can be safely 
removed without damaging the crystal.111  
5.1.2. Hirshfeld surface 
Between the 80s and the 90s, Desiraju claimed the role of 
crystal engineering and indicated to scientists the direction to 
achieve a fruitful molecular crystal analyzing.112   
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Crystal engineering aims to design novel materials with 
specific chemical and physical properties. As we have previously 
underlined, this is possible looking closely at the crystal structures, 
visualizing the molecule in its entirety and trying to unveil all the 
intermolecular interactions that simultaneously contribute to the 
packing.  
An overall view of the factors that interplay in the solid-state 
assembly should be desirable, and the quantification of each 
interaction would be extremely helpful in comparing similar crystal 
structures.  
To follow such guidelines, Spackman borrowed the 
“stockholder partitioning” scheme from Hirshfeld (1977),113 and 
generated surfaces that he named after him in his honor. Hirshfeld 
surfaces show the partitioning of molecular crystals electron 
densities into molecular fragments, providing an immediate 
visualization of the molecular packing.114 Mathematically, such 
surfaces can be defined as a weighting function wA(r) for a particular 
molecule A in a crystal:  
𝑤𝐴(𝒓) =  ∑ 𝜌𝑖
𝑎𝑡
𝑖 𝜖 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒 𝐴 (𝒓) / ∑ 𝜌𝑖
𝑎𝑡
𝑖 𝜖 𝑐𝑟𝑦𝑠𝑡𝑎𝑙 (𝒓) 
=  𝜌𝑝𝑟𝑜𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒 (𝒓)/𝜌𝑝𝑟𝑜𝑐𝑟𝑦𝑠𝑡𝑎𝑙 (𝒓) 
ρiat (r) are spherically-averaged electron densities of the 
various atoms i in the molecule A. The numerator is a sum over the 
electron densities of the atomic fragments in the molecule A (called 
promolecule) and the denominator is an analogous sum over the 
crystal (called procrystal). Since the atomic electron densities are 
sharply peaked near the nuclei and decay exponentially, wA(r) is a 
continuous function with 0<wA(r)<1, being 1.0 at molecule A, and 
zero at distances far from it. This can be plotted, for example, for a 
 119 
benzene molecule in the crystal (Figure 5.5). The contours of wA(r) 
surround the molecule and are closely spaced in the proximity of the 
van der Waals surface.  
 
Figure 5. 5. Contours of wA(r) surrounding a benzene molecule in the crystal. 
The isosurface defined by wA(r) = 0.5 is the Hirshfeld surface 
and envelops the molecule, defining the volume of space where the 
promolecule is in the maximum proximity of neighboring molecules. 
Furthermore, because of the nature of the weight function, the 
volumes never overlap. 
The Hirshfeld surface of a given compound can be 
generated by the program CrystalExplorer,115 once the crystal 
structure has been solved and well-characterized and any disorder 
present had been modeled.  
The properties of the Hirshfeld surface are a series of 
functions that embody information of intermolecular contacts. They 
are summarized in Table 5.2.114b  
As any other surface, Hirshfeld surface has two local 
principal curvature, k1 and k2, that define shape index S and 
curvedness C. Shape index on the Hirshfeld surface identifies 
complementary hollows and bumps where two molecular surfaces 
touch one another, displaying them in red and blue respectively (A, 
Figure 5.6). Curvedness indicates flat regions and positive large 
curvature as green areas separated by dark blue edges (B, Figure 
 120 
5.6).  S and C are useful to identify the packing mode and how 
neighboring molecules interact. 
Function Symbol and 
definition 
Mapping range 
distance from a 
point on the surface 
to the nearest 
nucleus outside 
the surface 
de red (short 
distances) through 
green to blue (long 
distances) 
distance from a 
point on the surface 
to the nearest 
nucleus inside the 
surface 
di red (short 
distances) through 
green to blue (long 
distances) 
shape index, S, a 
measure of ‘‘which’’ 
shape, defined in 
terms of principal 







) -1.0 (concave) 
through 0.0 
(minimal surface) to 
+1.0 (convex) 
curvedness, C, a 
measure of ‘‘how 
much’’ shape 
defined in terms of 
principal curvatures 










-4.0 (flat) through 
0.0 (unit sphere) to 
+0.4 (singular) 
normalized contact 
distance, defined in 
terms of de, di and 











𝒗𝒅 𝑾  
red (distances 
shorter than sum of 
vdW radii) through 
white to blue 
(distances longer 
than sum of vdW 
radii) 




Figure 5. 6. Front view of the Hirshfeld surface for 2-chloro-4-nitrobenzoic acid, 
mapped with shape index (A) and curvedness (B). 
Functions of distance, de and di represent the distance from 
a point on the surface to the nearest nucleus outside and inside the 
surface respectively. They can be plotted one versus the other 
providing a 2D map called Hirshfeld fingerprints (A and B, Figure 
5.7). The color of the pixel indicates the density of contacts; ranging 
from blue through green to red, we pass from few to many points. 
Moreover, this is a useful tool to display long-distance and short-
distance contacts. The appearance of a pair of spikes at the bottom 
left of the plot (short di and de, the upper one associated with the 
donor atom, the lower one with the acceptor), and the pattern of 
diffuse points in between these spikes occurs only for cyclic 
hydrogen bonds (A, Figure 5.7). An interesting feature is also the 
red region near the center of the map that shows the π-π staking 
between the planar rings (B, Figure 5.7).  
A combination of both de and di, each normalized by the vdW 
radius of the specific atoms involved in the close contact to the 
surface, generates the contact distance dnorm. 
The advantage of introducing this function is to visualize 
close contacts to large atoms like Br or I, as well as contacts to H, C 




Figure 5. 7. Hirshfeld fingerprint for 2-chloro-4-nitrobenzoic acid showing 
hydrogen bonding (A) and planar staking interactions (B). 
Figure 5.8 shows dnorm mapped on the Hirshfeld surface of 
2-chloro-4-nitrobenzoic acid. The red spots on the large blue surface 
show contacts shorter than the vdW separation. 
 
Figure 5. 8. dnorm mapped on the Hirshfeld surface of 2-chloro-4-nitrobenzoic acid. 
The introduction of Hirshfeld surfaces and Hirshfeld 
fingerprints is one more tool in the kit of crystallographers, 
fundamental to complete the structural analysis of a molecule at the 
solid state. Making use of the mapping and interpreting their meaning 
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is of primary importance in describing the packing and considering 
simultaneously all the interactions that contribute to the assembly.  
Bearing those lessons in mind, we exploited the potential of 
the Hirshfeld method and we provided a detailed analysis of our 
cyclic peptoids of interest, emphasizing the contacts that arise 
according to the side chains installed. 
5.2 AIM OF THE WORK: SYNTHESIS AND 
CHARACTERIZATION OF A LIBRARY OF 
CYCLIC HEXAPEPTOIDS WITH 
METHOXYETHYL AND PROPARGYL SIDE 
CHAINS 
5.2.1 Introduction  
Cyclic peptoids proved to assembly at the solid state in a 
very elegant fashion. The examples described in the literature also 
demonstrated that a certain degree of predictability emerges when 
peculiar side chains are introduced into the peptoidic backbone.   
Comparing the crystal structures of the cyclic hexamer of N-
methoxyethyl glycine19d 1.6 (A, Figure 5.9) with the octamers cyclo-
(Npm-Nme)410 5.3 (B, Figure 5.9) and cyclo-(Npa-Nme-Nph-Nph)2111 
5.4 (C, Figure 5.9), it is possible to highlight the role of the 
methoxyehtyl and propargyl side chains in the packing. Methoxyethyl 
side chains in 1.6 and 5.3 and propargyl side chains in 5.4 stretch 
vertically with respect to the plane occupied by the macrocycle and 
exert a pillar function in the columnar arrangement. In addition, for 
1.6 and 5.4, methoxyehtyl side chains, extending horizontally, 
provide side-by-side interactions that promote the intertubular 
contacts.     
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Figure 5. 9. Crystal packing of 1.6 (A), 5.3 (B) and 5.4 (C). 
 Remarkably, in the presence of propargyl side chains, the 
methoxyethyl ones give up to their pillar role and assume another 
structural function. 
Fascinated and intrigued by the role-playing game of those 
two diverse side chains in the cyclopeptoids, we decided to 
synthesize new compounds to study their influence on the solid-state 
assembly. Furthermore, applying the Hirshfeld surface method and 
the Hirshfeld fingerprint analysis, we aimed to highlight and quantify 
the different supramolecular interactions of those side chains. This 
information is an important concept of practical use in crystal 
engineering and indicates the best direction to follow in the crystal 
design.116 
We started investigating the complementary partner of 1.6, 
which is the cyclic hexamer of N-propargyl glycine (4.19, Figure 
5.10). Afterwards, we thought to mix up the methoxyethyl and 
propargyl side chains, and we considered the symmetric cyclic 
hexamer with two propargyl and four methoxyethyl side chains (4.16, 
Figure 5.10). Encouraged by the interesting properties it showed at 
the solid-state, we synthesized a library of analogues. We started 
from 4.16, progressively swapping the positions of one methoxyethyl 
with the adjacent propargyl side chain (5.5 and 5.6, Figure 5.10). 
Then, we synthesized its “specular” compound, featuring 4 propargyl 
and 2 methoxyethyl side chains (5.7, Figure 5.10), and afterwards 
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we moved one methoxyethyl side chain next to the other one (5.8, 
Figure 5.10). Finally, we ended up with the mono methoxyethylated 
cyclic hexapeptoid analogue (5.9, Figure 5.10). 
 
Figure 5. 10. Library of cyclic hexapeptoids 4.16, 4.19 and 5.5-5.9. 
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5.2.2 Results and Discussions 
The synthesis of the linear precursors of 4.16 and 4.19 has 
been described in the Scheme 4.1, followed by the explanation of 
the cyclization conditions. 
Analogously, the linear precursors of 5.5-5.9 were prepared 
on solid phase by means of the sub monomeric approach (Scheme 
5.1).   
Once the solid-phase synthesis of the desired linear 
oligomers was accomplished, 5.15-5.19 were detached from the acid 
labile 2-CTC resin under mild acidic conditions. They were collected 
in good yield, ranging from 59% to 97%, and in good purity, as 
evaluated via HPLC-PDA analysis. The crude products were rinsed 
with toluene and underwent to the macrocyclization reaction without 
further purification.  
Since HATU was used as coupling agent in the previous 
head-to-tail condensations showing good performances, this was 
once again of assistance for the preparation of the cyclic compounds 
5.5-5.9. Hence, the linear peptoid precursors 5.15-5.19 were 
dissolved in dry DMF and slowly add, by means of a syringe pump105, 
to a solution of HATU (4.0 equiv.) and DIPEA (6.2 equiv.) in dry DMF 
under high dilution conditions (3.0 × 10−3 M) and inert atmosphere. 
The macrocyclization proceeded smoothly to give the desired cyclic 
peptoids. After purification, compounds 5.5-5.9 were recovered in 
56%, 70%, 37%, 57%, 86%, overall yield respectively. 
With the library of cyclic peptoids in our hands, we were 
ready to explore their solid-state assembly properties.  
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Scheme 5. 1. Sub-monomer approach for the synthesis of precursors of cyclopeptoids 
5.5-5.9: (a) DIPEA, in dry DCM, 1.5h; (b) propargylamine or methoxyethyl amine when 
needed (10 equiv) in dry DMF, 30 min; (c) bromoacetic acid/DIC (10:11 equiv.) in dry 
DMF, 40 min; (d) HFIP 20% in dry DCM (2 x 30 min). 
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The all propargylated cyclohexapeptoid 4.19 (Figure 5.10) 
was crystallized by slow evaporation in hot acetonitrile (50°C) cooling 
down until room temperature.117  
Colorless prism-shaped crystals were obtained, whose 
dimension, smaller than 0.1 mm, required synchrotron X-rays. 
European synchrotron radiation facility (ESRF) provided high-quality 
X-ray diffraction data from single crystal analysis and a high-
resolution crystal structure was obtained (Figure 5.11).  
Figure 5. 11. Crystal structure of cyclic peptoid hexamer 4.19 showing: (A) the 
directions of the side chains and the presence of a molecule of acetonitrile and (B) the 
backbone. c - cis, t – trans. 
The unit cell contains two macrocycles with the same 
conformation and four molecules of acetonitrile. As all the other cyclic 
hexapeptoids described,14 4.19 has an overall rectangular form with 
four cis amide bonds at the turn and two trans amide bonds along 
the skeleton on the opposite sides. 
Figure 5.12 shows the packing of 4.19 along the cell axis. It 
is interesting to note that the all propargylated cyclic hexapeptoid, 
unlike the all methoxyethylated one, has two side chains extending 
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vertically from the backbone on the opposite face and providing the 
columnar arrangement. 
 
Figure 5. 12. Packing of 4.19 along the cell axis a (A), b (B) and c (C) 
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The other four protrude horizontally with respect the plane 
occupied by the macrocycle and enable lateral packing. Two of them, 
at the opposite corners of the macrocycle, interact with other two side 
chains from the adjacent macrocycle, with is rotated by 180° with res 
respect to the former and translated by a/2. The other two side 
chains, not only interact with the side chains from the neighbor 
molecule, but can also interdigitate in the cavity created by two 
contiguous macrocycles in the column. Finally, rows of cyclic 
peptoids are separated by rows of acetonitrile molecules, creating a 
layered structure made by cyclic peptoids alternating with guest 
molecules.  
The calculation of dnorm mapped on the Hirshfeld surface, 
provides a clearer image of the macrocycle 4.19 and shows the 
interactions with the surroundings (Figure 5.13). It is possible to 
immediately appreciate the volume and the shape of 4.19, as well as 
the short-distance contacts (shorter than the sum of vdW radii) 
depicted as red spots on the surface. Those correspond to the 
CH…OC contacts between the backbone carbonyl oxygen atoms and 
the propargyl side chain methine hydrogen atoms. Such contribution 
is quite important to the crystal packing and counts just shy of the 
H…H contacts between the side chains, as the Hirshfeld fingerprint 
fragmentations reveal.   
The  Hirshfeld  fingerprint  analysis  reveals  the significant 
contribution of C…H contacts between the side chains (32,1%) apart 
from O…H (20.7%) and H…H contacts (34,9%) (Figure 5.14). 
Furthermore, it enables a direct comparison with the all-
methoxyethylated analogue 1.6.14 In this case, the major contribution 
derives from H…H contacts (67.5%), which appear in a central green-
blue wide spike that also indicates the closest ones at 2.15 Å, 
corresponding to contacts among methylene hydrogen atoms of 
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adjacent columns. In addition, O…H contacts significantly contribute 
to the total interactions in the crystal (30.3%), whereas C…H poorly 
participate to the packing (1.3%). Finally, it is worth noting the 
compactness of the relative packing. The fingerprint of the 
macrocycle 4.19 extends up to 2.6 Å, the one of 1.6 stays in the limit 
of 2.4 Å, indicating that this last has a more compact packing, as  
result of the major contribution from the stronger O…H and H…H 
contacts. 
 
Figure 5. 13. Normalized contact distances dnorm mapped on the Hirshfeld 
surface of macrocycle 4.19.  
Having exchanged the methoxyethyl side chains with the 
propargyl ones has unaffected the columnar assembly at the solid 
state, even though the mode of forming the column has varied. The 
macrocycles 4.19 pile up thanks to two vertical side chains, whereas 
four of them provide the side-by-side assembly. The packing results 
less compact and acetonitrile, which is the crystallization solvent, can 
be host in the structure.   
This interesting result prompted us to further investigate the 
role of methoxyethyl and propargyl side chains in cyclic 
hexapeptoids. We were wondering what could have happened 
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mixing the typology of side chains in the same macrocycle, and to 
satisfy our curiosity we considered the compound 4.16.117-118 
 
Figure 5. 14. Comparison of full fingerprint plots and decomposed fingerprint plots 
into O⋯H, C⋯H and H⋯H intermolecular interactions respectively for cyclo-(Npa)6 
(4.19) acetonitrile solvate, and cyclo-(Nme)6 (1.6). 
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Cyclo-(Npa-Nme2)2 was crystallized by slow evaporation in 
hot acetonitrile (50°C) cooling down until room temperature. 
Transparent crystals were obtained and underwent X-rays analysis 
to yield the structure showed in Figure 5.15. Also in this case, the 
macrocycle presents an overall rectangular shape with the amide 
bonds configuration pattern cctcct. The cis geometries are in the 
correspondence of two methoxyethyl and two propargyl side chain 
and accommodate the backbone turn. They are situated on the 
opposing face of the macrocycle, according to the inversion center 
that is in the molecule.  
The unit cell of the crystal is composed of one macrocycle 
and four molecules of acetonitrile (Figure 5.16). 
 
Figure 5. 15. Crystal structure of cyclic peptoid hexamer 4.16 showing: (A) the 
directions of the side chains and (B) the backbone. c - cis, t – trans. 
For each cyclic peptoid molecule, the more apolar propargyl 
groups, stretching up vertically, provide the columnar arrangement. 
This is stabilized by the CH…OC hydrogen bonding between the 
alkynyl hydrogen atoms and the carbonyl oxygen atoms from the 
macrocycles above and below. The more hydrophilic methoxyethyl 
side groups on the cis bonds extends horizontally with respect to the 
plane occupied by the macrocycle. Protruding laterally, they enable 
lateral packing between rows of cyclic peptoids through side-by-side 
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CH…OC interactions. The vertical methoxyethyl side chains point up 
and down in the cavity between two contiguous macrocycles in the 
column and interact with molecules of acetonitrile. The solvent also 
interacts with the peptoidic backbone and other molecules of 
acetonitrile. Figure 5.16A shows the packing along the a axis and 
highlights rows of cyclic peptoids running in parallel, and molecules 
of acetonitrile that insert between them.  
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Figure 5. 16. Packing of 4.16 along the cell axis a (A),  b (B) and c (C) showing 
hydrogen bonding.  
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It is interesting to note that, as for compound 5.4,111 when 
propargyl side chains come into play, they are the ones who promote 
the columnar assembly via CH…OC hydrogen bonding. The 
presence of the methoxyethyl side chains guarantees intercolumnar 
contacts.  All the interactions can be better displayed on the Hirshfeld 
surface mapping dnorm (Figure 5.17). The red spots highlight the 
short contacts CH…OC within two macrocycles within a column.  
 
Figure 5. 17. Normalized contact distances dnorm mapped on the Hirshfeld surface of 
macrocycle 4.16. 
Those remarks pushed us to move on in such investigation. 
Hence, we decided to consider first the cyclic peptoid 5.7 from the 
library in Figure 5.10, given its analogy with compound 4.16. Indeed, 
with respect to 4.16, it keeps two methoxyethyl groups at opposite 
positions on the cyclic peptoid core but it has a higher content of 
propargyl side chains. 
Compound 5.7 was dissolved in hot acetonitrile and, slowly 
cooling the solution, it crystalized as white blocky and flat-plate 
crystals (Figure 5.18).  
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Figure 5. 18. Crystals of 5.7. View from the microscope.  
X-ray crystallography revealed a solvate structure with 
acetonitrile. The macrocycle has a crystallographic inversion center 
and the cyclic peptoidic backbone once again presents the amide 
bonds sequence cctcct with slightly distorted bond angles (Figure 
5.19). The cis geometries are in the correspondence of the four 
propargyl side chains and accommodate the backbone turn. Two of 
them extend horizontally in the equatorial directions, while the 
methoxyethyl, together with the remaining propargyl side chains, 
point vertically up and down with respect to the macrocycle plane 
(Figure 5.20). The alkynyl hydrogen atoms from the vertical 
propargyl side chains of the cyclic peptoid are involved in hydrogen 
bonding with the carboxyl oxygen atoms from the macrocycles above 
and below. Those CO…HC interactions provide a columnar 
arrangement along the shortest c axis, similarly to the analogue 4.16. 
Furthermore, methoxyethyl side chains do not contribute to CO…HC 
contacts, but rather to CH-pi interactions between both methylene 
and methyl hydrogen atoms, and the vertical propargyl group of the 
next cyclopeptoid molecule. 
 138 
 
Figure 5. 19. Crystal structure of cyclic peptoid hexamer 5.7 showing: (A) the 
directions of the side chains and one molecule of acetonitrile and (B) the backbone. c 
- cis, t – trans. 
The horizontal propargyl side chains enable lateral packing. 
Indeed, the methylene atoms act as H donors towards the triple bond 
pi system from the vertical propargyl side chains of the next 
cyclopeptoid molecules via CH-pi interactions.   
Acetonitrile molecules sit in the space between the 
cyclopeptoids rows, forming channels parallel to the c axis and 
alternating with cyclopeptoids. CH-pi interactions (N≡C…HC) 
between acetonitrile molecules link them together, whereas they 
poorly interact with cyclopeptoid molecules by means of the methyl 
hydrogen atoms to one carbonyl oxygen atom (CO···HC) and to the 




Figure 5. 20. Packing of 5.7 along the cell axis a (A), b (B) and c (C). Crystal structures 
includes acetonitrile molecules.  
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The Hirshfeld surface displaying dnorm for the compound 5.7 
reveals the red spots in the correspondence of the short CH…CO 
interactions, involving the vertical propargyl side chains and the 
carbonyl oxygen atom (Figure 5.21).  
The Hirshfeld fingerprint analysis provides the quantitative 
contribution of each type of interaction to the packing and enable for 
a comparison between the two parental structures from 4.16 and 5.9. 
Both the structures are acetonitrile solvate, but the first shows a more 
compact packing than the second one, as evidenced by its fingerprint 
extending in the limit of 2.3 Å. Indeed, it has a higher frequency of 
short-distance contacts that are indicated by the light blue-colored 
pixel in the fingerprint breakdown for H…H interactions. Those arise 
mainly from the methoxyethyl side chains interdigitating within the 
columns of cyclic peptoids. 




Figure 5. 22. Hirshfeld fingerprints for compound 4.16 and 5.9.  
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Remarkably, in both cases we evidence the same 
contribution from O…C hydrogen bonding, visible as two spikes in the 
fingerprint plot and counting for 22.8% and 24.8%. This confirms that 
the shortest interactions, fundamental for the columnar assembly, 
are a common feature in this compounds and can be addressed just 
to two propargyl side chains pointing up and down with respect to the 
plane of the macrocycle. C…H interactions poorly contribute to the 
crystal packing. They can be ascribed to the CH-pi interactions with 
the triple bond from the propargyl side chains and appear as lateral 
wings in the fingerprint breakdown. Having two more propargyl 
groups in the compound 5.9 is evidenced also by the higher 
percentage of such contacts in the structure (24.6% vs 14.8%). 
5.3 CONCLUSION 
Cyclic peptoids have been demonstrated to be extremely 
interesting to study by means of X-ray crystallography.  
The flexibility of the peptoidic backbone renders the role of 
the side chains of primary importance in defining cyclic peptoid 
structure at the solid state.  
Our aim was to gain a deep understating of side chains 
structural function, in order to get control over the conformation of 
such peptidomimetics and achieving the desired folding properties. 
To pursue our interest, we synthesized a library of cyclic 
hexapeptoids comprising methoxyethyl and propargyl side chains. 
We varied their relative content and positioning along the peptoidic 
backbone to shed light on their respective role in the assembly. 
From comparison X-ray crystal structures and making use of 
the Hirshfeld surfaces and fingerprints, we could grasp cyclic 
peptoids structural features. 
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Both of the side chains tend to promote a columnar 
assembly, in which the macrocycles stack on the top of each other. 
The columns form rows, which are alternated with molecules of 
acetonitrile entering into the structure.  
Independently from the total number of propargyl side chains 
in the cyclic hexapeptoids, just two of them are involved in the vertical 
assembly that gives rise to the columnar assembly. Two 
methoxyethyl side chains, on the other hand, extend horizontally in 
the plane of the macrocycle and provide side-by-side interactions, 
which stabilize the intercolumnar assembly. The last two side chains 
are of assistance, and can occupy either a vertical either a horizontal 
orientation. Depending on them and their interactions, the packing 
can result more or less compact. 
This result is extremely exciting and opens up new frontiers 
of investigation. Being able to manipulate the assistant side chains 
orientation within the same crystal would lead to materials featured 
by dynamicity. We managed to control the backbone conformation 
and side chains orientation creating columnar assemblies. Now it is 
time to add a further degree of control to in the search of new and 











6.1     CONCLUDING REMARKS 
Our journey into the realm of peptoids ends up here. 
Chasing new structures and properties, we contributed to the 
development of novel compounds that displayed interesting features 
and potential applications.  
We managed to synthesize a new class of “arylopeptoids”, 
by the insertion of an aromatic ring and a methylene unit into the 
peptoidic backbone (Chapter 2). Tested as ion transporters, the 
cyclic tetramer resulted to be too large to selective accommodate any 
ion, whereas the cyclic trimer is slightly active towards the mid-size 
alkaline cations (Na+, K+, Rb+), preferably transported with the iodide 
counterion, showing a symport carrier mechanism. 
Exploiting the ion complexation properties of cyclic peptoids, 
we synthesized two hexamers with three carboxyethyl side chains 
each, to promote the formation of Gd3+-complex as MRI-probes 
(Chapter 3). Binding studies revealed the importance of the structural 
flexibility of the host on its complexation ability. When carboxyethyl 
side chains are alternated with methoxyethyl side chains, the cyclic 
peptoid coordinates Gd3+ and displays good relaxometric properties, 
but if proline residues are introduced, the structure results too rigid 
to complex.     
The versatility of peptoids enable us to explore the field of 
glycoscience as well. A library of cyclic peptoids, ranging from 4-mer 
to 16-mer, with appended propargyl groups was synthesized and 
underwent click chemistry DNJ azido-derivatives (Chapter 4). This is 
the first example of cyclopeptoid-based iminosugar click-clusters, 
that showed acitivity towards α-mannosidases inhibition and the 
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highest multivalent effect in the correspondence of the 36-valent 
ligand. 
This impressive outcome is the result of the modular 
synthetic approach of peptoids that enables for the insertion of an 
unlimited numbers and types of side chains.  
Taking advantage of such feature, we synthesized a library 
of cyclic hexapeptoids with methoxyethyl and propargyl side chains, 
varying in the relative content and positions (Chapter 5). Studying 
their role in the solid-state assembly of cyclic hexapeptoids, they 
showed to promote a columnar arrangement in which the propargyl 
groups are the pillars and the methoxyethyl chains provide 
intercolumnar interactions and side-by-side contacts. 
The vast properties of peptoids and their versatility of use 
clearly emerge within the chapters of the thesis.  
The results obtained contribute to a better understanding of 
their structural features, providing tools to finely tune their properties 
in order to further expand their potential applications. Moreover, new 
and challenging questions arose along with these studies. Finding 
the right answer will be the task of the future science to broaden the 



































7.1     GENERAL PROCEDURES 
Starting materials and reagents purchased from commercial 
suppliers were generally used without purification unless otherwise 
mentioned. All the linear peptoids were synthesized in solid phase. 
Solid phase syntheses were undertaken manually in polypropylene 
syringes fitted with two polyethylene filter discs. All solvents and 
soluble reagents were removed by suction. Washings between 
coupling and displacement steps were carried out with DMF (3 × 1 
min) and DCM (3 × 1 min) using 4 mL solvent/g resin for each wash. 
The coupling efficiency was followed by chloranil colorimetric test. 
Each treatment was carried out in orbital shakers. Reaction 
temperatures were measured externally; reactions were monitored 
by TLC on Merck silica gel plates (0.25 mm) and visualized by UV 
light or by spraying with ninhydrin solution. Flash chromatography 
was performed on Merck silica gel 60 (particle size: 0.040-0.063 mm) 
and the solvents employed were of analytical grade. HPLC analysis 
were performed on a JASCO LC-NET II/ADC and a Thermo 
Scientific instruments. The first one comprises a JASCO Model PU-
2089 Plus Pump and a JASCO MD-2010 Plus UV-vis multiple 
wavelength detector set at 220 nm, the second one a Finnigan 
Surveyor LC Pump Plus and a Finnigan Surveyor UV/Vis Plus 
Detector set at 220 nm. The columns used were C18 reversed-phase 
analytical and semipreparative columns (Waters, Bondapak, 10 μ m, 
125 Å, 3.9 mm × 300 mm and 7.8 × 300 mm, respectively) run with 
linear gradients of ACN (0.1% TFA) into H2O (0.1% TFA) over 30 
min, at a flow rate of 1.0 mL/min for the analytical runs and 2.0 
mL/min for the semipreparative ones. High resolution ESI-MS 
spectra were recorded on a Q-Star Applied Biosystem mass 
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spectrometer. ESI-MS analysis in positive ion mode was performed 
using a Finnigan LCQ Deca ion trap mass spectrometer 
(ThermoFinnigan, San Josè, CA, USA) and the mass spectra were 
acquired and processed using the Xcalibur software provided by 
Thermo Finnigan. Samples were dissolved in 1:1 CH3OH/H2O, 0.1 
% formic acid, and infused in the ESI source by using a syringe 
pump; the flow rate was 5 μl/min. The capillary voltage was set at 4.0 
V, the spray voltage at 5 kV, and the tube lens offset at -40 V. The 
capillary temperature was 220 °C. Data were acquired in MS1 and 
MSn scanning modes. Zoom scan was used in these experiments. 
High-resolution ESI-MS spectra were recorded on a Q-Star Applied 
Biosystem mass spectrometer. 
NMR spectra were recorded on a Bruker DRX 600 (1H at 
600.13 MHz, 13C at 150.90 MHz), Bruker DRX 400 (1H at 400.13 
MHz, 13C at 100.03 MHz), Bruker DRX 300 (1H at 300.1 MHz, 13C at 
75.5 MHz) and Bruker DRX 250 (1H at 250.0 MHz, 13C at 62.5 MHz). 
Chemical shifts (δ) are reported in ppm relative to the residual solvent 
peak (CHCl3, δ = 7.26; 13CDCl3 , δ = 77.0; CD2HCN , δ = 1.94; 
13CD3CN , δ = 1.32) and the multiplicity of each signal is designated 
by the following abbreviations: s, singlet; d, doublet; t, triplet; m, 
multiplet; bs, broad singlet. Coupling constants (J) are quoted in 
Hertz. DEPT and COSY experiments completed  the  full assignment  
of  each  signal. Purity of all products described herein has been 




7.2     COMPOUNDS FROM CHAPTER 2 
7.2.1. Synthesis and Characterization 
Compound 2.24 
 
p-Tolylacetic acid (3.0 g, 20 mmol), N-bromosuccinimide (3.7 
g, 21 mmol) and benzoylperoxide (0.10 g, 0.41 mmol) were dissolved 
in 150 ml of CCl4. The mixture was refluxed for 15 h and filtered hot. 
The filtrate was concentrated in vacuo. The solid was rinsed with cold 
CCl4 to give 2.24 as a white amorphous solid with variable amounts 
of succinimide. Crude 2.24 (1.82 g, 40%, based on 1H NMR analysis) 
underwent the subsequent step without further purification.  
1H NMR: (300 MHz, CDCl3) δ: 7.30 (2H, d, J 8.0 Hz, Ar), 7.27 
(2H, d, J 8.0 Hz, Ar), 4.48 (2H, s, CH2Br), 3.66 (2H, s, CH2COOH).  
ESI-MS (positive, m/z): 229.0 m/z (100, [M + H]+), 231.0 m/z 
(98, [M + H]+). 
Compound 2.25 
 
To a solution of 4-(bromomethyl)phenylacetic acid (1.8 g, 7.9 
mmol) in MeOH (20 mL) was added trimethylsilyl chloride (1.6 mmol, 
0.20 mL), and the mixture was stirred for 5 h. The solvent was 
removed in vacuo and the residue was dissolved in again dissolved 
in MeOH (20 mL) and finally concentrated to give 2.25 as a thick oil 
(1.87 g, 97%).  
1H NMR: (250 MHz, CDCl3) δ:  7.35 (2H, d, J 8.0 Hz, Ar), 
7.25 (2H, d, J 8.0 Hz, Ar), 4.47 (2H, s, CH2-Br), 3.69 (3H, s, 
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COOCH3), 3.62 (2H, s, CH2COOCH3). 13C NMR: (62.5 MHz, CDCl3) 
δ: 171.6 (COOCH3), 136.5 (CCH2Br), 134.2 (CCH2CO), 129.6, (CH 
x 2) 129.2 (CH x 2), 52.0 (COOCH3), 40.7(CH2CO), 33.1 (CH2Br). 
ESI-MS: 243.0 m/z (100, [M + H]+), 245.0 m/z (98, [M + H]+).   
Compound 2.26 
 
To a solution of methoxyethyl amine (3.3 mL, 38 mmol) in 
dry DMF (4.0 mL) was slowly added (20 minutes) a solution of 4-
(bromomethyl)phenylacetate 2.25 (1.9 g, 7.7 mmol) in dry DMF (40 
mL). After the addition, the mixture was stirred for 2 h. The solvent 
was removed in vacuo to give the crude product 2.26 as a pale yellow 
oil (2.40 g, 98%), which was used in the next step without further 
purification.  
1H NMR: (250 MHz, CDCl3) δ: 7.59 (2H, d, J 8.0 Hz, Ar), 7.29 
(2H, d, J 8.0 Hz, Ar), 6.31 (2H, bs, NH2+), 4.20 (2H, s, CCH2-NH2+), 
3.78 (2H, t,  J 6.0 Hz, CH2OCH3), 3.68 (3H, s, COOCH3), 3.60 (2H, 
s, CH2COOH), 3.38 (3H, s, CH2OCH3), 3.07 (2H, t,  J 6.0 Hz, 
CH2NH2+). 13C NMR: (62.5 MHz, CDCl3) δ: 171.8 (COOCH3), 135.3 
(CCH2CO), 130.8 (CH x 2), 130.0 (CH x 2), 129.4 (CCH2NH2+), 
67.5(CH2OCH3), 59.0 (CH2OCH3), 52.1 (COOCH3), 51.0 
(CCH2NH2+), 45.4 (CCH2NH2+CH2), 40.6 (CCH2CO).  




To a stirred solution of crude 2.26 (2.4 g, 7.6 mmol) in 1,4-
dioxane (30 mL) at 0 °C, LiOH•H2O (0.79 g, 19 mmol) in H2O (30 mL) 
was added. After two hours, NaHCO3 (1.3 g, 15 mmol) and  Fmoc-
Cl (2.9 g, 11 mmol) were added. The reaction mixture was stirred 
overnight. Subsequently, KHSO4 was added (until pH=3) and the 
mixture was concentrated in vacuo to remove the excess of 1,4-
dioxane. CH2Cl2 (100 mL) was added to the mixture and the aqueous 
layer was extracted with CH2Cl2 (three times). The combined organic 
phases were dried over MgSO4, filtered and the solvent evaporated 
in vacuo to give a crude material (4.4 g, yellow amorphous oil). The 
residue was purified by flash chromatography (CH2Cl2/CH3OH, from: 
100/0 to 95/05, 0.1% AcOH) to give 2.27 (1.48 g, 44%).  
1H NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 7.85-7.02 
(12H, m, Ar and Ar[Fmoc]), 4.63 (1H, d,  J 6.6 Hz,  CH2[Fmoc] rot. 
a), 4.54-4.47 (3H, m, CH2[Fmoc] rot. b, CCH2N rot. a and rot. b), 4.26 
(0.55H, t, J 6.6 Hz,CH[Fmoc] rot. a),  4.21 (0.45H, t, J 6.6 Hz, 
CH[Fmoc] rot. b),  3.65 (1H, s, CH2-COOH rot. a), 3.63 (1H, s, 
CH2COOH rot. b), 3.52 (0.98H, t,  J 5.3 Hz, CH2OCH3 rot. a), 3.45 
(1.02H, t,  J 5.3 Hz, NCH2 rot. a), 3.32 (2H, m, CH2OCH3  and NCH2 
rot. b), 3.20 (1.54 H, s, OCH3 rot. a), 3.17 (1.46 H, s, OCH3 rot. b). 
13C NMR: (100 MHz, CDCl3, mixture of rotamers) δ: 176.7 (COOH), 
156.5 (CO[Fmoc] rot. a), 156.3 (CO[Fmoc] rot. b), 143.9 (C[Fmoc] 
rot. a), 143.8 (C[Fmoc] rot. b), 141.3 (C[Fmoc] rot. a), 141.2 (C[Fmoc] 
rot. b),  136.6, (C[Ar]), 132.4 (C[Ar] rot. a), 132.3 (C[Ar] rot. b), 130.0 
(CH[Ar] rot. a), 129.9 (CH[Ar] rot. b), 129.4, (CH[Ar]), 127.9 
(CH[Fmoc] rot. a), 127.5 (CH[Fmoc] rot. a), 127.2 (CH[Fmoc] rot. b), 
127.0 (CH[Fmoc] rot. a), 126.9 (CH[Fmoc] rot. b), 124.7 (CH2[Fmoc] 
rot. a), 124.6 (CH2[Fmoc] rot. b), 120.0 (CH[Fmoc] rot. b), 70.8 
(CH2[Fmoc] rot. a), 70.6 (CH2[Fmoc] rot. b), 67.3 (CH2OCH3 rot. a), 
66.9 (CH2OCH3 rot. b), 58.6 (CH2OCH3 rot. a), 58.5 (CH2OCH3 rot. 
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b), 51.0 (CCH2N rot. a), 50.8 (CCH2N rot. b), 47.3 (CH[Fmoc] rot. a), 
47.1 (CH[Fmoc] rot. b), 46.5 (NCH2 rot. a), 45.6 (NCH2 rot. b), 40.6 
(CH2COOH).  
ESI-MS: 446.3 m/z (100, [M + H]+), 468.1 m/z (71, [M + Na]+), 
484.1 m/z (98, [M + K]+). 
Linear peptoids 2.32 and 2.33 
 
Linear oligomeric N-substituted aminomethyl benzylamides 
2.32 and 2.33 were synthesized using a monomer solid-phase 
approach. In a typical synthesis, 2-chlorotrityl chloride resin (α-
dichlorobenzhydryl-polystyrene cross-linked with 1% DVB; 100 – 200 
mesh; 1.5 mmol g-1, 0.10 g, 0.15 mmol) was swollen in dry CH2Cl2 
(1 mL) for 45 min and washed twice with dry DMF (1 mL) and dry 
DCM (1 mL). The first monomer 2.27 was loaded on the resin with 
the following protocol; 0.67 equiv of 2.27 (90.0 mg, 0.20 mmol) and 
4.0 equiv of DIPEA (140 μL, 0.80 mmol) were dissolved in dry CH2Cl2 
(1 mL) and the solution was added onto the resin. The resulting 
mixture was shaken on a shaker platform for 90 min at room 
temperature, and then rinsed with CH2Cl2 (3 × 1 min) and DMF (3 × 
1 min). To terminate the excess of reactive positions, the resin was 
incubated with 1 mL of a capping solution; DCM/MeOH/DIPEA 
(17:2:1) and the reaction was shaken for 15 more min.  Then,  the  
solvents  were  removed  by  suction,  and the resin  washed  with  
DCM  (3  ×  1  min),  DMF  (3  ×  1  min)  and  DCM  (3  ×  1  min). 
The oligomer elongation was realized alternating deprotection and 
coupling steps, until the desired length was accomplished. The 
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Fmoc-deprotection treatment was carried out with Piperidine/DMF 
(1:4) (2 x 1 min, 2 x 5 min) and the subsequent coupling with 3.0 
equiv of 2.27 (133 mg, 0.30 mmol), 3.0 equiv of HATU (110 mg, 0.3 
mmol) and 6.0 equiv of DIPEA (104 µL, 0.60 mmol) in dry DMF (1 h). 
The resulting deprotected linear oligomer was cleaved using a 
HFIP/DCM (1:4) solution (2 x 30 min) and then washed with DCM. 
The resin was then filtered away and the combined filtrates were 
concentrated in vacuo. The final products were dissolved in 50% 
acetonitrile in HPLC grade water and analyzed by RP-HPLC [purity 
>90% for 2.32 and 2.33; conditions: 5 → 100% A in 30 min for the all 
oligomers (A, 0.1% TFA in acetonitrile, B, 0.1% TFA in water); flow: 
1 mL min− 1, 220 nm]. The linear oligomers were subjected to the 
cyclization reaction without further purification. 
2.32: 60% (crude residue); ES-MS: 634.3 m/z [M + H]+ ; tR : 
11.9 min. 
2.33: 60% (crude residue); ES-MS: 839.4 m/z [M + H]+ ; tR : 
13.6 min. 
Compounds 2.19 and 2.20 
A solution of the linear oligomers 2.32 and 2.33 (0.060 
mmol), previously co-evaporated three times with toluene, was 
prepared under nitrogen in dry DMF (4 mL). The mixture was 
dropwise added to a stirred solution of HATU (90 mg, 0.24 mmol) 
and DIPEA (64 μL, 0.37 mmol) in dry DMF (16 mL) by a syringe pump 
in 12 h, at room temperature in anhydrous atmosphere. After 24 h 
the resulting mixture was concentrated in vacuo, diluted with CH2Cl2 
(50 mL), and washed with a solution of HCl (1.0 M, 25 mL). The water 
layer was further extracted with CH2Cl2 (2 × 50 mL) and the 
combined organic phases were washed with water (100 mL), dried 
over anhydrous MgSO4, filtered and concentrated in vacuo. The 
cyclic products were dissolved in 50% acetonitrile and HPLC grade 
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water and analyzed by RP-HPLC [purity >95% for oligomers 2.19 
and 2.20, conditions: 5% – 100% A in 30 min for the two 
cyclopeptoids (A, 0.1% TFA in acetonitrile, B, 0.1% TFA in water); 
flow: 1 mL min− 1, 220 nm]. The crude residue 2.19 was purified by 
flash chromatography on a C18 silica gel, conditions: 20% – 60% A 
[(A, 0.1% TFA in acetonitrile, B, 0.1% TFA in water); while 2.20 by 
precipitation in ethyl acetate.  
 
Compound 1.19: 25%; pale yellow amorphous solid; tR: 13.3 
min (see general information for the conditions). 
1H NMR: (600 MHz, CD3CN, mixture of rotamers) δ : 7.31 
(1H, d, J 7.4 Hz, Ar), 7.28 (9H, m, Ar), 6.90 (2H, d, J 7.4 Hz, Ar), 
4.76-4.53 (6H, m, ArCH2N), 3.84-3.32 (18H, m, COCH2Ar, 
NCH2CH2OCH3, NCH2CH2OCH3), 3.29-3.20 (9H,mm, 
NCH2CH2OCH3). 13C NMR: (150 MHz, CD3CN, mixture of rotamers, 
broad signals) δ: 172.8, 172.6, 172.5, 172.3, 172.1, 138.1, 137.7, 
137.6, 137.4, 137.3, 137.0, 136.9, 136.2, 135.8, 135.6, 135.4, 130.5, 
130.3, 130.2, 129.9, 129.8, 129.5, 129.4, 129.1, 128.9, 128.8, 128.7, 
128.5, 127.6, 127.4, 127.3, 127.1, 71.7, 71.4, 71.2, 71.0, 70.8, 70.7, 
70.5, 70.4, 70.1, 70.0, 59.1, 59.0, 58.9, 58.8, 58.6, 58.5, 49.2, 49.0, 
48.9, 48.7, 48.6, 48.5, 48.4, 48.3, 48.0, 47.9, 47.8, 41.2, 41.0, 40.8, 
40.7, 40.6, 40.5, 40.4, 40.3, 30.7, 30.6, 30.3, 30.1. 
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ESI-MS: 616.6 m/z (100, [M + H]+), 638.7 m/z (93, [M + Na]+) 
and 654.6 m/z (20, [M + K]+). 
ESI-HR MS: [M + H]+ m/z 616.3356 (calcd for C36H46N3O6 
616.3387). 
 
Compound 2.20: 16%; white amorphous solid; tR: 14.7 min 
(see general information for the conditions). 
1H NMR: (600 MHz, CDCl3 , mixture of rotamers) δ: 7.33-
6.70 (16H, m, Ar), 4.57-3.06 (44H, m, ArCH2N, COCH2Ar, 
NCH2CH2OCH3, NCH2CH2OCH3, NCH2CH2OCH3). 13C-NMR: (150 
MHz, CDCl3, mixture of rotamers, broad signals) δ : 171.8, 171.5, 
136.1, 135.5, 134.9, 134.7, 134.6, 134.4, 134.1, 133.9, 129.9, 129.6, 
129.4, 129.3, 129.2, 129.1, 129.0, 128.6, 128.5, 128.4, 128.3, 128.1, 
128.0, 127.9, 127.8, 127.7, 127.6, 126.8, 126.7, 126.5, 126.4, 126.3, 
71.0, 70.4, 60.4, 59.2, 58.8, 52.8, 52.4, 52.2, 48.4, 48.0, 47.8, 47.5, 
47.0, 46.7, 46.4, 46.1, 46.0, 45.7, 40.8, 40.5, 40.3, 40.2, 40.0. 
ESI-MS: 821.4 m/z (39, [M + H]+), and 430.3 (100, [M + H + 
K]2+). 
ESI-HR MS: [M + H]+ m/z 821.4530 (calcd for C48H61N4O8 
821.4489); 
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7.3     COMPOUNDS FROM CHAPTER 3 
7.3.1. Synthesis and Characterization 
Compound 3.14 
 
To a stirred solution of the commercially available tert-butyl 
3-aminopropanoate  hydrochloride  3.13  (3.00  g,  16.5  mmol)  and 
DIPEA  (5.74  mL,  33.0  mmol)  in  DMF  dry  (15.0  mL),  ethyl 
bromoacetate  (0.915  mL,  8.25  mmol) was slowly added. The 
reaction mixture was stirred overnight, concentrated in vacuo to 
remove  the  excess  of  DMF,  dissolved  in  CH2Cl2 (100 mL) and  
washed  with  brine  solution.  The  aqueous  layer  was extracted  
three  times  with  CH2Cl2.  The  combined  organic phases  were  
dried  over  MgSO4,  filtered  and  the  solvent evaporated in vacuo 
to give crude 3.14 (2.4 g, yellow amorphous solid),  which  was  used  
in  the  next  step  without  further purification.    
1H  NMR:  (300.1  MHz,  CDCl 3 )  δ:  4.27  (2H,  q,  J  7.1 
Hz, CH3CH2), 3.65  (2H,  s,  OCCH2NH), 3.09  (2H,  t,  J  7.0  Hz, 
NHCH2CH2CO), 2.74 (2H, t, J 7.0  Hz,  NHCH2CH2CO), 1.47 (9H, s, 
C(CH3)3), 1.31 (3H, t, J 7.1 Hz, CH3CH2);  13C NMR: (75.5 MHz, CDCl 
3 ) δ: 170.8 (COOC(CH3)3), 168.9 (COOCH2CH3), 81.4 (C(CH3)3), 
61.7 (CH2CH3), 49.1 (NHCH2CO), 44.3 (NHCH2CH2), 33.5 






Method a. Synthesis from 3.14 
To a stirred solution of crude 3.14 (2.40 g) in 1,4-dioxane 
(30.0 mL) at 0 °C, LiOH•H2O (0.932 g, 22.2 mmol) in H2O (30.0 mL) 
was added.  After  two  hours,  NaHCO3   (1.52  g,  18.1  mmol)  and 
Fmoc-Cl (3.20 g, 10.4 mmol) were added. The reaction mixture was 
stirred overnight. Subsequently,  KHSO4 was  added  (until pH=3)  
and  the mixture was concentrated in vacuo to remove the excess of 
1,4-dioxane and dissolved in CH2Cl2 (100 mL). The  aqueous  layer  
was  extracted  with  CH2Cl2   (three  times). The combined organic 
phases were dried over MgSO4, filtered and  the  solvent  evaporated  
in  vacuo  to  give  a  crude  material (4.00  g,  yellow  amorphous  
solid).  The  residue  was  purified  by flash  chromatography  (CH2Cl2 
/CH3OH,  from:  100/0  to  98/02, 0.1%  AcOH)  to  give  3.15 (2.28 
g, 65% three steps). 
Method b. Synthesis from 3.19 
To a stirred solution of crude 3.19 (5.32 g) in 1,4-dioxane 
(82.0 mL) at 0 °C, LiOH•H2O (2.56 g, 61.1 mmol) in H2O (82.0 mL) 
was added.  After  two  hours,  NaHCO3   (4.5 g, 53.7 mmol)  and 
Fmoc-Cl (9.5 g, 36.6 mmol) were added. The reaction mixture was 
stirred overnight. Subsequently,  KHSO4 was  added  (until pH=3)  
and  the mixture was concentrated in vacuo to remove the excess of 
1,4-dioxane and dissolved in CH2Cl2 (250 mL). The  aqueous  layer  
was  extracted  with  CH2Cl2   (three  times). The combined organic 
phases were dried over MgSO4, filtered and  the  solvent  evaporated  
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in  vacuo  to  give  a  crude  material (8.30  g,  yellow  amorphous  
solid).  The  residue  was  purified  by flash  chromatography  (CH2Cl2 
/CH3OH,  from:  100/0  to  98/02, 0.1%  AcOH)  to  give  3.15 (4.74 
g, 50% three steps). 
  1H  NMR: (400.13 MHz, CDCl3, mixture of two rotamers) δ: 
7.78  (1.1H,  d,  J  7.3  Hz,  Ar-H[Fmoc]  rot.  a), 7.73 (0.9H, d, J 7.3 
Hz, Ar-H[Fmoc] rot. b), 7.60 (1.1H, d, J 7.3 Hz, Ar-H[Fmoc] rot. a),  
7.53 (0.9H, d, J 7.3 Hz, Ar-H[Fmoc] rot. b), 7.19-7.44  (4H,  m,  Ar-
H[Fmoc]),  4.54 (1.1H, d, J 6.0 Hz, CH2CH[Fmoc]  rot.  a), 4.44 (0.9H, 
d,  J  6.3  Hz,  CH2CH[Fmoc] rot.  b), 4.28 (0.55H, t, J 6.0 Hz, 
CH2CH[Fmoc] rot. a), 4.20 (0.45H, t, J 6.0 Hz, CH2CH[Fmoc] rot. b), 
4.13 (1.1H, s, OCCH2N rot. a), 4.05 (0.9H, s, OCCH2N rot.  b), 3.58 
(0.9H, t, J 6.0 Hz,  NCH2CH2CO rot.  b), 3.45 (1.1H, t, J 6.4 Hz, 
NCH2CH2CO rot.  a), 2.58 (0.9H, t, J 6.0  Hz,  NCH2CH2CO  rot.  b), 
2.32 (1.1H, t, J 6.4 Hz,  NCH2CH2CO rot. a), 1.46  (4.95H,  s,  C(CH3)3  
rot.  a), 1.44 (4.05H, s,  C(CH3)3  rot.  b); 13 C  NMR: (62.89  MHz,  
CDCl3,  mixture  of  two  rotamers)  δ: 174.1 (COOH rot. a), 173.9 
(COOH rot. b),171.5 (COOC rot. a), 171.0 (COOC rot. b),156.2 
(CO[Fmoc] rot. a), 155.7 (CO[Fmoc] rot. b), 143.5 (C[Fmoc] rot. a 
and rot.b), 141.1 (C[Fmoc] rot. a), 141.0 (C[Fmoc] rot. b), 127.5 
(C[Fmoc] rot. a), 127.4 (C[Fmoc] rot. b), 127.0 (C[Fmoc] rot. a), 126.9 
(C[Fmoc] rot. b), 124.6 (C[Fmoc] rot. a and rot.b),119.7 (C[Fmoc] rot. 
a),119.6 (C[Fmoc] rot. b), 80.9 (C(CH3)3 rot. a and rot.b), 67.6 
(CH2[Fmoc] rot. a), 67.5 (CH2[Fmoc] rot. b), 49.9 (CH2COOH rot. a), 
49.6 (CH2COOH rot. b), 46.9 (CH[Fmoc] rot. a), 46.8 (CH[Fmoc] rot. 
b), 45.0 (NCH2CH2 rot. a), 44.3 (NCH2CH2 rot. b), 34.5 0 (NCH2CH2 
rot. a), 34.3 (NCH2CH2 rot. b), 27.8 (C(CH3)3 rot. a), 27.7 (C(CH3)3 
rot. b). 





To 3.16 (5.00 g), 8% Na2CO3 (6.70 g) in H2O/brine (80 mL) 
were added under stirring, to obtain a homogeneous solution. The 
reaction mixture was extracted three times with CH2Cl2 (150 mL) and 
the combined organic phases were dried over MgSO4 and filtrated. 
To prevent the loss of 3.17, the solvent partially evaporated in vacuo 
and 3.16 was obtained as a yellow oil (6.84 g, 95%, based on 1H 
NMR analysis). 
1H NMR: (400 MHz, MeOD) δ: 3.72 (3H, s, CH3O), 3.37 (2H, 
s, COCH2NH2).  
Compound 3.19 
 
To a stirred solution of crude 3.17 (5.84 g, 65.0 mmol) in 
MeOH (70.0 mL), tert-butyl acrylate 3.18 was added (4.70 mL, 32.5 
mmol). The reaction mixture was refluxed overnight at 50°C. After 15 
hours, it was rinsed with toluene (2 x 50.0 mL) and the solvent was 
evaporated in vacuo to give 3.19 (5.30 g, 75%).  
1H NMR: (400 MHz, MeOD) δ:  3.72 (3H, s, CH3O), 3.40 (2H, 
s, CH2COOCH3), 2.81 (2H, t, J 6.7 Hz, NHCH2CH2CO), 2.44 (2H, t, 
J 6.7 Hz, NHCH2CH2CO), 1.46 (9H, s, OC(CH3)3).13C NMR: (100 
MHz, MeOD) δ: 173.3 (COC(CH3)3), 172.9 (COOCH3), 81.5 
(COC(CH3)3), 52.2 (CH3O), 50.8 (CH2COOCH3), 45.5 
(NHCH2CH2CO),  36.2 (NHCH2CH2CO), 28.4 (C(CH3)3). 
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Linear peptoid 3.20 (“monomer/submonomer” approach) 
 
Linear peptoid 3.20 was synthesized using a 
“monomer/submonomer” solid-phase approach. In a typical 
synthesis, 2-chlorotrityl chloride resin (α-dichlorobenzhydryl-
polystyrene cross-linked with 1% DVB; 100 – 200 mesh; 1.20 mmol 
g-1, 0.20 g, 0.24 mmol) was swollen in dry CH2Cl2 (2 mL) for 45 min 
and washed twice with dry DMF (2 mL) and dry DCM (2 mL). The 
first monomer 3.15 was loaded on the resin with the following 
protocol; 0.67 equiv of 3.15 (68.0 mg, 0.26 mmol) and 2.6 equiv of 
DIPEA (110 μL, 0.64 mmol) were dissolved in dry CH2Cl2 (2 mL) and 
the solution was added onto the resin. The resulting mixture was 
shaken on a shaker platform for 90 min at room temperature, and 
then rinsed with CH2Cl2 (3 × 1 min) and DMF (3 × 1 min). To 
terminate the excess of reactive positions, the resin was incubated 
with 2 mL of a capping solution; DCM/MeOH/DIPEA (17:2:1) and the 
reaction was shaken for 15 more min.  Then,  the  solvents  were  
removed  by  suction,  and the resin  washed  with  DCM  (3  ×  1  
min) and  DMF  (3  ×  1  min). The Fmoc-deprotection treatment was 
carried out with Piperidine/DMF (1:4) (2 x 1 min, 2 x 5 min) and the 
subsequent bromoacetylation reactions were accomplished by 
reaction the oligomer with a solution of bromoacetic acid (0.222 g, 
1.60 mmol) and DIC (0.272 mL, 1.76 mmol) in DMF (3.00 mL) on a 
shaker platform 40 min at room temperature. To the bromoacetylated 
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resin methoxyethlamine (0.138 mL, 1.60 mmol) in dry DMF (2 mL) 
was added. The mixture was left on a shaker platform for 30 min at  
room  temperature,  then  the  resin  was  washed  with DMF  (3  ×  
2.0  mL).  The  resin  was  then  incubated  with  a solution of 
monomer 3.15 (0.272 g, 0.64 mmol), HATU (0.236 g, 0.62  mmol),  
DIPEA  (0.222  mL,  1.28  mmol) in dry DMF (2 mL) on a shaker 
platform for 1 h, followed by extensive washes with DMF (3 × 3.0 
mL), DCM (3 × 3.0 mL) and DMF (3 × 3.0 mL).  Chloranil  test  was  
performed  and  once  the  coupling  was complete  the  Fmoc  group  
was  deprotected  with  piperidine  as described above and the resin 
washed again to prepare it for the bromoacetylation/amination  
reactions.  The  synthesis  proceded until  the  desired  oligomer  
length  was  obtained.  The  oligomer on the resin was then cleaved 
in 4.0 mL of 20% HFIP in DCM (v/v).  The cleavage was performed 
on a shaker platform for 30 min at room temperature and the resin 
was then filtered away. The resin was treated again with 4.0 mL of 
20% HFIP in DCM (v/v) for 5 min, washed twice with DCM (3.0 mL), 
filtered away and the  combined  filtrates  were  concentrated  in  
vacuo.  The final product was dissolved in 50% acetonitrile in HPLC 
grade water and analyzed by RP-HPLC [purity >90% for oligomer 
3.20; conditions: 5 → 100% A in 30 min for the all oligomers (A, 0.1% 
TFA in acetonitrile, B, 0.1% TFA in water); flow: 1 mL min− 1, 220 
nm]. The linear oligomer was subjected to the cyclization reaction 
without further purification. 
3.20: 91% (crude residue); HRMS (ES): [M+H]+,  m/z  found 
919.5248 C42H75N6O16+ requires 919.5234. tR : 15.1 min (see general 





Linear peptoid 3.21 (“monomer” approach) 
 
Linear  peptoid  3.21  was  synthesized  using  the  standard  
manual Fmoc  solid-phase  peptide  synthesis  protocol. 2-chlorotrityl  
chloride  resin  (Fluka;  2,α-dichlorobenzhydryl-polystyrene  
crosslinked  with  1%  DVB;  100-200  mesh;  1.50 mmol g-1, 0.70 g, 
1.05 mmol)  was  swelled  in  dry  DCM  (2.0  mL)  for  45  min  and  
washed twice in dry DCM (2.0 mL). Monomer 3.15 (0.716 g, 1.68 
mmol) in dry DCM (2.0 mL) and DIPEA (1.17 mL, 6.72 mmol) were 
added on a shaker platform for 1.5 h at room temperature,  followed 
by  washing  with  dry  DCM  (3.0  mL)  then  with  a mixture  of  
DCM/MeOH/DIPEA  (17:2:1)  (2  ×  3.0  mL)  and finally with DMF (3 
× 3.0 mL). Resin loaded with the first N-Fmoc N-alkylated  glycine  
was  incubated  twice  with  20% piperidine/DMF  (v/v,  3.0  mL)  on  
a  shaker  platform  (2 x 1 min, 2 x 5 min),  followed  by  extensive  
washes  with DMF (3 × 3.0 mL), DCM (3 × 3.0 mL) and DMF (3 × 3.0 
mL). After  loading  of  the  first  monomer  all subsequent addition of 
monomer 3.15, Fmoc deprotection steps and coupling of Fmoc-Pro-
OH were performed as follow, until the desired oligomer length was 
obtained. The resin was incubated with a solution of monomer 3.15 
(1.34 g, 3.15 mmol), or Fmoc-Pro-OH (1.06 g, 3.15 mmol) in the 
presence of HATU (1.16 g, 3.04 mmol) and DIPEA (1.10 mL, 6.30 
mmol) in DMF dry (7 mL)  on  a  shaker platform for 1 h and 2 h for 
the coupling of the second and third Fmoc-Pro-OH, followed by 
extensive washes with DMF (3 × 3.0 mL), DCM (3 × 3.0 mL) and 
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DMF (3 × 3.0 mL). Chloranil test  was  performed  and  once  the  
coupling  was  complete  the Fmoc  group  was  deprotected  with  
piperidine  as  described above  and  the  resin  washed  again  to  
prepare  it  for  the  next coupling.  The  oligomer-resin  was  cleaved  
in  7.0  mL  of  20% HFIP in DCM (v/v). The cleavage was performed 
on a shaker platform  for  30  min  at  room  temperature  the  resin  
was  then filtered away. The resin was treated again with 7.0 mL of 
20% HFIP  in  DCM  (v/v)  for  5  min,  washed  twice  with  DCM  (3.0 
mL),  filtered  away  and  the  combined  filtrates  were concentrated 
in vacuo. A small amount of the the final product was dissolved in 
50% ACN in HPLC grade water and analysed by RP-HPLC for 
analytical pourposes [purity >90% for oligomer 3.21; conditions: 5 → 
100% A in 30 min for the all oligomers (A, 0.1% TFA in acetonitrile, 
B, 0.1% TFA in water); flow: 1 mL min− 1, 220 nm]. The linear 
oligomer was subjected to the cyclization reaction without further 
purification. 
3.21: 47% (crude residue); ESI-MS (positive, m/z): 879.7 m/z 
(100, [M + H]+). tR: 13.4 min (see general information for the 
conditions). 
Compounds 3.24 and 3.25 
A solution of the linear oligomers 3.20 and 3.21 (0.200 
mmol), previously co-evaporated three times with toluene, was 
prepared under nitrogen in dry DMF (7.00 mL). The mixture was 
dropwise added to a stirred solution of HATU (0.304 g, 0.800 mmol) 
and DIPEA (217 μL, 1.24 mmol) in dry DMF (60.0 mL) by a syringe 
pump in 4 h, at room temperature in anhydrous atmosphere. After 18 
h the resulting mixture was concentrated in vacuo, diluted with 
CH2Cl2 (20.0 mL), and washed with a solution of HCl (0.01 M, 10.0 
mL). The water layer was further extracted with CH2Cl2 (2 × 20.0 mL) 
and the combined organic phases were washed two times with a 
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solution of HCl (0.01 M, 10.0 mL) and once with water (10.0 mL), 
dried over anhydrous MgSO4, filtered and concentrated in vacuo. 
The cyclic products were dissolved in 50% acetonitrile and HPLC 
grade water and analyzed by RP-HPLC [purity >95% for oligomers 
3.24 and 3.25, conditions: 5% – 100% A in 30 min for the two 
cyclopeptoids (A, 0.1% TFA in acetonitrile, B, 0.1% TFA in water); 
flow: 1 mL min− 1, 220 nm]. The crude residues 3.24 and 3.25 were 
purified by HPLC on a C18 reversed-phase preparative column, 
conditions: 20%-100% B in 30 min and 25%-100% B in 30 min 
respectively [A: 0.1% TFA in water, B: 0.1% TFA in acetonitrile], flow: 
2.0 mL/min,  220  nm.  The  samples  were  dried  in  a  falcon  tube 
under low pressure and analyzed by RP-HPLC [purity >95% for 
oligomers 3.24 and 3.25, conditions: 5% – 100% A in 30 min for the 
two cyclopeptoids (A, 0.1% TFA in acetonitrile, B, 0.1% TFA in 
water). 
 
Compound 3.24: 61%; tR: 13.3 min (see general information 
for the conditions). 
1H NMR: (400.13 MHz, CDCl3, complex mixture of 
conformers) δ:  3.94-4.65 (12H, b m, NCH2CO), 3.25-3.70 (33H, b 
m, CH2CH2COOtBu and CH2CH2OCH3), 1.43-1.46 (54H, b s, 
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C(CH3)3); 13C NMR (100.03 MHz, CDCl3, complex mixture of 
conformers) δ: 171.8, 171.7, 171.6, 171.2, 171.0, 170.9, 170.6, 
170.5, 170.2, 169.9, 169.6, 169.5, 169.2, 168.7, 168.1, 81.4, 81.0, 
80.7, 80.5, 71.5, 71.2, 70.6, 70.4, 70.2, 69.5, 68.7, 59.0, 58.7, 58.3, 
52.9, 50.7, 50.3, 49.8, 49.3, 49.0, 48.7, 48.4, 47.5, 46.0, 45.4, 45.2, 
44.8, 44.4, 43.9, 34.3, 34.2, 33.7, 28.3, 28.1, 27.9, 27.7. 
HRMS  (ES)  [M+H]+,  m/z  found  901.5138.  C42H73N6O5+ 
requires 901.5128.  
 
Compound 3.25: 70%; tR: 14.9 min (see general information 
for the conditions). 
1H NMR: (400.13 MHz, CD3CN:CDCl3=9:1, complex mixture 
of conformers) δ:  4.30-5.30 (9H, b m, NCH2CH2CH2CH  and 
NCH2CO), 3.32-3.93 (12H, b m, NCH2CH2CH2CH and 
CH2CH2COOtBu), 1.66-3.01 (18H, b m, NCH2CH2CH2CH and 
CH2CH2COOtBu, overlapped with the signal of CD2HCN), 1.34-1.55 
(27H, b s, C(CH3)3). 13C-NMR (100 MHz, CD3CN:CDCl3=9:1, 
complex mixture of conformers) δ:174.80, 173.90, 173.65, 173.50, 
173.19, 173.02, 172.11, 171.98, 171.88, 171.70, 171.52, 169.77, 
169.28, 169.05, 168.83, 163.99, 160.41, 160.01, 159.65, 159.28, 
120.93, 118.28, 115.19, 82.24, 82.17, 82.16, 82.14, 81.79, 81.56, 
81.22, 81.17, 80.98, 79.23, 79.10, 78.90, 78.58, 59.58, 59.44, 59.29, 
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59.20, 59.17, 57.65, 57.25, 52.77, 52.14, 51.74, 51.41 50.50, 49.73,  
49.49, 49.34, 48.56, 48.43, 48.08, 47.45, 47.37, 47.23, 46.44, 46.34, 
46.18, 45.93, 37.03, 36.35, 35.50, 34.75, 34.60, 34.41, 33.95, 32.60, 
32.43, 32.13, 31.70, 30.91, 30.67, 30.45, 30.30, 30.01, 29.45, 28.30, 
25.79, 25.68, 25.65. 
ESI-MS (positive, m/z): 847.5 m/z (100, [M + H]+). 
Compounds 3.10 and 3.11 
Cyclopeptoids  3.24  and 3.25 (0.079  mmol)  were  dissolved  
in  2.0 mL  of  TFA/m-cresol  (95:5),  stirred  for  one  hour  and 
concentrated  under  a  flux  of  nitrogen  to  one  third  of  the volume. 
The  mixtures  were  then  slowly  added  to  20.0  mL  of stirred cold 
diethyl ether. The white precipitates were centrifuged and washed 
twice with cold ether (10.0 mL). The white solids were dried in an 
Eppendorf vial to give 3.10 and 3.11, which were used in the 
complexation with gadolinium without further purification. A  small  
portion  of  cyclic  peptoids  was  dissolved  in  50% acetonitrile in 
HPLC grade water and analyzed by RP-HPLC. [purity >95% for 
oligomers 3.10 and 3.11, conditions:  5%-100%  B  in  30  min  [A:  
0.1%  TFA  in water, B: 0.1% TFA in acetonitrile].  
 
Compound 3.10: 64%; tR: 8.2 min (see general information 
for the conditions). 
 168 
1H NMR (300.1 MHz, CD3CN/CD3OD, 9:1, complex mixture 
of rotamers) δ: 4.75-3.66 (12H, m, NCH2CO), 3.65-3.24 (33H, 
complex signal, CH2CH2OCH3, CH2CH2COOH); 13C NMR:  (75.5  
MHz,  CD3CN/CD3OD,  40:15, complex  mixture  of  rotamers)  δ:  
171.3, 171.2, 171.1, 170.8, 170.7, 170.4,  170.1,  170.0,  169.7,  71.5,  
71.4,  71.3, 71.1, 70.8, 59.5, 59.2, 59.0, 58.8, 51.4, 51.2,  50.8,  50.6,  
50.3, 47.0,  46.4, 46.3,  46.0, 45.8, 45.5, 45.3, 45.2, 44.7, 43.8, 34.2, 
33.9, 33.7, 33.4, 33.1. 
HRMS  (ES) [M+H]+, m/z found 733.3241. C30H49N6O15+ 
requires 733.3250. 
 
Compound 3.11: 33%; tR: 6.7 min (see general information 
for the conditions). 
1H NMR (400 MHz, MeOD , rt, complex mixture of 
conformers) δ: 5.77-4.24 (9H, b m, NCH2CH2CH2CH  and NCH2CO 
water overlapped signals), 4.21-3.06 (12H, b m, NCH2CH2CH2CH 
and CH2CH2COOH), 3.04-1.42 (18H, b m, NCH2CH2CH2CH and 
CH2CH2COOH). 13C-NMR (100 MHz, MeOD, complex mixture of 
conformers) δ: 175.70,175.52, 174.86, 174.72, 174.31, 172.14, 
170.34, 170.03, 169.49, 169.38, 169.10,168.89, 118.27, 79.41, 
66.89, 59.92, 59.55, 59.20, 58.39, 57.79, 52.69, 52.43, 52.13, 34.01, 
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33.47, 33.00, 32.81, 32.76, 30.82, 30.69, 30.17, 26.64, 26.12, 26.01, 
23.74, 23.35.  
ESI-MS (positive, m/z): 679.4 m/z (100, [M + H]+). 
7.3.2. Complexation Of The Cyclic Peptoids In The Presence Of 
Sodium Picrate 
In an NMR tube, to a 4.0 mM solution of 3.24, 3.25, 3.10 and 
3.11 in CD3CN:CDCl3 9:1 (0.5 mL), 6.0 equivalents of sodium picrate 
were added (3.0 mg, 12.0 µmol). After the addition the suspension 
was vigorously stirred for 5 minutes and the 1H NMR spectrum was 
recorded.  
Compound Na-3.24 
1H NMR: (400.13 MHz, CD3CN:CDCl3 9:1, 4.0 mM solution) 
δ: 8.74 (~6H, s, picrate), 4.68 (3H, d, J 17.0 Hz, -OCCHHN), 4.64 
(3H, d, J 17.0 Hz, -OCCHHN), 3.89 (3H, d, J 17.0 Hz, -OCCHHN), 
3.81 (3H, d, J 17.0 Hz, -OCCHHN), 3.70-3.47 (18H, m, CH2CH2CO 
and CH2CH2OCH3), 3.32 (9H, s, CH2CH2OCH3), 2.54 (6H, t, J 6.0 
Hz, CH2CH2COOt-Bu),  1.44 (27H, s, C(CH3)3). 13C NMR (75.5 MHz, 
CD3CN:CDCl3 9:1) δ: 172.1, 171.0, 170.4, 163.1 (picrate), 143.0 
(picrate), 128.4 (picrate), 127.4 (picrate), 82.1, 71.4, 59.7, 50.9, 50.6, 
50.1, 45.8, 35.2, 28.7. 
ESI-MS(positive, m/z): 923,(100, [M+Na]+). 
Compound Na-3.25 
1H NMR: (400.13 MHz, CD3CN:CDCl3 9:1, 4.0 mM solution) 
δ: 4.65 (1H, t, J 7.68, NCH2CH2CH2CH), 4.44 (1H, d, J 17.0, 
NCH2CO), 3.78 (1H, m, J 6.92, CH2CH2COOtBu), 3.73 (1H, d, J 17.0, 
NCH2CO), 3.63-3.44 (3H, m, CH2CH2COOtBu e NCH2CH2CH2CH), 
2.59 (1.90H, m, J 6.92, CH2CH2COOtBu), 2.34 (1H, m, 
NCH2CH2CH2CH, overlapped with the water signal), 1.97 (2H, m 
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overlapped with the CD2HCN signal, NCH2CH2CH2CH), 1.76 (1.02 
H, m, J 6.98, NCH2CH2CH2CH), 1.42 (9H, s, C(CH3)3).  
ESI-MS(positive, m/z): 883.5,(100, [M+Na]+). 
Compound Na-3.10 
1H NMR: (300.1 MHz, CD3CN:CDCl3 9:1) δ: 8.68 (~6H, s, 
picrate), 4.83 (3H, d, J 18.0 Hz, -OCCHHN), 4.64 (3H, d, J 18.0 Hz, 
-OCCHHN), 3.84 (3H, d, J 18.0 Hz, -OCCHHN), 3.77 (3H, d, J 18.0 
Hz, -OCCHHN), 3.60-3.50 (18H, m, CH2CH2COOH and 
CH2CH2OCH3), 3.30 (9H, s, CH2CH2OCH3), 2.61 (6H, br s, 
CH2CH2COOH, overlapped with the water signal). 
ESI-MS(positive, m/z): 755, (100, [M+Na]+). 
Compound Na-3.11 
1H-NMR: (600 MHz, CD3CN:CDCl3 9:1, 4.0 mM solution)  δ: 
4.79 (1H, t, J 7.68, NCH2CH2CH2CH), 4.47 (1H, d, J 16.9, NCH2CO), 
3.83 (1H, m, J 6.74, CH2CH2COOH), 3.76 (1H, d, J 16.9, NCH2CO), 
3.61-3.51 (3H, m, CH2CH2COOH and NCH2CH2CH2CH), 2.68 (2H, t, 
J 6.74, CH2CH2COOH), 2.37 (1H, m, J 6.74, NCH2CH2CH2CH), 2.05-
1.94 (2H, m overlapped with CD2HCN signal, NCH2CH2CH2CH), 
1.80 (1H, m, NCH2CH2CH2CH, J 6.74). 13C-NMR (150 MHz, 
CD3CN:CDCl3 9:1) δ: 174.2, 162.6, 59.0, 51.5, 47.4, 46.2, 33.9, 29.4, 
25.4. 








7.4     COMPOUNDS FROM CHAPTER 4 
7.4.1. Synthesis and Characterization of Peptoidic Scaffolds 
General procedure for sub-monomer solid-phase synthesis of 
the linear peptoids 4.30–4.38 
 
Linear peptoid oligomers 4.30–4.38 were synthesized using 
a submonomer solid-phase approach. In a typical synthesis 2-
chlorotrityl chloride resin (α-dichlorobenzhydryl-polystyrene cross-
linked with 1% DVB; 100 – 200 mesh; 1.5 mmol g-1, 0.30 g, 0.45 
mmol) was swelled in dry CH2Cl2 (3 mL) for 45 min and washed twice 
with dry DMF (3 mL). The first submonomer was attached onto the 
resin by adding bromoacetic acid (100 mg, 0.72 mmol) in dry CH2Cl2 
(3 mL) and DIPEA (392 μL, 2.20 mmol) on a shaker platform for 60 
min at room temperature, followed by washing with dry CH2Cl2 (3 × 
1 min) and then with DMF (3 × 1 min). A DMF solution of the 
commercially available propargyl amine (1 M, 3.0 mL), or 
methoxyethyl amine (1 M, 3.0 mL) needed for the synthesis of 4.30, 
was added to the bromoacetylated resin. The mixture was left on a 
shaker platform for 30 min at room temperature, then the resin was 
washed with DMF (3 × 1 min), CH2Cl2 (3 × 1 min) and then again with 
DMF (3 × 1 min). Subsequent bromoacetylation reactions were 
accomplished by reacting the aminated oligomer with a solution of 
bromoacetic acid (625 mg, 4.50 mmol) and DIC (766 µL, 5.00 mmol) 
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in dry DMF (3 mL) for 40 min at room temperature. The filtrated resin 
was washed with DMF (3 × 1min), CH2Cl2 (3 × 1 min), DMF (3 × 1 
min) and treated again with the amine under the same conditions 
reported above. This cycle of reactions was iterated until the desired 
chain length was accomplished and the target oligomer obtained. 
The cleavage was performed by treating twice the resin, previously 
washed with CH2Cl2 (3 × 1 min), with a solution of HFIP in CH2Cl2 
(20% v/v, 6 mL) on a shaker platform at room temperature for 30 min 
and 5 min, respectively. The resin was then filtered away and the 
combined filtrates were concentrated in vacuo. The final products 
were dissolved in 50% acetonitrile in HPLC grade water and 
analyzed by RP-HPLC [purity >95% for oligomers 4.30-4.33, 82% for 
oligomer 4.34, 72% for oligomer 4.35, 70% for oligomer 4.36, 65% 
for oligomer 4.37, 60% for oligomer 4.38; conditions: 5 → 100% A in 
30 min for the all oligomers (A, 0.1% TFA in acetonitrile, B, 0.1% TFA 
in water); flow: 1 mL min− 1, 220 nm]. The linear oligomers were 
subjected to the cyclization reaction without further purification. 
4.30: 70% (crude residue); ESI-MS (positive, m/z): 669.05 
[M + H]+ ; tR : 9.01 min; 
4.31: quant. (crude residue); ESI-MS (positive, m/z): 399.1 
[M + H] + ; tR : 3.70 min; 
4.32: quant. (crude residue); ESI-MS (positive, m/z): 494.1 
[M + H] + ; tR: 4.04 min; 
4.33: 70% (crude residue); ESI-MS (positive, m/z): 589.2 [M 
+ H]+ ; tR : 7.0 min; 
4.34: 80% (crude residue); ESI-MS (positive, m/z): 779.0 [M 
+ H] + ; tR : 7.7 min; 
4.35: 66% (crude residue); ESI-MS (positive, m/z): 969.4 [M 
+ H] + ; tR: 10.1 min; 
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4.36: 70% (crude residue); ESI-MS (positive, m/z): 1160.7 
(60, [M + H]+) and 1182.2 (100, [M+Na]+); tR : 10.1 min  
4.37: 80% (crude residue); ESI-MS (positive, m/z): 1350.5 
(100, [M + H]+); 1372.6 (22, [M+Na]+) and 1388.5 (15, [M + K]+);  tR : 
11.1 min; 
4.38: 66% (crude residue); ESI-MS (positive, m/z): 1541.3 
(100, [M + H]+) and 1563.3 (100, [M+Na]+) tR: 11.9 min; 
Procedure for sub-monomer solid-phase synthesis of 
the linear peptoid 4.68 
 
Peptoid  oligomer 4.68  was  synthesized  on  a Fmoc-Rink-
Amide resin (aminomethyl-polystyrene cross-linked with 1% DVB; 
100 – 200 mesh) using  the  submonomer  methodology. 50  mg  of 
Rink  amide  resin  at  a  loading  level  of  0.59  mmol/g  was swollen 
in DMF for 40 minutes. Fmoc deprotection of the resin was performed 
by 20%  piperidine  in  DMF,  followed  by multiple washing steps 
using DMF (3 × 1 min), CH2Cl2 (3 × 1 min) and then again DMF (3 × 
1 min). Washing were performed between each step described 
below. Fmoc cleavage was followed by bromoacetylation,  in  which 
approximately  15 eq  bromoacetic  acid  (1.0  M in  DMF,  8.5  mL/g  
resin)  and  18  eq  of diisopropylcarbodiimide  (1.7  mL/g  resin)  were  
added,  followed  by  30  min  agitation. 15 equivalents of propargyl 
amine (1.0  M in  DMF,  8.5  mL/g  resin) were added and the amine 
displacement step was effected by 20 min agitation. The 
bromoacetylation and the propargyl amine displacement steps were 
repeated until the peptoid oligomer was  completely synthesized.  
4.68 was cleaved from the resin, previously washed with CH2Cl2 (3 
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× 1 min), by a treatment with a solution of TFA (50% v/v) and 1,3 
dimethoxybenzene (DMB) (4% v/v) in CH2Cl2 (1.0 mL) on a shaker 
platform at room temperature for 20 min. The resin was then 
extensively washed with DCM and filtered away. The cleavage 
cocktail was evaporated and the peptoid oligomer 4.68 was 
precipitated in cold diethyl ether (20 mL). The final product was 
dissolved in 50% acetonitrile in HPLC grade water and analyzed by 
RP-HPLC [purity 90%; conditions: 5 → 100% A in 30 min (A, 0.1% 
TFA in acetonitrile, B, 0.1% TFA in water); flow: 1 mL min− 1, 220 nm].  
 
4.68: 66%; white amorphous solid; ESI-MS (positive, m/z): 
602.1 (100, [M + 2 Na]2+); 1159.1 (65, [M + H]+) and 1181.1 (44, [M 
+ Na]+); tR : 9.9 min; 
1H-NMR: (600 MHz, CD3OD, mixture of rotamers) δ: 5.59- 
4.60 (bs, water overlapped, COCH2N and NCH2CCH), 4.28-3.98 (bs, 
40 H, COCH2N and NCH2CCH), 2.93 (bs, 4 H, NCH2CCH), 2.74 (bs, 
8 H, NCH2CCH). 13C-NMR: (150 MHz, CD3OD, mixture of rotamers, 
broad signals) δ: 170.9, 170.6, 170.4, 170.2, 169.8, 79.7, 78.8, 78.5, 
75.7, 75.4, 75.1, 74.8, 74.3, 48.3, 38.7, 37.6, 37.5, 37.4, 37.3, 37.1. 
General procedure for the cyclization reactions: synthesis of 
compounds 4.16-4.24 
A solution of the linear peptoids precursors of 4.30 – 4.38 (0.30 
mmol), previously co-evaporated three times with toluene, was 
prepared under nitrogen in dry DMF (20 mL). The mixture was added 
drop wise to a stirred solution of HATU (465 mg, 1.22 mmol) and 
DIPEA (330 μL, 1.90 mmol) in dry DMF (82 mL) by a syringe pump 
in 12 h, at room temperature in anhydrous atmosphere. After 65 h 
the resulting mixture was concentrated in vacuo, diluted with CH2Cl2 
(100 mL), and washed with a solution of HCl (1.0 M, 50 mL). The 
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mixture was extracted with CH2Cl2 (2 × 100 mL) and the combined 
organic phases were washed with water (150 mL), dried over 
anhydrous MgSO4, filtered and concentrated in vacuo. The cyclic 
products were dissolved in 50% acetonitrile in HPLC grade water and 
analyzed by RP-HPLC [purity 81% for oligomer 4.21, >95% for the 
others, conditions: 5% – 100% A in 30 min for all cyclic compounds 
(A, 0.1% TFA in acetonitrile, B, 0.1% TFA in water); flow: 1 mL min− 
1, 220 nm]. The crude residues 4.16 and 4.19 were purified by 
precipitation in hot acetonitrile, 4.17 by precipitation in ethyl acetate, 
4.18 by precipitation in acetonitrile/H2O 1:1 + 0.1%TFA , 4.20 by 
precipitation in hot acetonitrile 0.1% TFA, 4.21 by RP-HPLC on a C18 
reversed-phase semi-preparative column, tR : 10.9 min, conditions: 
25% – 100% A in 30 min [(A, 0.1% TFA in acetonitrile, B, 0.1% TFA 
in water); flow: 2 mL min− 1, 220 nm], 4.22, 4.23 and 4.24 were 
purified by flash chromatography over demetalated silica gel 
(CH2Cl2/CH3OH, from 100/0 to 95/05).  
 
Compound 4.16: 31%; white amorphous solid; ESI-MS 
(positive, m/z): 651.20 (100, [M + H]+), tR: 10.4 min; 
1H NMR: (400 MHz,CDCl3, mixture of rotamers) δ: 5.13-3.89 
(12H, m, COCH2N); 3.78-3.07(32H, m, NCH2CH2OCH3, 
NCH2CH2OCH3, NCH2CH2OCH3, NCH2CCH); 2.43-2.10 (2H, m, 
NCH2CCH); 13C NMR: (100 MHz, CDCl3, mixture of rotamers, broad 
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signals) δ: 170.9, 170.6, 169.8, 169.6, 169.5, 169.4, 169.2, 169.1, 
168.8, 168.7, 168.6, 168.4, 168.0, 167.9, 167.8, 167.7, 78.7, 78.7, 
73.8, 73.6, 73.1, 73.0, 72.8, 72.7, 72.4, 72.3, 72.1, 72.0, 71.8, 71.6, 
71.5, 71.0, 70.6, 70.5, 70.3, 70.2, 70.0, 69.7, 69.5, .68.8, 68.6, 59.3, 
59.1, 59.0, 58.7, 58.5, 58.4, 58.3, 58.2, 52.0, 51.0, 20.8, 50.6, 50.3, 
50.2, 50.0, 79.9, 49.8, 49.6, 49.5, 49.2, 49.0, 48.9, 48.8, 48.6, 48.5, 
48.2, 48.0, 47.9, 47.8, 47.7, 47.6, 47.6, 47.5, 47.4, 47.3, 47.3, 47.2, 
47.1, 47.0, 46.8, 46.6, 46.4, 46.2, 46.0, 45.8, 45.7, 45.6, 43.5, 43.2, 
42.6, 37.5, 37.4, 37.3, 37.2, 36.9, 36.8, 36.6, 36.2, 36.0, 35.8, 35.7, 
35.5, 35.4, 35.3, 31.8. 
 
Compound 4.17: 35%; white amorphous solid; ESI-MS 
(positive, m/z): 381.4 (100, [M + H]+), tR: 4.07 min; 
1H NMR: (600 MHz,CDCl3) δ: 5.26 (2H, d, J 14.1 Hz 
COCH2N); 4.94 (2H, dd, J 17.1 Hz, J 1.28 Hz  NCH2CCH); 4.37 (2H, 
d, J 18.1 Hz COCH2N); 4.31 (2H, d, J 18.1 Hz COCH2N); 4.07 (2H, 
dd, J 17.1 Hz, J 1.28 Hz  NCH2CCH); 3.84 (2H, dd, J 19.1 Hz, J 2.45 
Hz  NCH2CCH); 3.74 (2H, dd, J 19.1 Hz, J 2.45 Hz  NCH2CCH); 3.59 
(2H, d, J 14.1 Hz COCH2N); 3.39 (2H, t, J 1.28 Hz  NCH2CCH); 2.27 
(2H, t, J 2.45 Hz  NCH2CCH); 13C NMR: (150 MHz, DMSO) δ: 169.26 
(COCH2N), 168.08 (COCH2N), 79.91 (NCH2CCH), 78.62 
(NCH2CCH); 77.19 (NCH2CCH); 76.04 (NCH2CCH); 48.58 




Compound 4.18: 20%; white amorphous solid; ESI-MS 
(positive, m/z): 497.97 (100, [M + Na]+), tR: 5.40 min; 
1H NMR: (300 MHz, CDCl3, mixture of rotamers) δ: 5.04 – 
3.41 (20 H, m, COCH2N, NCH2CCH); 2.51 (1 H, bt, NCH2CCH); 2.40 
(1 H, bt, NCH2CCH); 2.33 (1 H, bt, NCH2CCH); 2.24 (1 H, bt, 
NCH2CCH); 2.15 (1 H, bt, NCH2CCH); 13C NMR: (75 MHz, CDCl3, 
mixture of rotamers, broad signals) δ: 169.8, 169.0, 168.4, 167.7, 
166.8, 78.3 (overlapped with the solvent signal), 74.3, 73.5, 73.2, 
72.3, 71.7,  48.8, 46.7, 47.1, 46.0, 38.9, 36.0, 35.6, 34.5, 35.1, 34.8. 
 
Compound 4.19: 31%; white amorphous solid; ESI-MS 
(positive, m/z): 593.2 m/z (100, [M + Na]+), tR: 8.6 min; 
1H NMR: (400 MHz, DMSO, mixture of rotamers) δ: 5.60 – 
2.90 (m, 30 H, COCH2N, NCH2CCH, NCH2CCH, water-overlapped 
signals). 13C NMR: (100 MHz, DMSO, mixture of rotamers, broad 
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signals) δ: 170.7, 169.8, 169.5, 169.3, 169.2, 169.0, 168.9, 168.8, 
168.6, 168.4, 168.2, 167.9 , 167.8, 167.7, 167.1, 79.5, 79.4, 79.3, 
79.1, 79.0, 78.8, 78.7, 78.5, 78.4, 78.3, 78.2, 78.0, 77.9, 76.3, 76.2, 
76.1, 75.9, 75.7, 75.6, 75.4, 75.2, 75.1, 74.7, 74.5, 49.4, 49.3, 49.0, 
48.4, 48.3, 47.9, 47.7, 47.6, 47.4, 47.3, 47.0, 46.8, 46.7, 37.2, 36.8, 
36.6, 36.4, 36.2, 36.0, 35.7, 35.3, 35.1, 34.7, 34.5, 34.4. 
 
 
Compound 4.20: 32%; white amorphous solid; ESI-MS 
(positive, m/z): 761.3 m/z (100, [M + H]+), 783.3 m/z (64, [M + Na]+); 
tR: 9.7 min; 
1H NMR: (400 MHz, CDCl3 , mixture of rotamers) δ: 4.97 (4 
H, m, COCH2N,), 4.75 (1H, d, J 16.8 Hz, COCH2N), 4.61 – 3.83 (23 
H, m, COCH2N and NCH2CCH), 3.71 (3 H, m, COCH2N), 3.34 (1H, 
d, J 16.8 Hz  COCH2N,), 2.46 (2 H, t, J 2.1 Hz, NCH2CCH), 2.39 (2 
H, t, J 2.3 Hz, NCH2CCH), 2.32 (2 H, t, J 2.5 Hz, NCH2CCH), 2.22 (2 
H, t, J 2.4 Hz, NCH2CCH); 13C NMR: (100 MHz, CDCl3, mixture of 
rotamers) δ : 169.0, 168.4, 168.2, 167.0, 78.3, 78.1, 77.2, 76.7, 74.6, 
74.2, 73.6, 73.3, 49.4, 48.6, 46.7, 46.5, 38.6, 38.1, 36.5, 35.8. 
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Compound 4.21: 12%, by HPLC; pale yellow amorphous 
solid; ESI-MS (positive, m/z): 951.3 m/z (40, [M + H]+), 973.3 m/z 
(100, [M + Na]+); tR : 10.9 min;  
1H NMR: (400 MHz, CDCl3, mixture of rotamers) δ: 4.74 – 
3.77 (37 H, m, COCH2N and NCH2CCH), 3.33 (3 H, bs, NCH2CCH), 
2.49 – 2.00 (10 H, m, NCH2CCH); 13C NMR: (100 MHz, CDCl3, 
mixture of rotamers, broad signals) δ: 169.6  , 169.4, 169.1, 168.7, 
168.5, 168.2, 168.1, 167.9, 167.7, 167.4, 167.1, 78.2, 78.0, 77.8, 
77.6, 74.8, 74.6, 74.4, 74.2, 74.0, 73.8, 73.7, 73.5, 73.3, 73.2, 73.1, 
72.8, 49.0, 48.8, 48.5, 48.2, 47.9, 47.7, 47.5, 47.1, 46.7, 46.4, 46.2, 
38.7, 38.6, 38.3, 38.1, 38.0, 37.8, 37.6, 37.4, 37.2, 37.0, 36.8, 36.6, 
36.4, 36.2, 36.0, 35.8, 35.6. 
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Compound 4.22: 10%; white amorphous solid; ESI-MS 
(positive, m/z): 1163.2 [M + Na]+; tR : 11.2 min;  
1H NMR: (300 MHz, CDCl3, mixture of rotamers) δ: 4.59 – 
3.38 (48 H, bs, COCH2N and NCH2CCH), 2.46-2.12 (12 H, m, 
NCH2CCH). 13C NMR: (100 MHz, CDCl3, mixture of rotamers, broad 
signals) δ: 168.07, 80.3, 73.9, 73.3, 46.6, 46.4, 37.6, 37.5, 37.3, 37.2, 
37.0, 36.7, 36.6, 35.9. 
 
Compound 4.23: 8%; white amorphous solid; ESI-MS 
(positive, m/z): 685.3 [M + K + H]2+; tR: 12.1 min;  
1H NMR: (600 MHz, CD3CN, mixture of rotamers) δ: 4.48 (7 
H, bs, COCH2N and NCH2CCH), 4.33-4.02 (49 H, bs, COCH2N and 
NCH2CCH), 2.73 (6 H, bs, NCH2CCH), 2.56 (8 H, bs, NCH2CCH). 
13C NMR: (150 MHz, CD3CN, mixture of rotamers, broad signals) δ: 
170.8, 170.6, 170.4, 170.2, 170.1, 170.0, 169.9, 169.8, 169.7, 169.5, 
169.4, 169.3, 169.2, 169.1, 169.0, 168.8, 168.7, 168.5, 168.3, 79.4, 
78.9, 78.6, 75.4, 74.8, 74.2, 48.3, 39.5, 38.5, 37.3. 
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Compound 4.24: 5%; white amorphous solid; ESI-MS 
(positive, m/z): 761.2 (100, [M + 2 H]2+) and 783.9 (33, [M + 2 Na]2+),   
tR : 12.8 min;  
1H NMR: (600 MHz, CD3CN, mixture of rotamers) δ: 4.47 (12 
H, bs, COCH2N and NCH2CCH), 4.30-4.05 (52 H, bs, COCH2N and 
NCH2CCH), 2.77-2.69 (6 H, bs, NCH2CCH), 2.56-2.54 (10 H, bs, 
NCH2CCH). 13C NMR: (150 MHz, CD3CN, mixture of rotamers, broad 
signals) δ: 169.3, 79.4, 78.6, 78.6, 75.4, 74.3, 48.3, 39.5, 38.6, 37.4 
7.4.2. Synthesis And Characterization Of Cyclopeptoid Based 
Iminosugar Click Clusters  
General procedure for the synthesis of cyclopeptoid 
based iminosugar click clusters 4.44a, 4.44b, 4.46a-4.48a, 4.46b-
4.48b, 4.54-4.59 and 4.66. 
Cyclopeptoid 4.16, or 4.19-4.24 (typically 5 to 15 mg) and 
ligand 4.43a, 4.43b or 4.53 (1.1 equiv/alkyne moiety) were placed in 
a microwave vial and dissolved in DMF (typically 0.5 to 1 mL). To this 
solution, a bright yellow suspension of CuSO4·5H2O (10 mol 
%/alkyne moiety) and sodium ascorbate (20 mol %/alkyne moiety) in 
water (typically 0.1 to 0.2 mL) were added. The mixture was stirred 
and heated under microwave irradiation for 3 h at 80 °C. The mixture 
was concentrated, diluted in a 9:1:1 (v/v/v) mixture of MeCN/water/ 
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30 wt %-NH4OH and filtrated with the same eluent (25 mL) over a 
small pad of SiO2 (typically 1 cm thick). The filtrate was concentrated 
and then filtrated again on another pad of SiO2 (typically 1 cm wide 
and 2 cm thick). To recover clean unclicked ligand, this was eluted 
with AcOEt/PE 4:6 (25 mL), and then with MeCN/water 8:2 (25 mL). 
Iminosugar click clusters 4.44a, 4.44b, 4.46a-4.48a, 4.46b-4.48b, 




20 = 0 (c 0.5, CHCl3);1H-NMR 
(CD3CN/CDCl3 9:1 + 1.9 eq Na picrate, 400 MHz) δ 7.76 (s, 2H; H-
1’), 5.06-4.94 (m, 4H; H-3 and H-4), 4.92 (d, J 16.7 Hz, 2H; H-3 or H-
5), 4.85 (td, J 9.7, 5.2 Hz, 2H; H-2), 4.76 (d, J 16.5 Hz, 2H; H-3’ or 
H-5’), 4.67 (d, J 16.7 Hz, 4H; H-7’), 4.46 (d, J 16.5 Hz, 2H; H-3’ or H-
5’), 4.35 (t, J 7.1 Hz, 4H; H-12), 4.15 (dd, J 12.7, 2.1 Hz, 2H; H-6a), 
4.10 (dd, J 12.8, 3.2 Hz, 2H; H-6b), 3.96 (d, J 16.7 Hz, 2H; H-3’ or H-
5’), 3.84 (dd, J 16.8, 6.2 Hz, 4H; H-7’), 3.70-3.22 (m, 28H; H-8’, H-9’ 
and MeO), 3.15 (dd, J 11.5, 4.8 Hz, 2H; H-1a), 2.80-2.65 (m, 2H; H-
7a), 2.69 (d, J 8.8 Hz, 2H; H-5), 2.59-2.47 (m, 2H; H-7b), 2.36 (t, J 
11.0 Hz, 2H; H-1b), 2.05-1.93 (m, 24H; Ac), 1.87 (m, 4H; H-11), 1.43 
(m, 4H; H-8), 1.31 ppm (m, 8H; H-9 and H-10); 13C-NMR 
(CD3CN/CDCl3 9:1, 100 MHz) δ 171.9, 171.8, 171.6, 171.4 (C=O Ac), 
171.0-170.5 (C-4’ and C-6’), 143.2 (C-2’), 124.1 (C-1’), 75.2 (C-2), 
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71.6-70.9 (C-8’ and C-9’), 70.4, 70.2 (C-3 and C-4), 62.1 (C-5), 60.5 
(C-6), 59.3 (MeO), 53.4 (C-1), 52.2 (C-7), 51.6-50.3 (C-7’), 50.8 (C-
12), 49.7, 44.9 (C-3’ and C-5’), 30.9, 27.2, 26.8, 25.3 (C-8 to C-11), 
21.1 ppm (CH3 Ac); IR (neat) 1743 (strong, C=O acetate), 1670 cm-
1 (strong, C=O amide); HRMS (ESI) m/z calcd for C70H111N14O26 
[M + H]+ 1563.7788; found 1563.7690. 
 
Compound 4.44b: [𝛼]𝐷
20 = +3.5 (c 1, CHCl3); 1H-NMR 
(CD3CN/CDCl3 9:1 + 1.8 eq Na picrate, 400 MHz) δ 7.75 (s, 2H; H-
1’), 5.05-4.92 (m, 4H; H-3 and H-4), 4.90 (d, J 16.9 Hz, 2H; H-3’ or 
H-5’), 4.83 (td, J 9.7, 4.9 Hz, 2H; H-2), 4.73 (d, J 16.3 Hz, 2H; H-3’ 
or H-5’), 4.65 (d, J 16.9 Hz, 4H; H-7’), 4.46 (d, J 16.3 Hz, 2H; H-3’ or 
H-5’), 4.33 (t, J 7.1 Hz, 4H; H-15), 4.14 (d, J 12.9, 1.9 Hz, 2H; H-6a), 
4.09 (dd, J 12.9, 3.0 Hz, 2H; H-6b), 3.95 (d, J 16.9 Hz, 2H; H-3’ or H-
5’), 3.83 (dd, J 16.9, 5.9 Hz, 4H; H-7’), 3.61-3.25 (m, 28H; H-8’, H-9’ 
and MeO), 3.13 (dd, J 11.3, 5.0 Hz, 2H; H-1a), 2.77-2.64 (m, 2H; H-
7a), 2.69 (d, J 8.5 Hz, 2H; H-5), 2.59-2.47 (m, 2H; H-7b), 2.37 (t, J 
11.3 Hz, 2H; H-1b), 2.04-1.91 (m, 24H; Ac), 1.85 (m, 4H; H-14), 1.41 
(m, 4H; H-8), 1.28 ppm (m, 20H; H-9, H-10, H-11, H-12 and H-13); 
13C-NMR (CD3CN/CDCl3 9:1, 100 MHz) δ 171.9, 171.8, 171.6, 171.4 
(C=O Ac), 171.1-170.6 (C-4’ and C-6’), 143.2 (C-2’), 124.0 (C-1’), 
75.3 (C-2), 71.9-70.9 (C-8’ and C-9’), 70.5, 70.2 (C-3 and C-4), 62.1 
(C-5), 60.5 (C-6), 59.3 (MeO), 53.4 (C-1), 52.4 (C-7), 51.8-50.2 (C-
7’), 51.0 (C-15), 49.7, 45.0 (C-3’ and C-5’), 31.0, 30.13, 30.07, 29.7, 
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27.8, 27.0, 25.5 (C-8 to C-14), 21.1 ppm (CH3 Ac); IR (neat) 1745 
(strong, C=O acetate), 1670 cm-1 (strong, C=O amide); HRMS (ESI) 
m/z calcd for C76H122N14O26Na [M + Na]+ 1669.8547; found 
1669.8459. MS (MALDI) m/z calcd for C76H123N14O26 [M + H]+ 




18 =+6.2 (c 1, CHCl3); 1H NMR 
(CD3CN/CDCl3 9:1 + 11 equiv sodium picrate, 400 MHz) δ 7.76 (6H, 
s, H-1'), 4.97 (12H, m, J  10.3 Hz, H-3, H-4), 4.85 (6H, d, J  16.3 Hz, 
H-3' or H-5'), 4.83 (6H, td, J  9.8, 5.3 Hz, H-2), 4.71 (6H; d, J  16.3 
Hz, H-3' or H-5'), 4.45 (6H, d, J  16.3 Hz, H-3' or H-5'), 4.32 (12H, t, 
J  7.0 Hz, H-12), 4.10 (12H, dd, J  19.4, 13.0 Hz, H-6), 3.97 (6H, d, J  
16.3 Hz, H-3' or H-5'), 3.11 (6H, dd, J 11.1, 5.3 Hz, H-1a), 2.70 (6H, 
m, H-7a), 2.68 (6H, d, J  8.8 Hz, H-5), 2.51 (6H, m, H-7b), 2.35 (6H, 
dd, J 12.7, 11.1 Hz, H-1b), 1.95 (72H, s, AcO), 1.85 (12H, m, H-11), 
1.40 (12H, m, H-8), 1.28 (24H, m, H-9, H-10) ppm; 13C NMR (CD3CN/ 
CDCl3 9:1, 100 MHz) δ 171.4, 170.94, 170.88, 170.6, 170.6–168.9, 
144.4–142.8, 124.7–123.8, 75.3, 70.5, 70.2, 62.1, 60.5, 53.4, 52.3, 
50.8, 50.3–48.5, 44.9–42.6, 30.9, 27.3, 27.0, 25.2, 21.1 ppm; 
HRMS–ESI (m/z): [M + 2H]2+ calcd for C150H224N30O54 1654.7847; 




20 = +5.8 (c 1, CHCl3); ¹H NMR 
(CD3CN/CDCl3 9:1 + 9 eq. sodium picrate, 400 MHz): δ 7.76 (s, 6H; 
H-1'), 4.97 (m, J 10.3 Hz, 12H; H-3, H-4), 4.85 (d, J 16.3 Hz, 6H; H-
3' or H-5'), 4.83 (dt, J 12.7, 5.6 Hz, 6H; H-2), 4.71 (d, J 16.3 Hz, 6H; 
H-3' or H-5'), 4.45 (d, J 16.3 Hz, 6H; H-3' or H-5'), 4.32 (t, J 7.0 Hz, 
12H; H-15), 4.10 (dd, J 19.4, 13.0 Hz, 12H; H-6), 3.97 (d, J 16.3 Hz, 
6H; H-3' or H-5'), 3.11 (dd, J 11.1, 5.3 Hz, 6H; H-1a), 2.70 (m, 6H; H-
7a), 2.68 (d, J 8.8 Hz, 6H; H-5), 2.51 (m, 6H; H-7b), 2.35 (dd, J 12.7, 
11.1 Hz, 6H; H-1b), 1.95 (s, 72H; AcO), 1.85 (m, 12H; H-14), 1.40 
(m, 12H; H-8), 1.28 ppm (m, 60H; H-9 to H-13); ¹³C-NMR 
(CD3CN/CDCl3 9:1, 100 MHz): δ 171.4, 170.94, 170.88, 170.6, 
144.4-142.8, 124.7-123.8, 75.3, 70.5, 70.2, 62.1, 60.5, 53.4, 52.5, 
51.1-50.6, 30.9, 30.2, 30.1, 29.7, 27.9, 27.2, 25.3, 21.1 ppm; HRMS 




24 =  +5.1 (c 1, CHCl3); 1H-NMR 
(CD3CN/CDCl3 9:1, 400 MHz): δ 7.78-76.8 (m, 8H; H-1’), 5.26-5.10 
(m, 4H; H-3’ or H-5’), 4.98 (m, 16H; H-3 and H-4), 4.95-3.83 (m, 28H; 
H-3’ and H-5’), 4.84 (m, 8H; H-2), 4.33 (m, 16H; H-12), 4.12 (s, 16H; 
H-6), 3.11 (m, 8H; H-1a), 2.69 (m, 16H; H-5 and H-7a), 2.55 (m, 8H; 
H-7b), 2.37 (m, 8H; H-1b), 1.99 (s, 96H; AcO), 1.88 (m, 16H; H-11), 
1.42 (br s, 16H; H-8), 1.31 ppm (br s, 32H; H-9 and H-10); 13C-NMR 
(CD3CN/CDCl3 9:1, 100 MHz): δ 171.2, 170.83, 170.79, 170.7, 
170.5, 169.8, 169.7, 167.5, 144.1, 143.2, 124.2, 124.1, 124.0, 123.8, 
75.2, 70.3, 70.1, 61.9, 60.4, 53.3, 52.2, 50.7, 50.0, 49.2, 48.8, 47.9, 
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44.4, 43.5, 42.55, 30.7, 27.1, 26.9, 25.1, 21.0 ppm; HRMS (ESI): m/z 
calcd for C200H299N40O72 [M + 3H]3+ 1471.0316; found 1471.0329. 
 
Compound 4.47b: [𝛼]𝐷
21 =  +5.9 (c 1, CHCl3); 1H-NMR 
(CD3CN/CDCl3 9:1, 400 MHz): δ 7.78-76.8 (m, 8H; H-1’), 5.26-5.10 
(m, 4H; H-3’ or H-5’), 4.99 (m, 16H; H-3 and H-4), 4.95-3.83 (m, 28H; 
H-3’ and H-5’), 4.85 (td, J 9.7, 5.1 Hz, 8H; H-2), 4.33 (m, 16H; H-15), 
4.13 (s, 16H; H-6), 3.14 (dd, J 11.7, 4.8 Hz, 8H; H-1a), 2.69 (m, 16H; 
H-5 and H-7a), 2.55 (m, 8H; H-7b), 2.37 (dd, J 11.9, 10.3 Hz, 8H; H-
1b), 1.99 (s, 96H; AcO), 1.88 (m, 16H; H-14), 1.42 (br s, 16H; H-8), 
1.31 ppm (br s, 80H; H-9 to H-13); 13C-NMR (CD3CN/CDCl3 9:1, 100 
MHz): δ 171.2, 170.83, 170.76, 170.7, 170.5, 169.8, 169.7, 167.5, 
144.1, 143.14, 143.07, 124.17, 124.05, 123.94, 123.8, 75.2, 70.3, 
70.1, 61.9, 60.4, 53.3, 52.2, 50.7, 50.0, 49.2, 48.8, 47.9, 44.4, 43.5, 
42.55, 30.8, 30.0, 29.6, 27.7, 27.1, 25.3, 21.0 ppm; HRMS (ESI): m/z 




20 =  +4.5 (c 1, CHCl3); 1H-NMR 
(CD3CN/CDCl3 9:1, 400 MHz): δ 8.05-7.64 (m, 10H; H-1’), 5.58-3.48 
(br m, 40H; H-3’ and H-5’), 4.98 (m, 20H; H-3 and H-4), 4.84 (m, 10H; 
H-2), 4.34 (br s, 20H; H-12), 4.12 (m, 20H; H-6), 3.12 (br s, 10H; H-
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1a), 2.69 (m, 20H; H-5 and H-7a), 2.56 (m, 10H; H-7b), 2.37 (m, 10H; 
H-1b), 1.99 (s, 120H; AcO), 1.87 (m, 20H; H-11), 1.51-1.15 ppm (m, 
60H; H-8 to H-10); 13C-NMR (CD3CN/CDCl3 9:1, 75.5 MHz): δ 171.9, 
171.4, 171.3, 171.1, 171.0-169.2, 145.0-143.3, 125.6-124.1, 75.7, 
70.9, 70.7, 62.5, 61.0, 53.9, 52.8, 51.4, 50.4-48.9, 45.2-42.3, 31.4, 
27.8, 27.5, 25.8, 21.6 ppm; HRMS (ESI): m/z calcd for 
C250H372N50O90 [M + 2H]2+ 2757.3029; found 2757.3300. 
 
Compound 4.48b: [𝛼]𝐷
21 =  +6.5 (c 1, CHCl3); 1H-NMR 
(CDCl3, 400 MHz): δ 8.14-7.44 (m, 10H; H-1’), 5.86-3.30 (br m, 40H; 
H-3’ and H-5’), 5.04 (m, 20H; H-3 and H-4), 4.93 (m, 10H; H-2), 4.33 
(br s, 20H; H-15), 4.14 (s, 20H; H-6), 3.18 (m, 10H; H-1a), 2.71 (m, 
10H; H-7a), 2.62 (d, J 8.8Hz, 10H; H-5), 2.54 (m, 10H; H-7b), 2.31 
(dd, J 11.6, 9.9 Hz, 10H; H-1b), 2.04 (m, 120H; AcO), 1.89 (m, 20H; 
H-14), 1.51-1.05 ppm (m, 120H; H-8 to H-13); 13C-NMR 
(CD3CN/CDCl3 9:1, 100 MHz): δ 171.4, 170.9, 170.8, 170.6, 170.2-
168.9, 144.4-142.2, 125.0-123.5, 75.3, 70.4, 70.2, 62.0, 60.5, 53.4, 
52.5, 50.9, 50.4-47.0, 45.3-41.5, 31.0, 30.2, 30.1, 29.7, 27.9, 27.2, 
25.4, 21.1 ppm; MS (MALDI-TOF): m/z calcd for average mass of 
C280H430N50O90Na [M + Na]+ 5959.1; found 5958.7. 
 
Compound 4.54: [𝛼]𝐷
20 = +4.2 (c 1, CHCl3); 1H-NMR (CDCl3, 
500 MHz) δ 8.28-7.43 (m, 6H; H-1’), 7.56 (s, 18H; H-16), 5.07-4.96 
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(m, 36H; H-3 and H-4), 4.96-4.89 (m, 18H; H-2), 4.83-3.71 (br m, 
24H; H-3’ and H-5’), 4.50 (m, 48H; H-18 and H-25), 4.27 (m, 36H; H-
15), 4.11 (s, 36H; H-6), 3.94-3.79 (m, 12H; H-24), 3.58-3.31 (m, 72H; 
H-19, H-21, H-22 and H-23), 3.15 (dd, J 11.2, 5.1 Hz, 18H; H-1a), 
2.73-2.64 (m, 18H; H-7a), 2.60 (d, J 8.7 Hz, 18H; H-5), 2.56-2.48 (m, 
18H; H-7b), 2.29 (dd, J 11.2, 10.4 Hz, 18H; H-1b), 2.07-1.92 (m, 
216H; C(O)CH3), 1.85 (m, 36H; H-14), 1.45-1.10 ppm (m, 216H; H-
8, H-9, H-10, H-11, H-12 and H-13); 13C-NMR (CDCl3, 125 MHz) δ 
171.0, 170.4, 170.1, 169.8 (C(O)CH3), 169.5-167.0 (C-4’), 145.2 (C-
17), 143.9-141.3 (C-2’), 125.3-123.6 (C-1’), 122.6 (C-16), 74.7 (C-2), 
71.1, 71.0, 70.2, 69.9 (C-21 to C-24), 69.52, 59.46 (C-3 and C-4), 
69.2 (C-18), 65.1 (C-19), 61.4 (C-5), 59.5 (C-6), 53.0 (C-1), 51.9 (C-
7), 50.3 (C-15 and C-25), 49.4-47.1 (C-3’ or C-5’), 45.4 (C-20), 44.3-
41.0 (C-3’ or C-5’), 30.5, 29.5, 29.1, 27.3, 26.6, 24.6 (C-8 to C-14), 
20.95, 20.93, 20.82, 20.76 ppm (C(O)CH3); IR (neat) 1744 (strong, 
C=O acetate), 1672 cm-1 (strong, C=O amide); HRMS (ESI) average 
m/z calcd for C552H870N96O180 [M + 6H]6+ 1955.2008; found 
1955.2005; MS (MALDI) m/z calcd for C552H864N96O180Na [M + Na]+ 
11748.32; found 11751.97. 
 
Compound 4.55: [𝛼]𝐷
20 = +4.1 (c 1, CHCl3); 1H-NMR (CDCl3, 
500 MHz) δ 7.90-7.39 (m, 32H; H-16 and H-1’), 5.08-4.96 (m, 48H; 
H-3 and H-4), 4.92 (m 24H; H-2), 4.75-3.72 (br m, 32H; H-3’ and H-
5’), 4.56-4.42 (m, 64H; H-18 and H-25), 4.33-4.22 (m, 48H; H-15), 
4.12 (s, 48H; H-6), 3.91-3.77 (m, 16H; H-24), 3.61-3.27 (m, 96H; H-
19, H-21, H-22 and H-23), 3.15 (dd, J 11.2, 4.9 Hz, 24H; H-1a), 2.74-
2.64 (m, 24H; H-7a), 2.60 (d, J 8.9 Hz, 24H; H-5), 2.57-2.47 (m, 24H; 
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H-7b), 2.30 (dd, J 11.2, 10.3 Hz, 24H; H-1b), 2.07-1.93 (m, 288H; 
C(O)CH3), 1.85 (m, 48H; H-14), 1.45-1.12 ppm (m, 288H; H-8, H-9, 
H-10, H-11, H-12 and H-13); 13C-NMR (CDCl3, 125 MHz) δ 171.0, 
170.4, 170.1, 169.8 (C(O)CH3), 169.3-165.0 (C-4’), 145.2 (C-17), 
144.0-141.4 (C-2’), 124.9-123.4 (C-1’), 122.6 (C-16), 74.7 (C-2), 
71.1, 70.9, 70.3, 69.9 (C-21 to C-24), 69.55, 69.49 (C-3 and C-4), 
69.3 (C-18), 65.1 (C-19), 61.4 (C-5), 59.5 (C-6), 53.0 (C-1), 51.9 (C-
7), 50.3 (C-15 and C-25), 50.0-46.8 (C-3’ or C-5’), 45.4 (C-20), 44.2-
41.3 (C-3’ or C-5’), 30.5, 29.5, 29.1, 27.3, 26.6, 24.6 (C-8 to C-14), 
20.96, 20.94, 20.84, 20.77 ppm (C(O)CH3); IR (neat) 1745 (strong, 
C=O acetate), 1676 cm-1 (strong, C=O amide); HRMS (ESI) average 
m/z calcd for C736H1164N128O240 [M + 12H]12+ 1303.7751; found 
1303.7710; MS (MALDI) m/z calcd for C736H1152N128O240Na [M + Na]+ 
15656.8; found 15647.2. 
 
Compound 4.56: [𝛼]𝐷
20 = +4.3 (c 1, CHCl3); 1H-NMR (CDCl3, 
500 MHz) δ 8.14-7.40 (m, 40H; H-16 and H-1’), 5.10-4.97 (m, 60H; 
H-3 and H-4), 4.93 (m, 30H; H-2), 4.73-3.72 (br m, 56H; H-3’ and H-
5’), 4.60-4.37 (m, 80H; H-18 and H-25), 4.29 (t, J 7.1 Hz, 60H; H-15), 
4.12 (s, 60H; H-6), 3.92-3.74 (m, 20H; H-24), 3.61-3.30 (m, 120H; H-
19, H-21, H-22 and H-23), 3.16 (dd, J 11.4, 5.0 Hz, 30H; H-1a), 2.75-
2.65 (m, 30H; H-7a), 2.61 (d, J 8.9 Hz, 30H; H-5), 2.58-2.48 (m, 30H; 
H-7b), 2.30 (t, J 10.7 Hz, 30H; H-1b), 2.07-1.93 (m, 360H; C(O)CH3), 
1.85 (m, 60H; H-14), 1.49-1.11 ppm (m, 360H; H-8, H-9, H-10, H-11, 
H-12 and H-13); 13C-NMR (CDCl3, 125 MHz) δ 171.0, 170.4, 170.1, 
169.8 (C(O)CH3), 169.9-166.5 (C-4’), 145.3 (C-17), 144.0-141.0 (C-
2’), 125.2-123.2 (C-1’), 122.5 (C-16), 74.7 (C-2), 71.1, 71.0, 70.3, 
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69.9 (C-21 to C-24), 69.6, 69.5 (C-3 and C-4), 69.3 (C-18), 65.1 (C-
19), 61.4 (C-5), 59.5 (C-6), 53.0 (C-1), 51.9 (C-7), 60.4 (C-15 and C-
25), 49.2-47.7 (C-3’ or C-5’), 45.4 (C-20), 44.6-40.9 (C-3’ or C-5’), 
30.5, 29.5, 29.0, 27.3, 26.6, 24.6 (C-8 to C-14), 20.98, 20.96, 20.86, 
20.79 ppm (C(O)CH3); IR (neat) 1744 (strong, C=O acetate), 1676 
cm-1 (strong, C=O amide); HRMS (ESI) average m/z calcd for 
C920H1452N160O300Na + HCOOH [M + 12H + Na + HCOOH]13+ 
1508.5584; found 1508.9507; MS (MALDI) m/z calcd for 
C920H1440N160O300Na [M + Na + HCOOH]+ 19565.20; found 19575.83. 
 
Compound 4.57: [𝛼]𝐷
20 = +3.1 (c 1, CHCl3); 1H-NMR (CDCl3, 
400 MHz) δ 8.07-7.46 (m, 48H; H-16 and H-1’), 5.10-4.84 (m, 108H; 
H-2, H-3 and H-4), 4.80-3.72 (br m, 48H; H-3’ and H-5’), 4.50 (m, 
96H; H-18 and H-25), 4.28 (m, 72H; H-15), 4.12 (s, 72H; H-6), 3.86 
(br s, 24H; H-24), 3.62-3.26 (m, 144H; H-19, H-21, H-22 and H-23), 
3.15 (dd, J 11.2, 4.8 Hz, 36H; H-1a), 2.68 (m, 36H; H-7a), 2.60 (d, J 
8.7 Hz, 36H; H-5), 2.52 (m, 36H; H-7b), 2.29 (dd, J 11.2, 10.3 Hz, 
36H; H-1b), 2.11-1.90 (several singlets, 432H; C(O)CH3), 1.85 (m, 
72H; H-14), 1.50-1.07 ppm (m, 432H; H-8 to H-13); 13C-NMR (CDCl3, 
100 MHz) δ 170.9, 170.4, 170.0, 169.8 (C(O)CH3), 169.9-166.5 (C-
4’), 145.2 (C-17), 144.0-141.0 (C-2’), 125.2-123.2 (C-1’), 122.6 (C-
16), 74.8 (C-2), 71.1, 71.0, 70.2, 69.9 (C-21 to C-24), 69.6, 69.5 (C-
3 and C-4), 69.3 (C-18), 65.1 (C-19), 61.5 (C-5), 59.6 (C-6), 53.0 (C-
1), 51.9 (C-7), 50.3 (C-15 and C-25), 49.5-47.5 (C-3’ or C-5’), 45.4 
(C-20), 44.5-40.5 (C-3’ or C-5’), 30.5, 29.5, 29.1, 27.3, 26.6, 24.8 (C-
8 to C-14), 20.93, 20.82, 20.8 ppm (C(O)CH3); IR (neat) 1743 
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(strong, C=O acetate), 1673 cm-1 (strong, C=O amide); MS (ESI) 




20= +2.1 (c 1, CH3OH); 1H-NMR (CDCl3, 
400 MHz) δ 8.10-7.45 (m, 56H, H-16, H-1’), 5.12-5.00 (m, 84H, H-4, 
H-3), 5.00-4.93 (m, 42H, H-2), 4.83-3.68 (br m, 56H; H-3’ and H-5’), 
4.52 (m, 112H, H-18, H-25), 4.34-4.26 (m, 84H, H-15), 4.16 (s, 84H, 
H-6), 3.91 (br s, 28H, H-24), 3.65-3.32 (m, 168H, H-19, H-21, H-22 
and H-23), 3.20 (dd, J 11.0, 4.5 Hz, 42H, H-1a), 2.80-2.53 (m, 126H, 
H-5, H-7), 2.32 (dd, J 11.0, 10.5 Hz, 42H, H-1b), 2.08-1.97 (several 
singlets, 504H, C(O)CH3), 1.87 (m, 84H, H-14), 1.49-1.12 (m, 504H, 
H-8 to H-13) ppm ; 13C-NMR (CDCl3, 100 MHz) δ 170.9, 170.4, 
170.1, 169.8 (C(O)CH3), 169.9-168.5 (C-4’), 145.3 (C-17), 144-142.0 
(C-2’), 125.4-123.5 (C-1’), 122.7 (C-16), 74.8 (C-2), 71.2, 71.0, 70.3, 
70.0 (C-21 to C-24), 69.6, 69.5 (C-3 and C-4), 69.3 (C-18), 65.1 (C-
19), 61.5 (C-5), 59.6 (C-6), 53.0 (C-1), 51.9 (C-7), 50.4 (C-15 and C-
25), 49.5-47.5 (C-3’ or C-5’), 45.5 (C-20), 44.5-40.5 (C-3’ or C-5’), 
30.5, 29.6, 29.2, 27.3, 26.7, 24.8 (C-8 to C-14), 20.98, 20.96, 20.86, 
20.80 (C(O)CH3) ppm ; IR (neat) 1743 (strong, C=O acetate), 1673 
(strong, C=O amide) cm-1 ; MS (ESI) average m/z calcd for 
C1288H2028N224O420 [M + 12H]12+ 2280.96; found 2280.53 ; MS 





20 = +3.0 (c 1, CHCl3); 1H-NMR (CDCl3, 
400 MHz) δ 8.09-7.52 (m, 64H; H-16 and H-1’), 5.13-4.86 (m, 144H; 
H-2, H-3 and H-4),  4.85-3.68 (br m, 64H; H-3’ and H-5’), 4.50 (m, 
128H; H-18 and H-25), 4.29 (m, 96H; H-15), 4.13 (s, 96H; H-6), 3.88 
(br s, 32H; H-24), 3.65-3.25 (m, 192H; H-19, H-21, H-22 and H-23), 
3.17 (dd, J 11.3, 4.8 Hz, 48H; H-1a), 2.70 (m, 48H; H-7a), 2.62 (d, J 
8.9 Hz, 48H; H-5), 2.54 (m, 48H; H-7b), 2.31 (dd, J 11.3, 10.5 Hz, 
48H; H-1b), 2.10-1.92 (several singlets, 576H; C(O)CH3), 1.86 (m, 
96H; H-14), 150-1.09 ppm (m, 576H; H-8 to H-13); 13C-NMR (CDCl3, 
100 MHz) δ 170.9, 170.4, 170.1, 169.8 (C(O)CH3), 169.9-166.5 (C-
4’), 145.2 (C-17), 144.0-141.0 (C-2’), 125.2-123.2 (C-1’), 122.7 (C-
16), 74.8 (C-2), 71.1, 71.0, 70.2, 70.0 (C-21 to C-24), 69.6, 69.5 (C-
3 and C-4), 69.3 (C-18), 65.1 (C-19), 61.5 (C-5), 59.6 (C-6), 53.0 (C-
1), 51.9 (C-7), 50.3 (C-15 and C-25), 49.5-47.5 (C-3’ or C-5’), 45.5 
(C-20), 44.5-40.5 (C-3’ or C-5’), 30.5, 29.6, 29.2, 27.3, 26.7, 24.8 (C-
8 to C-14), 20.98, 20.95, 20.85, 20.79 ppm (C(O)CH3); IR (neat) 1743 
(strong, C=O acetate), 1672 cm-1 (strong, C=O amide); MS (MALDI) 
m/z calcd for C1472H2305N256O480 [M + H]+ 31268.5; found 31265.0. 
 
Compound 4.66: [𝛼]𝐷
20 =  +2.5 (c 1, CH3OH); 1H-NMR 
(CDCl3, 400 MHz) δ 8.15-7.53 (m, 14H; H-1’), 5.10-4.99 (m, 28H; H-
3 and H-4), 4.99-4.90 (m, 14H; H-2), 4.83-3.72 (br m, 56H; H-3’ and 
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H-5’), 4.33 (br s, 28H; H-15), 4.15 (br s, 28H; H-6), 3.22-3.14 (m, 
14H; H-1a), 2.78-2.65 (m, 14H; H-7a), 2.65-2.60 (m, 14H; H-5), 2.59-
2.50 (m, 14H; H-7b), 2.32 (t, J 10.8 Hz, 14H; H-1b), 2.09-1.96 (m, 
168H; C(O)CH3), 1.93-1.84 (m, 28H; H-14), 1.38-1.13 ppm (m, 168H; 
H-8 to H-13); 13C-NMR (CDCl3, 75 MHz) δ 170.9, 170.4, 170.0, 169.8 
(C(O)-CH3), 169.5-168.0 (C-4’), 144.8-141.5 (C-2’), 124.9-122.6 (C-
1’), 74.9 (C-3), 69.8, 69.6  (C-4 and C-2), 61.7 (C-5), 59.8 (C-6), 53.1 
(C-1), 52.0 (C-7), 50.6 (C-15), 30.4 (C-14), 29.8, 29.6, 29.2, 27.4, 
26.8 (from C-9 to C-13), 25.0 (C-8), 21.0, 20.9, 20.84, 20.78 
(C(O)CH3) ppm; IR (neat) 1745 (strong, C=O acetate), 1673 cm-1 
(strong, C=O amide); HRMS (ESI) average m/z calcd for 
C392H606N70O126 [M + 4H]4+ 2078.6075; found 2078.6117. 
 
General procedure for the synthesis of deprotected 
cyclopeptoid-based iminosugar click clusters 4.45a, 4.45b, 
4.49a-4.51a, 4.49b-4.51b, 4.60-4.65, and 4.67.    
Acetate-protected iminosugar click clusters 4.44a, 4.44b, or 
4.46a-4.48a, 4.46b-4.48b, 4.54-4.59, and 4.66  were dissolved in a 
1:1 mixture of water/MeOH (typically 600 µL/µmol). To the resulting 
mixture, Amberlite IRA400 (OH– ) (5.5n g/mmol of substrate; n = 
number of acetate groups) was added. The suspension was gently 
stirred overnight at 40 °C and the mixture was filtrated. Then the 
filtrate was concentrated to give deprotected iminosugar click 




20 =  -7.8 (c 1, MeOH); 1H-NMR 
(CD3OD, 400 MHz) δ 8.18-7.78 (m, 2H; H-1’), 5.10-3.08 (m, 52H; H-
2, H-4, H-12, H-3’, H-5’, H-7’, H-8’, H-9’ and MeO), 3.86 (m, 4H; H-
6), 3.16 (m, 2H; H-3), 2.98 (dd, J 11.0, 4.4 Hz, 2H; H-1a), 2.80 (m, 
2H; H-7a), 2.56 (m, 2H; H-7b), 2.16 (t, J 11.0 Hz, 2H; H-1b), 2.11 (d, 
J 10.7 Hz, 2H; H-5), 1.93 (m, 4H; H-11), 1.51 (m, 4H; H-8), 1.36 ppm 
(m, 8H; H-9 and H-10);13C-NMR (CD3OD, 100 MHz) δ 174.0-171.0 
(C-4’ and C-6’), 146.2-143.3 (C-2’), 125.0 (C-1’), 80.8 (C-3), 72.2 (C-
4), 72.6-70.9 (C-8’ and C-9’), 70.9 (C-2), 67.6 (C-5), 59.8 (C-6), 59.5 
(MeO), 57.9 (C-1), 53.7 (C-7), 51.4 (C-12), 51.2-49.6, 45.6-43.9 (C-
3’, C-5’ and C-7’), 31.4, 28.1, 27.5, 25.3 ppm (C-8 to C-11); IR (neat) 
3376 (broad, O-H), 1651 cm-1 (strong, C=O amide); MS (MALDI) m/z 
calcd for C54H94N14O18Na [M + H]+ 1227.694; found 1227.729. 
 
  Compound 4.45b: [𝛼]𝐷
20 =  -6 (c 1, MeOH); 1H-NMR 
(CD3OD, 400 MHz) δ 8.15-7.77 (m, 2H; H-1’), 5.04-3.10 (m, 52H; H-
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2, H-4, H-15, H-3’, H-5’, H-7’, H-8’, H-9’ and MeO), 3.86 (m, 4H; H-
6), 3.15 (m, 2H; H-3), 3.00 (dd, J 10.8, 4.9 Hz, 2H; H-1a), 2.80 (m, 
2H; H-7a), 2.57 (m, 2H; H-7b), 2.18 (t, J 10.8 Hz, 2H; H-1b), 2.11 (d, 
J 9.4 Hz, 2H; H-5), 1.91 (m, 4H; H-14), 1.50 (m, 4H; H-8), 1.35 ppm 
(m, 20H; H-9, H-10, H-11, H-12 and H-13); 13C-NMR (CD3OD, 100 
MHz) δ 174.6-169.3 (C-4’ and C-6’), 146.0-143.5 (C-2’), 125.0 (C-1’), 
80.6 (C-3), 72.0 (C-4), 71.8, 70.9 (C-8’ and C-9’), 70.7 (C-2), 67.4 
(C-5), 59.5 (C-6), 59.7-58.7 (MeO), 57.7 (C-1), 53.8 (C-7), 51.3 (C-
15), 51.9-49.5, 45.5-43.5 (C-3’, C-5’ and C-7’), 31.3, 30.5, 30.0, 28.5, 
27.4, 25.1 ppm (C-8 to C-14); IR (neat) 3401 (broad, O-H), 1660 cm-
1 (strong, C=O amide); HRMS (ESI) m/z calcd for C60H107N14O18 
[M + H] + 1311.7882; found 1311.7881. 
 
Compound 4.49a: [𝛼]𝐷
20 =  -28.0 (c 0.1, H2O/DMSO 1:1 + 
0.1% TFA); 1H NMR (D2O + 0.1% TFA, 500 MHz) δ 8.21–7.60 (m, 
6H, H-1’), 5.20–3.72 (br m, 12H, H-3’ and H-5’), 4.35 (s, 12H, H-12), 
3.85 (s, 12H, H-6), 3.59 (s, 6H, H-2), 3.43 (s, 6H, H-4), 3.31 (s, 6H, 
H-3), 3.16 (s, 6H, H-1a), 2.91 (s, 6H, H-7a), 2.78 (s, 6H, H-7b), 2.56 
(s, 12H, H-1b and H-5), 1.84 (s, 12H, H-11), 1.51 (s, 12H, H-8), 1.25 
(s, 24H, H-9 and H-10) ppm; 13C NMR (D2O + 0.1% TFA, 125 MHz) 
δ 173.4–169.3, 145.6–142.8, 127.4–124.6, 78.9, 70.4, 69.3, 66.8, 
57.5, 55.9, 53.9, 51.9, 51.5–49.3, 46.3–43.3, 30.9, 27.3, 26.8, 24.0 
ppm; HRMS–ESI (m/z): [M + 2H]2+ calcd for C102H174N30O30 




20 = -14.0 (c 0.0625, H2O/DMSO 1:1 + 
0.1% TFA); 1H-NMR (D2O/CD3OD 1:1, 400 MHz): δ 8.13-7.68 (m, 
6H; H-1’), 5.09-3.89 (br m, 12H; H-3’ and H-5’), 4.36 (s, 12H; H-15), 
3.80 (dd, J 19.6, 12.8 Hz, 12H; H-6), 3.47 (td, J 9.2, 5.0 Hz, 6H; H-
2), 3.32 (t, J 9.6 Hz, 6H; H-4), 3.16 (t, J 9.4 Hz, 6H; H-3), 2.93 (dd, J 
10.6, 5.0 Hz, 6H; H-1a), 2.67 (s, 6H; H-7a), 2.56 (s, 6H; H-7b), 2.20 
(dd, J 10.6, 9.2 Hz, 6H; H-1b), 2.13 (d, J 9.6 Hz, 6H; H-5), 1.83 (s, 
12H; H-14), 1.40 (s, 12H; H-8), 1.23 ppm (s, 60H; H-9 to H-13); 13C-
NMR (D2O + 0.1% TFA, 125 MHz): δ 173.5-169.4, 144.6-142.7, 
127.1-124.7, 77.5, 68.7, 67.8, 66.7, 55.2, 54.8, 54.7, 52.2, 51.7-48.8, 
46.4-43.2, 31.0, 30.2-28.9, 27.7-26.4, 24.8 ppm; HRMS (ESI): m/z 
calcd for C120H212N30O30 [M + 2H]2+ 1276.7987; found 1276.7991. 
 
Compound 4.50a:  [𝛼]𝐷
20 =  -9.6 (c 1, H2O); 1H-NMR 
(D2O/CD3OD 1:1, 400 MHz): δ 8.05-7.77 (m, 8H; H-1’), 5.11-4.02 (br 
m, 32H; H-3’ and H-5’), 4.37 (m, 16H; H-12), 3.77 (m, 16H; H-6), 3.47 
(br s, 8H; H-2), 3.31 (m, 8H; H-4), 3.16 (m, 8H; H-3), 2.91 (br s, 8H; 
H-1a), 2.66 (br s, 8H; H-7a), 2.53 (br s, 8H, H-7b), 2.14 (m, 16H; H-
1b and H-5), 1.85 (br s, 16H; H-11), 1.39 (br s, 16H; H-8), 1.25 ppm 
(m, 32H; H-9 and H-10); 13C-NMR (D2O/CD3OD 1:1, 100 MHz): δ 
171.7, 171.4, 170.9, 170.3, 169.3, 144.2, 144.1, 143.5, 143.3, 125.5, 
79.8, 71.4, 70.9, 70.2, 66.5, 59.1, 56.9, 53.3, 51.5, 50.9-49.8, 44.7-
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43.2, 30.7, 27.6, 26.9, 24.0 ppm; MS (MALDI-TOF): m/z calcd for 
C136H233N40O40 [M + H]+ 3066.7; found 3066.8. 
 
Compound 4.50b:  [𝛼]𝐷
20 ==  -10.0 (c 1, MeOH); 1H-NMR 
(CD3OD, 400 MHz): δ 8.11-7.80 (m, 8H; H-1’), 5.25-3.99 (br m, 32H; 
H-3’ and H-5’), 4.40 (m, 16H; H-15), 3.84 (s, 16H; H-6), 3.49 (td, J 
9.5, 4.5 Hz, 8H; H-2), 3.36 (t, J 9.0 Hz, 8H; H-4), 3.16 (t, J 9.0 Hz, 
8H; H-3), 2.98 (dd, J 9.8, 4.4 Hz, 8H; H-1a), 2.75 (m, 8H; H-7a), 2.57 
(m, 8H; H-7b), 2.18 (t, J 10.7 Hz, 8H; H-1b), 2.12 (d, J 10.9 Hz, 8H; 
H-5), 1.89 (br s, 16H; H-14), 1.47 (br s, 16H; H-8), 1.31 ppm (m, 80H; 
H-9 to H-13); 13C-NMR (CD3OD, 100 MHz): δ 172.0, 171.2, 170.6, 
169.3, 144.7, 144.5, 143.9, 143.6, 125.4, 125.33, 125.29, 125.23, 
80.6, 72.1, 70.8, 67.3, 59.6, 57.7, 53.9, 51.6, 51.0-49.6, 44.6, 44.3, 
44.0, 43.7, 31.4, 30.6, 30.2, 28.7, 27.6, 25.1 ppm; MS (MALDI-TOF): 
m/z calcd for C160H281N40O40 [M + H]+ 3403.1; found 3403.3. 
 
Compound 4.51a: [𝛼]𝐷
20 = -10.2 (c 1, H2O); 1H-NMR (D2O, 
500 MHz): δ 8.15-7.62 (m, 10H; H-1’), 5.69-3.85 (br m, 40H; H-3’ and 
H-5’), 4.35 (m, 20H; H-12), 3.76 (m, 20H; H-6), 3.47 (m, 10H; H-2), 
3.30 (m, 10H; H-4), 3.17 (m, 10H; H-3), 2.90 (m, 10H; H-1a), 2.61 
(m, 10H; H-7a), 2.50 (m, 10H; H-7b), 2.15 (m, 20H; H-1b and H-5), 
1.80 (m, 20H; H-11), 1.35 (m, 20H; H-8), 1.18 ppm (m, 40H; H-9 and 
H-10); 13C-NMR (D2O, 125 MHz): δ 171.5-167.7, 143.5-141.1, 124.6, 
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78.3, 70.0, 68.8, 65.0, 57.5, 55.3, 51.9, 50.4, 49.3-47.0, 43.9-41.5, 
29.4, 26.1, 25.5, 22.5 ppm; HRMS (ESI): m/z calcd for 
C170H292N50O50 [M + 2H]2+ 1917.0916; found 1917.1349. 
 
Compound 4.51b:[𝛼]𝐷
20 = -6.5 (c 0.5, MeOH/H2O 1:1); 1H-
NMR (D2O/CD3OD 1:1, 400 MHz): δ 8.16-7.71 (m, 10H; H-1’), 5.64-
4.03 (br m, 40H; H-3’ and H-5’), 4.37 (m, 20H; H-15), 3.82 (m, 20H; 
H-6), 3.50 (t, J 9.7, 4.7 Hz, 10H; H-2), 3.35 (t, J 9.7 Hz, 10H; H-4), 
3.18 (t, J 9.4 Hz, 10H; H-3), 2.96 (d, J 9.4 Hz, 10H; H-1a), 2.70 (m, 
10H; H-7a), 2.59 (m, 10H; H-7b), 2.22 (t, J 11.1 Hz, 10H; H-1b), 2.16 
(d, J 9.5 Hz, 10H; H-5), 1.86 (m, 20H; H-14), 1.43 ppm (m, 20H; H-
8), 1.24 (m, 100H; H-9 to H-13); 13C-NMR (CD3CN/CD3OD 1:1, 100 
MHz): δ 172.4-168.4, 144.7-141.6, 124.7, 79.6, 71.1, 69.9, 66.3, 
58.7, 56.8, 53.1, 51.1, 50.3, 59.0, 44.1-42.0, 30.6, 29.9, 29.4, 28.0, 
26.9, 24.0 ppm; MS (MALDI-TOF): m/z calcd for C200H351N50O50 [M 
+ H]+ 4253.7; found 4254.1. 
 
Compound 4.60: [𝛼]𝐷
20 =  -10.0 (c 1, MeOH); 1H-NMR 
(CD3OD, 500 MHz) δ 8.20-7.78 (m, 6H; H-1’), 7.94 (s, 18H; H-16), 
4.62-4.42 (m, 48H; H-18 and H-25), 4.36 (s, 36H; H-15), 3.94-3.76 
(m, 48H; H-6 and H-24), 3.58-3.28 (m, 108H; H-2, H-4, H-19, H-21, 
H-22 and H-23), 3.19 (t, J 9.2 Hz, 18H; H-3), 2.98 (dd, J 11.0, 4.9 Hz, 
18H; H-1a), 2.80-2.68 (m, 18H; H-7a), 2.65-2.53 (m, 18H; H-7b), 
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2.22 (t, J 11.0 Hz, 18H; H-1b), 2.16 (d, J 9.8 Hz, 18H; H-5), 1.85 (s, 
36H; H-14), 1.45 (s, 36H; H-8), 1.25 ppm (s, 180H; H-9 to H-13); 13C-
NMR (CD3OD/D2O 2.75:1, 125 MHz) δ 174.1-168.2 (C-4’), 146.0 (C-
17), 145.0-142.8 (C-2’), 125.8 (C-1’), 125.3 (C-16), 80.2 (C-3), 72.0 
(C-21 or C-22 or C-23 or C-24), 71.7 (C-4), 71.2 (C-21 or C-22 or C-
23 or C-24), 70.7 (C-21 or C-22 or C-23 or C-24), 70.5 (C-2), 70.3 
(C-21 or C-22 or C-23 or C-24), 69.9 (C-18), 66.9 (C-5), 65.3 (C-19), 
59.3 (C-6), 57.4 (C-1), 53.7 (C-7), 51.5 (C-15 and C-25), 46.4 (C-20), 
45.8-43.8 (C-3’ or C-5’), 31.3 (C-14), 30.5, 30.0, 28.6, 27.4 (C-9 to 
C-13), 24.6 ppm (C-8); IR (neat) 3343 (broad, O-H), 1668 cm-1 
(strong, C=O amide); HRMS (ESI) average m/z calcd for 
C408H726N96O108 [M + 6H]6+ 1450.740; found 1450.722; MS (MALDI) 
m/z calcd for C408H721N96O108 [M + H]+ 8699.7; found 8700.1. 
 
Compound 4.61: [𝛼]𝐷
20 =  -10.0 (c 1, MeOH); 1H-NMR 
(CD3OD/D2O 2.25:1, 500 MHz) δ 8.20-7.73 (m, 32H; H-16 and H-1’), 
4.60-4.40 (m, 64H; H-18 and H-25), 4.40-4.24 (m, 48H; H-15), 3.97-
3.74 (m, 64H; H-6 and H-24), 3.59-3.25 (m, 144H; H-2, H-4, H-19, 
H-21, H-22 and H-23), 3.19 (t, J 9.3 Hz, 24H; H-3), 2.97 (dd, J 11.1, 
4.7 Hz, 24H; H-1a), 2.80-2.66 (m, 24H; H-7a), 2.66-2.52 (m, 24H; H-
7b), 2.22 (t, J 11.1 Hz, 24H; H-1b), 2.15 (d, J 9.7 Hz, 24H; H-5), 1.84 
(m, 48H; H-14), 1.44 (m, 48H; H-8), 1.36-1.08 ppm (m, 240H; H-9 to 
H-13); 13C-NMR (CD3OD/D2O 2.25:1, 125 MHz) δ 172.4-168.4 (C-
4’), 145.9 (C-17), 144.7-142.7 (C-2’), 125.9 (C-1’), 125.3 (C-16), 80.2 
(C-3), 72.0 (C-21 or C-22 or C-23 or C-24), 71.7 (C-4), 71.2 (C-21 or 
C-22 or C-23 or C-24), 70.7 (C-21 or C-22 or C-23 or C-24), 70.5 (C-
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2), 70.3 (C-21 or C-22 or C-23 or C-24), 69.9 (C-18), 66.9 (C-5), 65.3 
(C-19), 59.2 (C-6), 57.3 (C-1), 53.7 (C-7), 51.5 (C-15 and C-25), 46.4 
(C-20), 45.0-43.2 (C-3’ or C-5’), 31.3 (C-14), 30.5, 30.0, 28.6, 27.4 
(C-9 to C-13), 24.6 ppm (C-8); IR (neat) 3351 (broad, O-H), 1674 cm-
1 (strong, C=O amide); HRMS (ESI) average m/z calcd for 
C544H969N128O144 [M + 9H]9+ 1289.584; found 1289.598; MS (MALDI) 
m/z calcd for C544H961N128O144 [M + H]+ 11599.25; found 11601.85. 
 
Compound 4.62: [𝛼]𝐷
20 =  -10.0 (c 1, MeOH); 1H-NMR 
(CD3OD/D2O 2.25:1, 500 MHz) δ 8.22-7.85 (m, 40H; H-16 and H-1’), 
4.63-4.41 (m, 80H; H-18 and H-25), 4.41-4.25 (m, 60H; H-15), 3.98-
.372 (m, 80H; H-6 and H-24), 3.60-3.25 (m, 180H; H-2, H-4, H-19, 
H-21, H-22 and H-23), 3.20 (t, J 9.1 Hz, 30H; H-3), 3.04-2.90 (m, 
30H; H-1a), 2.80-2.67 (m, 30H; H-7a), 2.65-2.52 (m, 30H; H-7b), 
2.23 (t, J 11.0 Hz, 30H; H-1b), 2.16 (d, J 9.5 Hz, 30H; H-5), 1.83 (m, 
60H; H-14), 1.44 (m, 60H; H-8), 1.24 ppm (m, 300H; H-9, H-10, H-
11, H-12 and H-13); 13C-NMR (CD3OD/D2O 2.25:1, 125 MHz) δ 
172.1-169.4 (C-4’), 145.9 (C-17), 144.6-142.9 (C-2’), 126.0 (C-1’), 
125.2 (C-16), 80.1 (C-3), 72.0 (C-21 or C-22 or C-23 or C-24), 71.6 
(C-4), 71.2 (C-21 or C-22 or C-23 or C-24), 70.6 (C-21 or C-22 or C-
23 or C-24), 70.4 (C-2), 70.3 (C-21 or C-22 or C-23 or C-24), 69.9 
(C-18), 66.8 (C-5), 65.3 (C-19), 59.2 (C-6), 57.3 (C-1), 53.7 (C-7), 
51.5 (C-15 and C-25), 46.4 (C-20), 45.1-42.5 (C-3’ and C-5’), 31.3 
(C-14), 30.5, 30.0, 28.5, 27.4 (C-9 to C-13), 24.6 ppm (C-8); IR (neat) 
3350 (broad, O-H), 1677 cm-1 (strong, C=O amide); MS (MALDI) m/z 




20 = -4.8 (c 0.47, MeOH/H2O 75/10); 1H-
NMR (CD3OD, 400 MHz) δ 8.16-7.85 (m, 48H; H-16 and H-1’), 4.57-
4.42 (m, 96H; H-18 and H-25), 4.39-4.29 (m, 72H; H-15), 3.92-3.76 
(m, 96H; H-6 and H-24), 3.58-3.24 (m, 216H; H-2, H-4, H-19, H-21, 
H-22 and H-23), 3.19 (t, J 9.0 Hz, 36H; H-3), 3.02-2.90 (m, 36H; H-
1a), 2.80-2.66 (m, 36H; H-7a), 2.65-2.50 (m, 36H; H-7b), 2.21 (t, J 
11.2 Hz, 36H; H-1b), 2.15 (d, J 10.6 Hz, 36H; H-5), 1.87-1.76 (m, 
72H; H-14), 1.49-1.36 (m, 72H; H-8), 1.32-1.15 ppm (m, 360H; H-9, 
H-10, H-11, H-12 and H-13); 13C-NMR (CD3OD, 100 MHz) δ 172.1-
169.4 (C-4’), 145.9 (C-17), 125.0 (C-16), 80.0 (C-3), 71.9 (C-21 or C-
22 or C-23 or C-24), 71.5 (C-4), 71.0 (C-21 or C-22 or C-23 or C-24), 
70.3 (C-2), 70.1 (C-21 or C-22 or C-23 or C-24), 69.8 (C-18), 66.7 
(C-5), 65.1 (C-19), 59.1 (C-6), 57.2 (C-1), 53.7 (C-7), 51.3 (C-15 and 
C-25), 46.2 (C-20), 31.1 (C-14), 30.3, 29.8, 28.4, 27.2 (C-9 to C-13), 
24.5 (C-8) ppm; IR (neat) 3335 (broad, O-H), 1671 cm-1 (strong, C=O 
amide); MS (ESI) average m/z calcd for C816H1449N92O216 [M + 9H]9+ 
1934.1; found 1934.1; MS (MALDI) m/z calcd for C816H1441N192O216 
[M + H]+; 17398.369, found 17398.151. 
 
Compound 4.64: [𝛼]𝐷
20 = -4.3 (c 0.345, MeOH/H2O 75/10); 
1H-NMR (CD3OD, 400 MHz) δ 8.16-7.85 (m, 56H; H-16 and H-1’), 
4.52-4.43 (m, 112H; H-18 and H-25), 4.39-4.31 (m, 84H; H-15), 3.92-
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3.77 (m, 112H; H-6 and H-24), 3.58-3.04 (m, 294 H; H-2, H-3, H-4, 
H-19, H-21, H-22 and H-23) 3.02-2.94 (dd, J 10.5, 5.0 Hz, 42H; H-
1a), 2.82-2.68 (m, 42H; H-7a), 2.62-2.51 (m, 42H; H-7b), 2.21 (t, J 
10.5 Hz, 42H; H-1b), 2.12 (d, J 9.6 Hz, 42H; H-5), 1.88-1.79 (m, 84H; 
H-14), 1.50-1.39 (m, 84H; H-8), 1.37-1.20 ppm (m, 420H; H-9, H-10, 
H-11, H-12 and H-13); 13C-NMR (CD3OD, 100 MHz) δ 172.1-169.4 
(C-4’), 146.0 (C-17), 144.6-142.9 (C-2’), 126.5-125.7 (C-1’), 125.0 
(C-16), 80.4 (C-3), 72.1 (C-21 or C-22 or C-23 or C-24), 71.9 (C-4), 
71.2 (C-21 or C-22 or C-23 or C-24), 70.6 (C-2), 70.5 (C-21, C-22, 
C-23 or C-24), 69.9 (C-18), 67.1 (C-5), 65.4 (C-19), 59.4 (C-6), 57.6 
(C-1), 53.7 (C-7), 51.4 (C-15 and C-25), 46.5 (C-20), 45.1-42.5 (C-3’ 
and C-5’), 31.4 (C-14), 30.6, 30.1, 28.6, 27.5 (C-9 to C-13), 24.3 ppm 
(C-8); IR (neat) 3351 (broad, O-H), 1671 cm-1 (strong, C=O amide); 




20 = -6.2 (c 0.487, MeOH/H2O 75/10); 
1H-NMR (CD3OD, 400 MHz) δ 8.22-7.85 (m, 64H; H-16 and H-1’), 
4.56-4.41 (m, 128H; H-18 and H-25), 4.39-4.30 (m, 96H; H-15), 3.92-
3.76 (m, 128H; H-6 and H-24), 3.58-3.07 (m, 336H; H-2, H-3, H-4, 
H-19, H-21, H-22 and H-23), 3.02-2.94 (dd, J 10.8, 4.2 Hz, 48H; H-
1a), 2.81-2.66 (m, 48H; H-7a), 2.63-2.51 (m, 48H; H-7b), 2.21 (t, J 
10.8 Hz, 48H; H-1b), 2.12 (d, J 9.8 Hz, 48H; H-5), 1.90-1.77 (m, 96H; 
H-14), 1.52-1.37 (m, 96H; H-8), 1.37-1.20 ppm (m, 480H; H-9, H-10, 
H-11, H-12 and H-13); 13C-NMR (CD3OD, 100 MHz) δ 145.9 (C-17), 
125.0 (C-16), 80.2 (C-3), 70.3 (C-21 or C-22 or C-23 or C-24), 70.0 
(C-18), 66.9 (C-5), 65.4 (C-19), 59.3 (C-6), 57.4 (C-1), 53.7 (C-7), 
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51.5 (C-15 and C-25), 46.4 (C-20), 31.3 (C-14), 30.5, 30.0, 28.5, 27.4 
(C-9 to C-13), 24.7 ppm (C-8); IR (neat) 3351 (broad, O-H), 1671 cm-
1 (strong, C=O amide); MS (ESI) average m/z calcd for 
C1088H1932N256O288 [M + 12H]12+ 1934.0; found 1934.0; MS (MALDI) 
m/z calcd for C1088H1921N256O288 [M + H]+ 23197.49; found 23196.22.  
 
Compound 4.67: 1H-NMR (CDCl3, 400 MHz) δ 8.15-7.81 (m, 
14H; H-1’), 4.49-4.18 (m, 28H; H-15), 3.90-3.77 (m, 28H; H-6), 3.50 
(td, J 9.9 and 4.2 Hz, 14H, H-2), 3.36 (t, J 9.9 Hz, 14H, H-4), 3.17 (t, 
J 9.9Hz, 14H, H-3), 2.97 (dd, J 10.9 and 4.2 Hz, 14H, H-1a), 2.81-
2.67 (m, 14H, H-7a), 2.63-2.50 (m, 14H, H-7b), 2.19 (t, J 9.9 Hz, 14H, 
H-1b), 2.13 (d, J 9.9, 14H, H-5), 1.99-1.72 (m, 28H, H-14), 1.52-1.39 
(m, 28H, H-8), 1.36-1.15 (m, 140H, from H-9 to H-13) ppm; 13C-NMR 
(CDCl3, 100 MHz) δ 125.4 (C-1’), 80.3 (C-3), 71.8 (C-4), 70.5 (C-2), 
67.0 (C-5), 59.4 (C-6), 57.4 (C-1), 53.7 (C-7), 51.5 (C-15), 44.6-42.4 
(C-3’ or C-5’), 31.2 (C-14), 30.5, 30.0, 28.5, 27.4 (from C-9 to C-13), 
24.8 (C-8) ppm; IR (neat) : 3348 (broad, O-H), 1655 cm-1 (strong, 
C=O amide); HRMS (ESI) m/z calcd for C280H497N70O70 [M + 7H]7+ 
851.535; found 851.971 and C280H496N70O70 [M + 6H]6+ 993.290; 
found 993.965. 
7.5     COMPOUNDS FROM CHAPTER 5 
7.5.1. Synthesis and Characterization of Peptoidic Scaffolds 
General procedure for sub-monomer solid-phase synthesis of 
the linear peptoids 5.15–5.19 
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Linear peptoid oligomers 5.15-5.19 were synthesized using 
a submonomer solid-phase approach. In a typical synthesis 2-
chlorotrityl chloride resin (α-dichlorobenzhydryl-polystyrene cross-
linked with 1% DVB; 100 – 200 mesh; 0.89 mmol g-1, 0.400 g, 0.356 
mmol was swelled in dry CH2Cl2 (3 mL) for 45 min and washed twice 
with dry DMF (3 mL). The first submonomer was attached onto the 
resin by adding bromoacetic acid (79.7 mg, 0.57 mmol) in dry CH2Cl2 
(3.0 mL) and DIPEA (310 μL, 1.78 mmol) on a shaker platform for 60 
min at room temperature, followed by washing with dry CH2Cl2 (3 × 
1 min) and then with DMF (3 × 1 min). A DMF solution of the 
commercially available propargyl amine (228 µl, 3.56 mmol), or 
methoxyethyl amine (307 µl, 3.56 mmol) was added to the 
bromoacetylated resin. The mixture was left on a shaker platform for 
30 min at room temperature, then the resin was washed with DMF (3 
× 1 min), CH2Cl2 (3 × 1 min) and then again with DMF (3 × 1 min). 
Subsequent bromoacetylation reactions were accomplished by 
reacting the aminated oligomer with a solution of bromoacetic acid 
(494 mg, 3.56 mmol) and DIC (607 µL, 3.91 mmol) in dry DMF (3.0 
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mL) for 40 min at room temperature. The filtrated resin was washed 
with DMF (3 × 1min), CH2Cl2 (3 × 1 min), DMF (3 × 1 min) and treated 
again with the amine under the same conditions reported above. This 
cycle of reactions was iterated until the desired chain length was 
accomplished and the target oligomer obtained. The cleavage was 
performed by treating twice the resin, previously washed with CH2Cl2 
(3 × 1 min), with a solution of HFIP in CH2Cl2 (20% v/v, 6 mL) on a 
shaker platform at room temperature for 30 min and 5 min, 
respectively. The resin was then filtered away and the combined 
filtrates were concentrated in vacuo. The final products were 
dissolved in 50% acetonitrile in HPLC grade water and analyzed by 
RP-HPLC [purity 82% for oligomer 5.15, 85% for oligomer 5.16, 
>95% for oligomer 5.17, 76% for oligomer 5.18, >95% for oligomer 
5.19; conditions: 5 → 100% A in 30 min for the all oligomers (A, 0.1% 
TFA in acetonitrile, B, 0.1% TFA in water); flow: 1 mL min− 1, 220 nm]. 
The linear oligomers were subjected to the cyclization reaction 
without further purification. 
5.15: 78% (crude residue); ESI-MS (positive, m/z): 669.4 [M 
+ H]+ ; tR : 8.4 min; 
5.16: 59%. (crude residue); ESI-MS (positive, m/z): 669.4 [M 
+ H]+; 691.9 [M + Na]+; tR : 8.5 min; 
5.17: 98% (crude residue); ESI-MS (positive, m/z): 629.2 [M 
+ H]+ ; tR: 7.4 min; 
5.18: 90% (crude residue); ESI-MS (positive, m/z): 591.3 [M 
+ H]+; 613.5 [M + Na]+; 629.4 [M + K]+   tR : 7.6 min; 
5.19: 95% (crude residue); ESI-MS (positive, m/z): 629.2 [M 
+ H] + ; tR : 7.6 min; 
 
General procedure for the cyclization reactions: synthesis of 
compounds 5.5-5.9 
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A solution of the linear peptoids precursors of 5.15 – 5.19 (0.348 
mmol), previously co-evaporated three times with toluene, was 
prepared under nitrogen in dry DMF (20.0 mL). The mixture was 
added drop wise to a stirred solution of HATU (528 mg, 1.39 mmol) 
and DIPEA (376 μL, 2.16 mmol) in dry DMF (82.0 mL) by a syringe 
pump in 12 h, at room temperature in anhydrous atmosphere. After 
24 h the the resulting mixture was concentrated in vacuo, diluted with 
CH2Cl2 (100 mL), and washed with a solution of HCl (1.0 M, 50 mL). 
The mixture was extracted with CH2Cl2 (2 × 100 mL) and the 
combined organic phases were washed with water (150 mL), dried 
over anhydrous MgSO4, filtered and concentrated in vacuo. The 
cyclic products were dissolved in 50% acetonitrile in HPLC grade 
water and analyzed by RP-HPLC [purity >95% for oligomer 5.5-5.9, 
conditions: 5% – 100% A in 30 min for all cyclic compounds (A, 0.1% 
TFA in acetonitrile, B, 0.1% TFA in water); flow: 1 mL min− 1, 220 nm]. 
The crude residues 5.5-5.9 were purified by precipitation in hot 
acetonitrile. 
 
Compound 5.5: 56%; white amorphous solid; ESI-MS 
(positive, m/z): 651.9 (100, [M + H]+), 673.9 (100, [M + Na]+); tR: 10.1 
min; 
1H NMR: (600 MHz,CD3CN + 2% D2O, mixture of rotamers) 
δ: 4.54-3.86 (12H, m, COCH2N); 3.57-3.22 (34H, m, NCH2CH2OCH3, 
NCH2CH2OCH3, NCH2CH2OCH3, NCH2CCH); 2.75-2.40 (2H, m, 
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NCH2CCH overlapped with water signal); 13C NMR: (150 MHz, 
CDCl3, mixture of rotamers, broad signals) δ: 171.8, 171.6, 171.2, 
171.0, 170.8, 170.6, 170.3, 170.0, 80.0, 79.9, 79.7, 79.5, 75.1, 74.7, 
73.9, 73.6, 73.2, 71.4, 71.3, 71.2, 70.9, 70.8, 70.7, 70.6, 70.3, 70.1, 
69.1, 59.5, 59.4, 59.3, 59.2, 58.9, 58.8, 58.5, 58.2, 51.0, 50.8, 50.7, 
50.3, 50.1, 49.9, 49.5, 49.4, 49.2, 49.0, 48.9, 48.8, 48.5,  48.2, 48.1, 
47.7, 47.2, 46.9, 38.8, 37.6, 37.5, 37.4, 37.1, 37.0, 36.9. 
 
Compound 5.6: 56%; white amorphous solid; ESI-MS 
(positive, m/z): 651.9 (77, [M + H]+), 673.9 (100, [M + Na]+); tR: 10.1 
min; 
1H NMR: (600 MHz,CD3CN + 2% D2O, mixture of rotamers) 
δ: 4.56-3.79 (12H, m, COCH2N); 3.56-3.23 (34H, m, NCH2CH2OCH3, 
NCH2CH2OCH3, NCH2CH2OCH3, NCH2CCH); 2.75-2.40 (2H, m, 
NCH2CCH overlapped with water signal); 13C NMR: (150 MHz, 
CDCl3, mixture of rotamers, broad signals) δ: 170.9, 170.4, 79.8, 
73.8, 73.5, 73.0, 71.4, 71.2, 70.9, 70.7, 70.6, 59.5, 59.4, 59.2, 58.9, 
50.7, 49.8, 49.4, 49.3, 49.1, 48.5, 48.4, 48.3, 48.0, 37.5, 37.4. 
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Compound 5.7: 37%; white amorphous solid; ESI-MS 
(positive, m/z): 611.1 (100, [M + H]+), 633.4 (94, [M + Na]+) and 649.1 
(30, [M + K]+), tR: 8.5 min; 
1H NMR: (600 MHz,DMSO, mixture of rotamers) δ: 4.80-3.77 
(12H, m, COCH2N), 3.76-3.36 (8H,m, NCH2CCH), 3.35-3.27 (4H,m, 
NCH2CH2OCH3), 3.26-3.02 (14H, m, NCH2CH2OCH3, 
NCH2CH2OCH3, and NCH2CCH); 13C NMR: (150 MHz, DMSO, 
mixture of rotamers, broad signals) δ: 171.5, 171.0, 170.9, 170.5, 
169.6, 169.5, 169.1, 81.1, 80.9, 80.7, 80.6, 80.4, 80.0, 77.2, 77.1, 
77.0, 76.7, 76.3, 76.2, 76.1, 76.0, 75.8, 71.9, 71.7, 71.6, 71.3, 71.2, 
70.9, 70.8, 70.5, 60.1, 60.0, 59.9, 59.8, 59.7, 59.5, 59.3, 50.7, 50.4, 
50.1, 49.9, 49.6, 49.4, 49.0, 48.9, 48.8, 48.6, 48.1, 47.8, 38.0, 37.6, 
37.0, 37.2, 36.0, 35.6. 
 
Compound 5.8: 57%; white amorphous solid; ESI-MS 
(positive, m/z): 611.1 (100, [M + H]+), 633.4 (40, [M + Na]+); tR: 8.6 
min;  
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1H NMR: (400 MHz, CD3CN, mixture of rotamers) δ: 4.53-
3.86 (16H, m, COCH2N and NCH2CH2OCH3), 3.58-3.24 (18H, m, 
NCH2CH2OCH3, NCH2CH2OCH3 and NCH2CCH), 2.40-2.70 (4H,m, 
NCH2CCH); 13C NMR: (100 MHz, CD3CN, mixture of rotamers, broad 
signals) δ: 170.3, 169.8, 79.2, 74.6, 73.9, 73.5, 73.3, 70.9, 70.2, 59.1, 





Compound 5.9: 86%; white amorphous solid; ESI-MS 
(positive, m/z): 591.3 (100, [M + H]+), 613.3 (70, [M + Na]+); tR: 8.3 
min;  
1H NMR: (400 MHz, CD3CN + 2% D2O, mixture of rotamers) 
δ: 4.54-3.86 (14H, m, COCH2N and NCH2CH2OCH3), 3.65-3.20 
(15H, m, NCH2CH2OCH3, NCH2CH2OCH3, NCH2CH2OCH3 and 
NCH2CCH), 2.70-2.50 (5H,m, NCH2CCH overlapped with water 
signal); 13C NMR: (100 MHz, CD3CN + 2% D2O, mixture of rotamers, 
broad signals) δ: 171.1, 170.9, 170.3, 169.9, 169.8, 169.6, 169.4, 
169.2, 169.1, 79.4, 79.1, 78.6, 78.2, 78.0, 77.5, 74.7, 74.3, 74.0, 
73.7, 73.6, 73.5, 73.4, 73.1, 72.8, 71.0, 70.2, 59.2, 59.0, 58.7, 49.7, 
49.3, 49.0, 48.9, 48.8, 48.7, 48.5, 48.3, 48.1, 47.8, 47.5, 37.3, 37.2, 




7.5.2. Single Crystal X-Ray Diffraction 
Compound 4.16 
Compound 4.16 was dissolved in hot acetonitrile and crystallized by 
slowly cooling the acetonitrile solution. 
Diffraction data were collected at 100 K with a Rigaku AFC7S 
diffractometer equipped with an CCD Mercury detector using Mo Kα 
radiation. Crystals were mounted using Mitegen loops. Data 
reduction was performed with the crystallographic package 
CrystalClear. The structure was solved by direct methods using the 
program SIR2011 and refined by means of full matrix least-squares 
based on F2 using the program SHELXL97. All non-hydrogen atoms 
were refined anisotropically, hydrogen atoms were positioned 
geometrically and included in structure factors calculations but not 
refined. 
 4.16 
Formula C30H46N6O10·4 CH3CN 
Formula weight 650.33 
System triclinic 
Space group P -1 
a (Å) 8.575(6) 
b (Å) 9.743(6) 
c (Å) 14.182(7) 
(°) 74.68(8) 
V (Å3) 1102.14 
 
Compound 4.19 
Compound 4.19 was dissolved in hot acetonitrile and crystallized by 
slowly cooling the acetonitrile solution, yielding prismatic crystals. 
Diffraction data were collected at 100 K with a ID13 diffractometer at 
ESRF (Grenoble, France). Crystals were mounted using Mitegen 
loops. Data reduction was performed with the crystallographic 
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package SADABS. The structure was solved by direct methods using 
the program SIR2011 and refined by means of full matrix least-
squares based on F2 using the program SHELXL97. All non-
hydrogen atoms were refined anisotropically, hydrogen atoms were 
positioned geometrically and included in structure factors 






Formula C30H30N6O6·2 CH3CN 
Formula weight 570.22 
System monoclinic 
Space group P 21/c 
a (Å) 11.717(6) 
b (Å) 17.333(9) 
c (Å) 8.824(5) 
(°) 106.290(6) 




Compound 5.7 was dissolved in hot acetonitrile and crystallized by 
slowly cooling the acetonitrile solution, yielding white blocky and flat-
plate crystals. 
Diffraction data were collected at 100 K with a Bruker Smart 
diffractometer equipped with an APEXII CCD detector using Mo Kα 
radiation. Crystals were mounted using Mitegen loops. 
Data reduction was performed with the crystallographic package 
APEX. The structure was solved by direct methods using the 
program SHELXS and refined by means of full matrix least-squares 
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based on F2 using the program SHELXL97. The software X-Seed 
was used as GUI. All non-hydrogen atoms were refined 
anisotropically, hydrogen atoms were positioned geometrically and 







Formula C30H38N6O8·2 CH3CN 
Formula weight 692.77 
System monoclinic 
Space group P 21/c 
a (Å) 9.773(5) 
b (Å) 20.961(10) 
c (Å) 8.500(4)  
(°) 90.990(7) 






R (I>2I) 0.0465 (2958) 
wR2 (all) 0.1173 (3594) 
N. of param. 226 
GooF 1.057 
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Org. Lett. 2014, 16, 2780 − 2783. 
17. Maulucci, N., Izzo, I., Bifulco, G., Aliberti, A., De Cola, C., 
Comegna, D., Gaeta, C., Napolitano, A., Pizza, C., Tedesco, C., Flot, 
D., De Riccardis, F. , Chem. Comm. 2008, 3927–3929. 
 215 
18. (a) Maayan, G., European Journal of Organic Chemistry 
2009, 2009 (33), 5699-5710; (b) Lee, B.-C., Chu, T. K., Dill, K. A., 
Zuckermann, R. N. , .J. Am. Chem. Soc. 2008, 130, 8847-8855  
19. (a) De Cola, C., Licen, S., Comegna, D., Cafaro, E., Bifulco, 
G., Izzo, I., Tecilla, P., De Riccardis, F. , Org. Biomol. Chem. 2009, 
7, 2851–2854; (b) Della Sala, G., Nardone, B., De Riccardis, F., Izzo, 
I., Organic & Biomolecular Chemistry 2013, 11 (5), 726-731; (c) De 
Cola, C., Fiorillo, G., Meli, A., Aime, S., Gianolio, E., Izzo, I., De 
Riccardis, F. , Org. Biomol. Chem. 2014, 12, 424–431; (d) Izzo, I., 
Ianniello, G., De Cola, C., Nardone, B., Erra, L., Vaughan, G., 
Tedesco, C., De Riccardis, F. , Org. Lett. 2013, 15, 598–601. 
20. Schettini, R., Nardone, B., De Riccardis, F., Della Sala, G.; 
Izzo, I. , Eur. J. Org. Chem. 2014, 7793–7797. 
21. (a) Fowler, S. A., Blackwell, H. E., Org. Biomol. Chem. 2009, 
7, 1508–1524; (b) Chongsiriwatana, N. P., Patch, J. A.,Czyzewski, 
A. M., Dohm, M. T., Ivankin, A., Gidalevitz, D., Zuckermann, R. N., 
Barron, A. E., Proc Natl Acad Sci U S A 2008, 105 (8), 2794-9. 
22. (a) Maayan, G., Ward, M. D., Kirshenbaum, K., Proceedings 
of the National Academy of Sciences of the United States of America 
2009, 106 (33), 13679-13684; (b) Prathap, K. j. J., Maayan, G., 
Chemical Communications 2015, 51 (55), 11096-11099. 
23. (a) Comegna, D., Benincasa, M., Gennaro, R., Izzo, I., De 
Riccardis, F., Bioorganic & Medicinal Chemistry 2010, 18 (5), 2010-
2018; (b) Huang, M., Shin, S. B. Y., Benson, M. A.,Torres, V. J., 
Kirshenbaum, K., ChemMedChem 2012, 7, 114-122. 
24. Huang, M. L., Benson, M. A., Shin, S. B. Y., Torres, V. J., 
Kirshenbaum, K., European Journal of Organic Chemistry 2013, 
2013 (17), 3560-3566. 
25. Smith, P. T., Huang, M. L., Kirshenbaum, K., Biopolymers 
2014, 103 (4), 227-236. 
26. Zuckermann, R. N., Martin,  E. J., Spellmeyer, D. C.,Stauber,  
G. B., Shoemaker, K. R., Kerr, J. M., Figliozzi,  G. M., Goff,  D. A., 
Siani, M. A., Simon, R., Banville, S. C., Brown,  E. G., Wang, L., 
Richter,  L. S., Moos, W. H., J. Med. Chem. 1994, 37, 2678–2685. 
 216 
27. Park, S., Kwon, Y., ACS Combinatorial Science 2015, 17 (3), 
196-201. 
28. Gao, Y. K., T., ACS Comb. Sci. 2015, 17, 190. 
29. Seo, J., Lee, B. C., Zuckermann, R. N., Peptoids-Synthesis,; 
Characterization, a. N. I. C. B.; Ducheyne, P., Healy, K. E., 
Hutmacher, D. W., Grainger, D. W.,; Kirkpatrick, C. J., Eds.; Elsevier: 
2011; Vol. 2, pp 53 − 76., Comprehensive Biomaterials. 
30. Hille, Ion Channels of Excitable Membranes. third ed. 
Sinauer Associates, I., Ed. Sunderland, MA, 2001. 
31. Gouaux, E., MacKinnon, R., Science 2005, 310, 1461-1465. 
32. Gokel, G., W., Carasel, I., A.  , Chem. Soc. Rev. 2007, 36, 
378-389. 
33. Matile, S., Jentzsch, A., V., Montenegro, J., Fin, A., Chem. 
Soc. Rev. 2011, 40, 2453–2474. 
34. (a) Rao, S., Si, K., J., Yap, L., W., Xiang, Y, Cheng, W., ACS 
Nano 2015, Ahead of Print; (b) Ko, S., K., Kim, S., K., Share, A., 
Lynch, V., M., Park, J., Namkung, W., Rossom, W., V., Busschaert, 
N., Gale, P., A., Sessler, J., L., Shin, S., I., Nature Chemistry 2014, 
6, 885-892; (c) Gadsby, D., C., Nature 2004, 427, 795-797. 
35. Dutzler., R., Current Opinion in Structural Biology 2006, 16, 
439-446. 
36. Kelkar, D., A., Chattopadhyay, A., Biochimica et Biophysica 
Acta 2007, 1768, 2011-2025. 
37. MacKinnon, R., Angew. Chem. 2004, 43, 4265-4277. 
38. Cragg, P., Science Progress 2002, 85, 219-241. 
39. Gokel, G., W., et al., Bioorg. Med. Chem. 2004, 12, 1291–
1304. 
40. De Riccardis, F., Izzo, I., Montesarchio, D., Tecilla, P., 
Accounts of Chemical Research 2013, 46 (12), 2781–2790. 
 217 
41. Lalgee, L., J., Grierson, L., Fairman, R., A., Jaggernauth, G., 
E., Schulte, A., Benz, R., Winterhalter, M., Biochimica et Biophysica 
Acta 2014, 1838, 1247–1254. 
42. Fyles, T., M., Chem. Soc. Rev. 2007, 36, 335–347. 
43. Murakami, Y., Kikuchi, J., Hisaeda, Y., Hayashida, O., 
Chem. Rev. 1996, 96, 721-758. 
44. Takeuchiw, T., Matile, S., Chem. Commun. 2013, 49, 19-29. 
45. (a) Fernandez-Lopez, S., Hui-Sun, K., Choi, E. C., Delgado, 
M., Granja, J. R., Khasanov A., Kraehenbuehl, K., Long, G., 
Weinberger, D. A., Wilcoxen, K. M., Ghadiri, M. R., Nature 2001, 412, 
452–455; (b) Montenegro, J., Ghadiri, M. R., Granja, J., R., Accounts 
of Chemical Research 2013, 46 (12), 2955-2965; (c) Yu, Z., Li, J., 
Zhu, J., Zhu, M., Jiang, F., Zhang, J., Li, Z., Zhong, M., Kaye, J., B., 
Du, J., Shen, B., J. , Mater. Chem. B 2014, 2, 3809–3818; (d) El 
Ghoul, Y., Renia, R., Faye, I., Rassou, S., Badi, N., Bennevault-
Celton, V., Huin, C., Guégan, P., Chem. Commun. 2013, 49, 11647-
11649. 
46. Riley, K. E., Merz, K., M., The Journal of Physical Chemistry 
A 2007, 111 (9), 1688-1694. 
47. Sakai, N., Mareda, J., Matile, S., , Mol. BioSyst. 2007, 3, 
658–666. 
48. Maayan, G. W., M., D.; Kirshenbaum, K.; , Chem. Commun. 
2009, 56–58. 
49. (a) Rasmussen, J. E., Boccia, M. M., Nielsen, J., 
Taillefumier, C., Faure, S., Hjelmgaard, T. , Tetrahedron Lett. 2014, 
55, 5940–5943; (b) Hjelmgaard, T., Roy, O., Nauton, L., El-Ghozzi, 
M., Avignant, D., Didierjean, C., Taillefumier C., Faure, S., Chem. 
Commun. 2014, 22, 3564–3567; (c) Hjelmgaard, T., Nielsen, J., Eur. 
J. Org. Chem. 2013, 3574–3589; (d) Hjelmgaard, T., Faure, S., De 
Santis, E., Staerk, D., Alexander, B. D., Edwards, A. A., Taillefumier, 
C., Nielsen, J., Tetrahedron Lett. 2012, 68, 4444–4454; (e) 
Hjelmgaard, T., Faure, S., Staerk, D., Taillefumier C., Nielsen, J., 
Org. Biomol. Chem. 2011, 9, 6832–6843; (f) Hjelmgaard, T., Plesner, 
M., Dissing, M. M., Andersen, J. M., Frydenvang, K., Nielsen, J., Eur. 
J. Org. Chem. 2014, 3971–3975. 
 218 
50. (a) Hjelmgaard, T., Faure, S., Staerk, D., Taillefumier C., 
Nielsen, J. , Eur. J. Org. Chem. 2011, 4121–4132; (b) Combs, D. J., 
Lokey, R. S., Tetrahedron Lett. 2007, 48, 2679–2682. 
51. Axén, A., Andersson, H., Lindeberg, G., Rönnholm, H., 
Kortesmaa, J., Demaegdt, H., Vauquelin, G., Karlén, A., Hallberg, 
M., J. Pept. Sci. 2007, 13, 434-444. 
52. (a) Gea, A., Farcy, N., Roqué i Rossell, N., Martins, J. C., De 
Clercq, P. J., Madder, A., Eur. J. Org. Chem. 2006, 4135–4146; (b) 
Nevill, C. R., Jakubowski, Jr. J. A., Fuchs, P. L., Biomed. Chem. Lett. 
1991, 1, 83–86. 
53. Westaway, S., M.; Brown, S., L.; Fell, S., C., M.; Johnson, 
C., N.; MacPherson, D., T.; Mitchell, D., J.; Myatt, J., W.; Stanway, 
S., J.; Seal, J., T.; Stemp, G.; Thompson, M.; Lawless, K.; McKay, 
F.; Muir, A., I.; Barford, J., M.; Mahmood, S., R.; Matthews, K., L.; 
Mohamed, S.; Smith, B., B.; Stevens, A., J.; Bolton, V., J.; Jarvie, E., 
M.; Sanger, G., J. Med. Chem. 2009, 52, 1180–1189. 
54. Sakai, N., Matile, S., J. Phys. Org. Chem. 2006, 19, 452–
460. 
55. Izzo, I., Licen, S., Maulucci, N., Autore, G., Marzocco, S., 
Tecilla, P., De Riccardis, F., Chem. Commun. 2008, 2986–2988. 
56. Runge, V., M., Clinical MRI. 1st Ed. ed.; Saunders: 2002. 
57. Freedman, J., D.; Lusic, H.; Wiewiorski, M.; Farley, M.; 
Snyder, B., D.; Grinstaff, M., W.; , Chem. Commun. 2015, 51, 11166-
11169. 
58. (a) Amouroux, G., Pan, J., Jenni, S., Zhang, C., Zhang, Z., 
Hundal-Jabal, N., Colpo, N., Liu, Z., Bénard, F., Lin, K., Mol. 
Pharmaceutics 2015, 12, 2879-2888; (b) Baker, J., H., E., McPhee, 
K., C., Moosvi, F., Saatchi, K., Häfeli, U., O., Minchinton, A. I., 
Reinsberg, S., A., Contrast Media Mol. Imaging 2015; (c) Ye, D., 
Shuhendler, A., J., Pandit, P., Brewer, K., D.,Tee, S., S., Cui, 
L.,Tikhomirov, G., Rutt, B., Rao, J., Chem. Sci. 2014, 5, 3845-3852; 
(d) Gianolio, E., Cabella, C., Colombo Serra , S., Valbusa, G., Arena, 
F., Maiocchi, A., Miragoli, L., Tedoldi, F., Uggeri, F., Visigalli, M., 
Bardini, P., Aime, S., J. Biol. Inorg. Chem. 2014, 19, 715-726; (e) 
Zhou, Z., Qutaish, M., Han, Z., Schur, R., M., Liu, Y., Wilson, D., L., 
Lu, Z., Nat Commun 2015, 6. 
 219 
59. Bort, G. C., S.; Borderies, H.; Kebsi, A.; Ballet, S.; Louin, G.; 
Port, M.; Ferroud, C., European Journal of Medicinal Chemistry 
2014, 87, 843-861. 
60. (a) Leung, A., H., Jin, J., Wang, S., Lei, H., Wong, W., T., 
Bioconjugate Chem. 2014, 25, 1112-1123; (b) Caravan, P., Ellison, 
J., McMurry, T., J., Lauffer, R., B.,, Chem. Rev. 1999, 99, 2293-2352; 
(c) Lauffer, R., B., Chem. Rev. 1987, 87, 901-927  
61. Henderson, R., G. , Journal of the Royal Society of Medicine 
1983, 76, 206-212. 
62. Pykett, I. L., Sci. Am. 1982, 246 (78). 
63. Werner, E., J., Datta, A., Jocher, C., J., Raymond, K., N., 
Angewandte Chemie International Edition 2008, 47 (45), 8568-8580. 
64. Aime, S., Geninatti Crich, S., Gianolio, E, Giovenzana, G., 
B.,Tei, L., Terreno, E., Coordination Chemistry Reviews 2006, 250, 
1562-1579. 
65. Aime, S., Botta, M., Fasano, M., Terreno, E., Chemical 
Society Reviews 1998, 27, 19-29. 
66. Verwilst, P., Park, S., Yoon, B., Kim, J., S., Chem. Soc. Rev. 
2015, 44, 1791-1806. 
67. (a) Baker, J. H. E., McPhee, K. C., Moosvi, F., Saatchi, K., 
Häfeli, U. O., Minchinton, A. I., Reinsberg, S. A., Contrast Media & 
Molecular Imaging 2015; (b) Luo, K., Liu, G., She, W., Wang, Q., 
Wang, G., He, B., Ai, H., Gong, Q., Song, B., Gu, Z., Biomaterials 
2011, 32 (31), 7951-7960. 
68. Loukopoulos, E., Griffiths, K., Akien, G., Kourkoumelis, N., 
Abdul-Sada, A., Kostakis, G., Inorganics 2015, 3 (4), 448-466. 
69. Vaccaro, M., Mangiapia, G., Paduano, L., Gianolio, E., 
Accardo, A., Tesauro, D., Morelli, G., ChemPhysChem 2007, 8 (17), 
2526-2538. 
70. (a) Bonnet, C., S., Fries, P.,l H., Crouzy, S., Sénèque, O., 
Cisnetti, F., Boturyn, D., Dumy, P., Delangle, P., Chemistry – A 
European Journal 2009, 15 (29), 7083-7093; (b) Caravan, P., 
 220 
Greenwood, J., M., Welch, J., T., Franklin, S., J., Chemical 
Communications 2003,  (20), 2574-2575. 
71. (a) Kölmel, D. K., Rudat, B., Schepers, U. Bräse, S., 
European Journal of Organic Chemistry 2013, 2013 (14), 2761-2765; 
(b) De León-Rodríguez, L. M., Lubag, A., Udugamasooriya, D. G., 
Proneth, B., Brekken, R. A., Sun, X., Kodadek, T., Sherry, D. A., 
Journal of the American Chemical Society 2010, 132 (37), 12829-
12831. 
72. Fulton, D., A., Elemento, E., M., Aime, S., Chaabane, L., 
Botta, M., Parker, D., Chemical Communications 2006,  (10), 1064-
1066. 
73. Caravan, P., Accounts of Chemical Research 2009, 42 (7), 
851-862. 
74. Miller, S. M., Simon, R.J., Ng, S., Zuckermann, R.N., Kerr, 
J.M. & Moos, W.H. , Bioorg. Med. Chem. Lett. 1994, 4, 2657-2662. 
75. Gellerman, G., Elgavi, A., Salitra, Y., Kramer, M.  , J. Peptide 
Res. 2001, 57, 277 – 291. 
76. (a) Kajimoto, T., Node, M., Current Topics in Medicinal 
Chemistry 2009, 9, 13-33; (b) Davies, G. J., Gloster, T. M., Henrissat, 
B., Current Opinion in Structural Biology 2005, 15 (6), 637-645; (c) 
Vocadlo, D. J., Davies, G. J., Current Opinion in Chemical Biology 
2008, 12 (5), 539-555. 
77. Gerber-Lemaire, S., Juillerat-Jeanneret, L., Mini-Reviews in 
Medicinal Chemistry 2006, 6, 1043-1052. 
78. (a) Bernacki, R. J., Niedbala, M. J., Korytnyk, W., Cancer 
metastasis reviews 1985, 4 (1), 81-101; (b) Herscovics, A., 
Biochimica et Biophysica Acta (BBA) - General Subjects 1999, 1473 
(1), 96-107. 
79. (a) Rye, C. S., Withers, S. G., Current Opinion in Chemical 
Biology 2000, 4 (5), 573-580; (b) Vasella, A., Davies, G. J., Böhm, 
M., Current Opinion in Chemical Biology 2002, 6 (5), 619-629. 
80. Gloster, T. M., Davies, G., J., Organic & Biomolecular 
Chemistry 2010, 8 (2), 305-320. 
 221 
81. Pauling, L., Chem. Eng. News 1946, 24, 1375–1377. 
82. Inouye, S., Tsuroka, T., Nida, T., J. Antibiot. 1966, 19, 288–
292. 
83. Yagi, M., Kouno, T., Aoyagi, Y., Murai, H., Nippon Nogei 
Kagaku Kaishi 1976, 50, 571–572. 
84. Katsilambros, N., Philippides, P., Toskas, T., Protopapas, J., 
Frangaki, D., Marangos, M., Siskoudis, P., Anastasopoulou, K., 
Xefteri, H., Hillebrand, I., Arzneimittelforschung 1986, 36, 1136–
1138. 
85. Platt, F., M., Neises, G., R., Dwek, R., A., Butters, T., D., J. 
Biol. Chem. 1994, 269, 8362–8365. 
86. Birault, V., Solari, R., Hanrahan, J., Thomas, D. Y.  , Curr. 
Opin. Chem. Biol.  2013, 17, 353–360. 
87. Butters, T., D., Curr. Opin. Chem. Biol. 2007, 11, 412-418. 
88. Kolter, T., Sandhoff, K. , Biochim. Biophys. Acta 2006, 1758, 
2057-2079. 
89. Wraith, J. E., J. Inherit. Metab. Dis. 2006, 29, 442-447. 
90. Butters, T. D., Dwek, R. A., Platt, F. M. , Chem. Rev. 2000, 
100, 4683-4696. 
91. Lubamba, B., Dhooghe, B., Noel, S., Leal, T. , Clin. Biochem. 
2012, 45, 1132-1144. 
92. Becq, F., Mall,  M. A., Sheppard, D. N. , Conese,  M., 
Zegarra-Moran, O., J. Cystic Fibrosis 2011, 10, S129–S145. 
93. (a) Asano, N., Ikeda, K., Yasuda, K., Kizu, H., Kameda, Y., 
Kato, A., Okamato, T., Ishii, S., Compain, P., Martin, O. R., Fan, J.-
Q., Glycoconj J 1999, 16 (4-5), 2-175; (b) Oulaıdi, F., Front-
Deschamps, S., Gallienne, E., Lesellier, E., Ikeda, K., Asano, N., 
Compain, P., Martin, O., R., ChemMedChem 2011, 6, 353-361; (c) 
Compain, P., Martin, O., R., Boucheron, C., Godin, G., Yu, L., Ikeda, 
K., Asano, N., ChemBioChem 2006, 7, 1356-1359; (d) Compain, P., 
Synlett. 2014, 25, 1215-1240; (e) Schönemann, W., Gallienne, E., 
Compain, P., Ikeda, K., Asano, N., Martin, O., N., Bioorg. Med. 
 222 
Chem. 2010, 18, 2645-2650; (f) Yu., L., Ikeda, K., Kato, A., Adachi, 
I., Godin, G., Compain, P., Martin, O., Asano, N., Bioorg. Med. Chem. 
2006, 14, 7736-7744. 
94. Decroocq, C., Joosten, A., Sergent, R., Mena Barragán, T., 
Ortiz Mellet, C., Compain, P. , ChemBioChem 2013, 14, 2038–2049. 
95. Compain, P., Bodlenner, A., ChemBioChem 2014, 15 (9), 
1239-1251. 
96. Kiessling, L., L., Gestwicki, J., E., Strong, L., E., Angewandte 
Chemie International Edition 2006, 45 (15), 2348-2368. 
97. Compain, P., Decroocq, C., Iehl, J., Holler, M., Hazelard, D., 
Mena Barragán, T., Ortiz Mellet, C., Nierengarten, J., Angewandte 
Chemie International Edition 2010, 49 (33), 5753-5756. 
98. (a) Decroocq, C., Rodriguez-Lucena, D.Russo, V., Mena 
Barragan, T., Ortiz Mellet, C., Compain, P., Chem. Eur. J. 2011, 17 
(49), 13825-31; (b) Joosten, A., Schneider, J., P. Lepage, M., L., 
Tarnus, C., Bodlenner, A., Compain, P., European Journal of 
Organic Chemistry 2014, 2014 (9), 1866-1872. 
99. Brissonet, Y., Ortiz Mellet, C., Morandat, S., Garcia-Moreno, 
M. I., Deniaud, D., Matthews, S. E., Vidal, S., Sestak, S., El Kirat, K., 
Gouin, S. G. , J. Am. Chem. Soc 2013, 135, 18427–18435. 
100. (a) Singhamahapatra, A., Sahoo, L., Loganathan, D., J. Org. 
Chem. 2013, 78, 10329 − 10336; (b) Fürniss, D., Mack, T., Hahn, F., 
Vollrath, S. B. L., Koroniak, K., Schepers, U., Bräse, S., Beilstein 
Journal of Organic Chemistry 2013, 9, 56-63; (c) Khan, S. N., Kim, 
A., Grubbs, R.H., Kwon, Y., Organic Letters 2012, 14 (12), 2952-
2955; (d) Ahn, M., Murugan, R. N., Nan, Y. H., Cheong, C., Sohn, H., 
Kim, E., Hwang, E., Ryu, E. K., Kang, S. W., Shin, S. Y., Bang, J. K., 
Bioorganic & Medicinal Chemistry Letters 2011, 21 (20), 6148-6153; 
(e) Norgren, A. S., Budke, C., Majer, Z., Heggemann, C., Koop, T., 
Sewald, N., Synthesis 2009, 3 (488–494); (f) Seo, J., Michaelian, N., 
Owens, S. C., Dashner, S. T., Wong, A. J., Barron, A. E., Carrasco, 
M. R., Org. Lett. 2009, 11 (22), 5210-5213; (g) Burger, K., Boettcher, 
C., Radics, G., Hennig, L., Tetrahedron Letters 2001, 42, 3061–
3063; (h) Marcaurelle, A. L., Bertozzi, R. C. , Chem. Eur. J. 1999, 5 
(5), 1384-1390; (i) Dechantsrciter, M. A., Burkhart, F., Kessler, H., 
Tetrahedron Letters 1998, 39, 253-254 ; (j) Kim, J. M., Roy, R., 
Tetrahedron Letters 1997 38 (20), 3487-3490; (k) Kim, J. M., Roy, 
R.,, Carbohydrate Research 1997, 298, 173-179. 
 223 
101. (a) Caumes, C., Gillon, E., Legeret, B., Taillefumier, C., 
Imberty, A., Faure, S., Chemical Communications 2015, 51 (61), 
12301-12304; (b) Cecioni, S., Faure, S., Darbost, U., Bonnamour, I., 
Parrot-Lopez, H., Roy, O., Taillefumier, C., Wimmerov, M., Praly, J., 
Imberty, A., Vidal, S., Chem. Eur. J. 2011, 17, 2146 – 2159; (c) 
Comegna, D., De Riccardis, F., Org. Lett. 2009, 11 (17), 3898-3901. 
102. (a) Himo, F., Lovell, T., Hilgraf, R., Rostovtsev, V. V., 
Noodleman, L., Sharpless, K. B., Fokin, V. V., J. Am. Chem. Soc. 
2005, 127, 210-216; (b) Appukkuttan, P., Dehaen, W., Fokin, V. V., 
Van der Eycken, E., Organic letters 2004, 6 (23), 4223-5. 
103. Holub, J. M., Jang, H., Kirshenbaum, K., Org Biomol Chem 
2006, 4 (8), 1497-502. 
104. (a) Wu, C. W., Sanborn, T. J., Zuckermann, R. N., Barron, A. 
E., J. Am. Chem. Soc. 2001, 123, 2958 - 2963; (b) Kirshenbaum, K. 
B., A. E.; Armand, P.; Goldsmith, R.; Bradley, E.; Cohen, F. E.; Dill, 
K. A.; Zuckermann, R. N. , Proc. Natl. Acad. Sci., U.S.A. 1998, 95, 
4303 - 4308; (c) Murphy, J. E. U., T.; Hamer, J. D.; Cohen, F. E.; 
Dwarki, V.; Zuckermann, R. N. , Proc. Natl. Acad. Sci. U.S.A. 1998, 
95, 1517 - 1522. 
105. Malesevic, M., Strijowski, U., Bachle, D., Sewald, N. , J. 
Biotechnol. 2004, 112, 73-77. 
106. Joosten, A., Decroocq, C., de Sousa, J., Schneider, J., 
Etamé, E., Bodlenner, A., Butters, T. D., Compain, P., 
ChemBioChem 2014, 15, 309–319. 
107. Lepage, M. L., Meli, A., Bodlenner, A., Tarnus, C., De 
Riccardis, F., Izzo, I., Compain, P., Beilstein journal of organic 
chemistry 2014, 10, 1406-1412. 
108. Culf, A. S., Ouellette, R. J. , Molecules 2010, 15, 5282-5335. 
109. Sui, Q., Borchardt, D., Rabenstein, D. L., J. Am. Chem. Soc. 
2007, 129, 12042-12048. 
110. Armand, P., Kirshenbaum, K., Goldsmith, R. A., Farr-Jones, 
S., Barron, A. E., Truong, K. T. V., Dill, K. A., Mierke, D. F., Cohen, 
F. E., Zuckermann, R. N., Bradley, E. K., Proceedings of the National 
Academy of Sciences 1998, 95 (8), 4309-4314. 
 224 
111. Vollrath, S. B. L., Chunhua, H., Bräse, S., Kirshenbaum, K., 
ChemComm 2013, 49, 2317-2319. 
112. (a) Desiraju, G. R., Crystal Engineering: The Design of 
Organic Solids. Elsevier: Amsterdam, 1989; (b) Desiraju, G. R., 
Chem. Commun. 1997, 1475–1482; (c) Nangia, A., Desiraju, G. R., 
In Design of Organic Solids, Weber, E., Ed. Springer-Verlag: Berlin, 
1998; pp 57-95. 
113. Hirshfeld, L., F. , Theor. Chim. Acta 1977, 44 (2), 129-138  
114. (a) McKinnon, J., J. Spackman, M. A., Mitchell, A., S., Acta 
Cryst. 2004, B60, 627-668; (b) Spackman, M., Jayatilaka, D., 
CrystEngComm. 2009, 11, 19-32; (c) Spackman, M. A., Phys.Scr. 
2013, 87 (4); (d) Spackman., M. A., McKinnon, J. J. , 
Cryst.Eng.Comm 2002, 4 (66), 378-392. 
115. Wolff, S. K., Grimwood, D. J., McKinnon, J. J., Turner,  M. J., 
Jayatilaka, D., Spackman, M. A., University of Western Australia, 
2012. 
116. Desiraju, G. R., Journal of the American Chemical Society 
2013, 135 (27), 9952-9967. 
117. Ricciardulli, A. G., Autoassemblaggio di ciclopeptoidi allo 
stato solido. Tesi di laurea magistrale Anno accademico 2013-
2014. 
118. Gallo, G., Verso il controllo dell'assemblaggio allo stato 








Continuous Flow Chemistry. Application of 
Diazomethane for Synthesis in Drug Discovery. 
The following work has been performed at the Global 
Discovery Chemistry laboratories of NIBR (Novartis Institutes for 
Biomedical Research) in Basel (Switzerland) and it is protected by 
the industrial secret. For that reason, I am going to explain the 
methodology studied during my research stay and I am using generic 
molecular structures to elucidate its application. 
A.1 INTRODUCTION 
Synthetic chemistry achieved a central role in all areas of 
Science, driven by remarkable improvements in the development of 
new reactions, reagents and catalysts as well as ever more powerful 
analytical tools.1 
Despite the sheer complexity of methods to address the 
challenge of chemical transformations, most equipment to usually 
run reactions consists in standardized glassware such as round-
bottomed flasks or reaction vessels.2 Indeed, batch reactors offer 
several advantages for synthesis in chemistry laboratories; they are 
easy to handle and allow a practical follow-up of the reaction 
proceeding in them.1b Hence, there is no point in simply replacing 
such versatile batch mode, unless a clear benefit can been 
obtained.3 
New chemical processing techniques are required when a 
high level of control over a certain reaction is needed.  
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In this context, microreactors and continuous flow 
technologies are emerging in the portfolio of the synthetic chemist’s 
devices.  
Continuously flowing microreactors, featured by small 
dimensions of the order of less than 1000 µm, offer a high surface-
to-volume ratio that allows for rapid and homogeneous mixing.4 Such 
efficient mixing provides an homogeneous mass transport in the 
reactor and guarantees an optimal thermal management, which is 
necessary either to avoid runaway reactions, that could lead to 
explosion, either to gain kinetic and thermodynamic control when two 
different pathways are possible.5 Hence, reactions can be carried out 
quickly with increases in both yields and selectivity and added 
efficiency and safety.   
Furthermore, the small volumes of reactive material used by 
microreactors at any one time, enable to run reactions with highly 
toxic or explosive intermediates.6 Such hazardous reagents would 
also be less problematic since they are flowing in a contained 
environment, so avoiding any direct contact with the worker. 
Another benefit of continuous flow synthesis is that such 
processes are suitable for automation, since solutions of starting 
materials and reagents are fed by pumps and their flow rate are 
controlled by a computer.1b Consequently, once the reaction 
conditions are optimized, these can be easily transferred from 
laboratory reactors to production scales.7 Overall higher safety 
standards and a fast, reliable and directly scalable chemical process 
are so achieved, making continuous flow reactors a new and 
powerful tool for laboratory synthesis and for production in chemical 
and pharmaceutical industries. 
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A.1.1 Diazomethane As A Powerful Toll In Organic 
Synthesis 
 One of the most interesting and versatile reagents in 
synthetic chemistry is diazomethane, as it can perform a plethora of 
reactions under mild conditions (Scheme A.1).9 
 
Scheme A. 1. Synthetic applications of diazomethane. 
However, its hazardous properties such as explosiveness, 
toxicity, and carcinogenicity are well-known, and make its use in 
laboratory or pilot-plant scale quite problematic.10 In the laboratory, 
special techniques and safety precautions are needed, such as 
dedicated glassware carefully fire-polished or explosion protection. 
For industrial-scale production of diazomethane, the equipment 
necessary for its safe handling is elaborate and expensive. 
Furthermore, diazomethane not only has to be prepared, 
conveniently generated through the reaction of a suitable precursor 
with bases, but also separated and purified for the subsequent 
reaction, and routine separation processes like distillation are not 
certainly appropriate for a toxic gas. 
The use of continuous flow microreactors offers a solution to 
these safety issues, providing a total reaction system in which the 
toxic and explosive reagent is first self-generated and then separated 
within, to be reacted for the formation of the desired product. Being 
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always contained in-line, diazomethane is so readily accessible for 
both laboratory and industrial applications. 
A.2 AIM OF THE WORK 
A.2.1. Introduction 
Herein, we describe a convenient procedure for the 
preparation on lab-scale of a vast platform of organic compounds 
using diazomethane by means of a reliable and robust flow-
chemistry system (Figure A.1). They will serve as model examples 
to elucidate the several advantages of the method and to explore the 
selectivity of diazomethane in terms of chemoselectivity and 
regioselectivity. 
 
Figure A. 1. Diazomethane-flow generator.  
A.2.2 Results and Discussion 
In-flow generation of diazomethane has been applied for the 
methylation of carboxylic acids into methyl esters and for the 
cyclopropanation of double bonds.  
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Continuous flow esterification is a very elegant process, 
where diazomethane is generated and reacted in-situ with carboxylic 
acids to give clean, quantitative and instantaneous reactions.9a  
For the continuous flow process we developed, two 
connected reactors were used. In the first one, diazomethane was 
produced from a feed containing N-methyl-N-nitroso urea (NMU) 
0.45 M in 2-MeTHF/Et2O 1:1 and a second feed of potassium 
hydroxide (1.5 equiv relative to NMU) 1.5 M in water. The two 
streams were pumped with flow rates of 4.31 ml min-1 and 1.94 ml 
min-1 respectively, mixed, and reacted in a PFA (Perfluoroalcoxy 
alkane) coiled tube reactor of 5 mL (0.8 min residence time) cooled 
at 10°C. Diazomethane was formed and pumped from the outlet of 
the first reactor, where a back pressure regulator (BPR, 8.0 bar) was 
attached to ensure a stable flow rate, to a phase separator equipped 
with a semipermeable, microporous and hydrophobic membrane. 
The diazomethane in the organic solvent crossed the membrane, 
whereas the aqueous phase was retained and discarded into an 
acetic acid quench solution to decompose any unconsumed 
diazomethane. After the separation of the organic solution, this was 
mixed in a standard T-mixer with a third stream containing the 
carboxylic acid dissolved in 2-MeTHF (0.5 M), at a flow rate ranging 
from 2.33 ml min-1 to 1.55 ml min-1 depending on the substrate. The 
combined streams then entered the second reactor, which consisted 
of a 5 mL PFA coil at room temperature, and the product mixture 
from the outer tube was collected in a flask into a quenching solution 
of acetic acid and analyzed by LC-MS. Applying the parameters 
stated above, the residence time for the methylation process was set 
from ≈ 0.8 min to ≈1.1 min depending on the case. 
To check the efficiency of diazomethane formation and its 
separation by the membrane under these general reaction 
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conditions, a set of preliminary experiments was carried out 
converting the m-nitrobenzoic acid to the corresponding ester, which 
is known to take place quantitatively and instantaneously. This 
enabled us not only to evaluate the setting of the parameters, but 
also the concentration of the outcoming diazomethane, which was 
estimated ≈ 0.3 M. With these features in mind, we optimized the 
reaction stoichiometry in flow and on small scale for all the substrates 
studied in this work.  
In the preliminary screenings performed on small scale, the 
number of equivalents of diazomethane relative to the starting 
material was varied from time to time, ranging from 1.0 to 2.0 
equivalents. Transferring such conditions on large scale, it was 
possible to get full conversion of the carboxylic acids into esters. 
Scheme A.2 shows the general reaction scheme for the 
conversion of a carboxylic acid into the corresponding methyl ester. 
 
Scheme A. 2. In-flow methylation of carboxylic acids. 
The major advantage of such process is the formation of up 
to 10 grams of the desired product within 30 minutes, and no work-
up is subsequently needed in most of the cases. Otherwise, the 
extraction procedure is enough to isolate the desired products. 
Esters were obtained in quantitative yields, with rates of 138 mg min-
1 up to 400 mg min-1, highlighting the terrific and impressive efficiency 
of such process. 
It is noteworthy that carboxylic acid substrates containing 
functional groups sensitive to diazomethane, such as primary 
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amines, primary alcohols or double bonds, yielded methyl esters via 
a chemoselective reaction. Such control was achieved by adjusting 
the number of equivalents of diazomethane with respect to the 
starting material and the reaction time.  
For example, when the system examined bore a carboxylic 
acid together with a primary alcohol (A.1, Scheme A.3), using DAM 
in ≈ 1.0 equivalent led to the complete conversion to the ester A.2 
within 1 minute. The dimethylated compound A.3 was obtained in the 
presence of an excess DAM. Ranging from 3.0 to 10 equivalents of 
diazomethane and monitoring the progress of the reaction over the 
time, the conversion to A.3 showed to have a comparable rate within 
the first hour, reaching the 30%. After this point, the reaction slowed 
down, until it stopped in 4 hours with a conversion of 55%. This result 
shows that a large excess of diazomethane is not beneficial for the 
reaction, since it decomposes over the time anyhow.  
Scheme A. 3. Chemoselective methylation with diazomethane. 
However, when we tested substrates with more acidic 
alcoholic functions, we recovered 6% of the demethylated product 
even under a treatment with 1.0 equivalent of diazomethane within 
1-minute reaction time.  
This outcome is perfectly consistent with the proposed 
mechanism of methylation with diazomethane (Scheme A.2), which 
implies a correlation between the acidity of the reacting species and 
the rate of alkylation.11 Indeed it was suggested that the 
diazomethane is first protonated to give the methyldiazonium ion 




Scheme A.2. Mechanism of diazomethane alkylation 
When applied to our system, the hydroxyl group protonates 
CH2N2 to CH3N2+, which then reacts with the alkoxyde to give the 
ether. This explains why if the substrate is not acidic enough, the 
protonation of diazomethane is reversible and, after a while, it 
reaches the equilibrium with the starting material. Furthermore, in 
case the nucleophile attack is not fast, the methyldiazonium ion 
would react more rapidly with the traces of water that are eventually 
in the reaction medium, leading to the formation of methanol and the 
consumption of diazomethane. 
To further investigate the selectivity in the methylation 
reactions with diazomethane, we studied more complex substrates, 
which allowed also for the exploration of the regiochemistry. 
We considered carboxylic acids bearing two alcoholic 
functions with different reactivity and a disubstituted alkene (Scheme 
A.4). To focus on the methylation of the hydroxyl functions, we 
performed first the esterification of the carboxylic acid that, under a 
treatment with 1.0 equivalent of diazomethane within 1-minute 
reaction time, yielded exclusively A.5. 
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Scheme A. 4. Chemoselective methylation with diazomethane. 
A.5 was treated with 2.0, 5.0, 10, 15 and 20 equivalents of 
DAM for 30 minutes (Scheme A.5).  Within 10 equivalents, the more 
reactive hydroxyl function was converted into the corresponding 
methyl ether A.6 in 60%. We also recovered 24% of the dimethylated 
compound A.7 and 16% of unreacted ester A.5. Increasing the 
amount of diazomethane to 15 and 20 equivalents led to the 
progressive increase of side reactions and decreased the 
methylation of the –OH groups. Possible [3+2] cycloaddition could 
occur under such conditions, as demonstrated by a LC-MS peak 
whose mass matched the one of compound A.8. 
 
Scheme A. 5. Chemo- and regioselectivity studies for methylation with DAM. 
The outcome of such studies points out that a certain 
reaction control is possible playing around with the equivalents of 
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diazomethane and the reaction time, so that a high chemoselectivity 
towards the carboxylic acids, and a discrete regioselectivity between 
the hydroxyl groups were observed. 
To expand the portfolio of selective methylation by 
diazomethane, we took into account the catalytic cyclopropanation.  
The cyclopropanation of double bonds is one of the most 
widely used reactions in organic synthesis, that subtly alter the 
structure of a given scaffold achieving higher rigidity and peculiar 
electronic properties through the incorporation of the cyclopropane 
ring.15 Such modification could affect its biological activities and for 
this reason cyclopropanation represents a key-step in drug 
discovery. 
 Herein, the reaction of diazomethane with olefinic 
substrates assisted by transition metal complexes has been studied 
for the cyclopropanation of double bonds.  
Rhodium (II) and palladium (II) complexes have been tested 
as catalysts since they have emerged as the most usual and efficient 
agents for the reliable methylation of olefins by diazomethane.12 
Diazomethane was always generated by a continuous flow 
process and subsequently used in the catalytic in-batch 
transformations. The development of such user-friendly reaction 
protocol allowed us to study a plethora of substrates with different 
electronical and structural features, ranging from α,β-unsaturated 
carbonyl compounds to endo- and exocyclic double bonds. 
α,β-unsaturated carbonyl compounds are electron-deficient 
activated alkenes that readily undergo cyclopropanation especially 
when palladium(II) salts are the catalysts of choice.13 
A.9 (Scheme A.6) was the starting point of our study, 
considering different reaction conditions in order to get the highest 
conversion to the cyclopropane derivative A.10. 
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Scheme A. 6. Catalytic cyclopropanation of double bond with DAM. 
Palladium (II) acetate, bis(benzonitrile) palladium(II) 
chloride,  bis(triphenylphosphine) palladium(II) chloride and 
rhodium(II) acetate dimer were tested as catalysts. The only metal 
which formed cyclopropane in significant conversion was palladium. 
Furthermore, in a control experiment it was demonstrated that 
diazomethane alone gave no reaction over a several hour period at 
0°C, showing that a catalyst is needed for the reaction to proceed. 
Addition of 1-2 equivalents of diazomethane to a chilled 
(0°C) solution of the olefin and 1-2 mol% Pd(OAc)2 led to modest 
conversions, as monitored by LC-MS. In each case, the reaction 
stopped within 1 hour. 
Keeping the amount of diazomethane constant to 4 
equivalents and varying the catalyst loading from 0.5 to 1.5 mol% 
gave an increased conversion, that however dropped down again 
when Pd(OAc)2 was used in 2 mol% and 4 mol%. Consequently, we 
envisioned that, depending on the relative amount of catalyst and 
diazomethane, the former might give unreactive adducts with CH2N2 
or otherwise become deactivated after a certain time. Indeed, in the 
course of these studies, we have noticed the reduction of palladium 
(II) acetate to palladium (0) with the precipitation of palladium-black 
in the reaction mixture. This species exits the catalytic cycle and so 
it is no longer catalytically active. Hence, the right balance between 
the catalyst loading and the amount of diazomethane has to be 
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chosen, in order to avoid the deactivation of Pd(OAc)2 in the very first 
stages of the reaction. 
To broaden our knowledge regarding the selectivity of 
diazomethane, we reconsidered the compound A.5 previously 
obtained, but this time we focused on the difference between the O- 
and the C-methylation (Scheme A.7). 
Keeping the catalyst-loading constant at 2 mol%, the amount 
of diazomethane ranged from 2.0 to 6.0 equivalents. LC-MS analysis 
showed 30% of starting material left when the reaction was 
performed with 2.0 equivalents, while full conversion was gained with 
4.0 and 6.0 equivalents. However, the highest excess of 
diazomethane also led to the side products of dimethylation and 
trimethylation (14% and 13% respectively). 
 
Scheme A. 7. Chemoselective cyclopropanation with DAM. 
We therefore performed the scale-up as indicated in the 
Scheme A.7, recovering 79% conversion of the starting material into 
the cyclopropane ring but no undesired side products. 
This example shows that the rate of cyclopropanation is 
faster than the O-methylation, enabling a chemoselective reaction, 
which involves exclusively the double bond even in presence of an 
excess of diazomethane. 
It is reported that the success of palladium catalyzed 
cyclopropanation reactions is strongly dependent on features of the 
employed alkene.14 Electronic and steric effects influence the 
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outcome of the reaction so much that excellent to extremely 
disappointing results can be obtained. Electron poor alkenes display 
good reactivity while electron rich alkenes usually give only low 
conversion. Terminal and strained alkenes are also good substrates, 
while the reactivity systematically drops with an increase of its 
substitution degree. For example, endo- double bonds like in 
cycloalkenes do not react with the system diazomethane/palladium 
(II) acetate, unless they are extremely strained like norbonene 
derivatives.14, 15 
We investigated the response of A.12 (Scheme A.8) to the 
cyclopropanation treatment. 
 
Scheme A. 8. Cyclopropanation of endocyclic double bond. 
Attempts to carry out the reaction were almost unsuccessful, 
giving just a partial conversion to the cyclopropane derivative. 
Roughly 20% conversion was always recovered after the treatments 
with 2, 4 and 6 equivalents of diazomethane either with 1 mol% and 
2 mol% of palladium (II) acetate at 0°C for 5 minutes. Applying a 
huge excess of diazomethane and a higher catalyst loading (3-5 
mol%) also led to the same result. A.12 proved to have the same 
reactivity even under tris(dibenzylideneacetone) dipalladium(0) 
catalysis. 
The results collected so far show that such substrate stops 
reacting after a while, reaching a maximum conversion, no matter the 
reaction conditions. 
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With this clue in mind, we thought that reiterated treatments 
with diazomethane and fresh catalyst might have been useful to push 
A.12 to full conversion.  
Hence, six portions of diazomethane (2 equivalents each) 
were added in series to a cooled solution (0°C) of the olefin and 1mol 
% of palladium (II) acetate. Each time the former catalyst was filtered 
and the fresh one was added. The mixture was allowed to stir for 10 
minutes and assayed by LC-MS, and then the next 2 equivalents of 
diazomethane were added, until no more starting material was 
detected. The reaction mixture was finally filtrated over celite, 
concentrated and silica gel chromatography was performed to give 
A.13. 
We managed to completely convert A.12 into the 
corresponding cyclopropane derivative, even if quite strong reaction 
conditions are needed. 
Non functionalized terminal alkene also undergo 
cyclopropanation with high yield. Consequently, carbene transfer to 
alkenyl substituted cycloalkenes occurs highly regioselective. 
According to this, we were able to selectively insert the 
cyclopropyl moiety into the terminal alkene of A.14 in the presence 
of an endocyclic double bond (Scheme A.9). 
 
Scheme A. 9. Regioselective cyclopropanation of double bond. 
A.14 underwent cyclopropanation with diazomethane and 
Pd(OAc)2 without further purifications. From the initial screening it 
was clear that harsh reaction conditions were needed, requiring a 
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huge excess of diazomethane. Indeed, with 8 equivalents and 
Pd(OAc)2 2 mol% the conversion observed was 26%, while 
performing reiterated treatments with 4 equivalents and Pd(OAc)2 1 
mol% the conversion after the third addition was still 44%. Hence, 12 
equivalents of diazomethane were added to an ice-bath cooled 
solution of A.14 0.5M in 2-MeTHF and Pd(OAc)2 1 mol%, resulting 
in the complete conversion of the starting material into A.15.  
It is well known that diazomethane can act as a 1,3-dipole 
taking an important role in the vast area of [3+2]-cycloaddition 
chemistry. Depending on the substitution pattern of the alkene, some 
of these cycloadducts are stable enough to be isolated. Others can 
instead rearrange or eliminate nitrogen to form cyclopropane.  
Methylation of A.14 in the absence of catalyst with 5.0 
equivalents of diazomethane led to the respective A.16 in essentially 
quantitative conversion (Scheme A.10).  
 
Scheme A. 10. Regioselective [3+2] cycloaddition with diazomethane. 
Again, the reaction resulted completely regioselective. 
Furthermore, also the cycloaddition of the 1,3-dipoled occurred in a 
regioselective fashion into the exo-double bond. 
 A.3 CONCLUSION 
We have studied the chemistry of diazomethane, a powerful 
C1 building block in the vast scenario of organic synthesis.  
The in-flow technology, applied on lab-scale for its safe 
generation and handling, enabled us to explore the reactivity of 
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diazomethane towards carboxylic acids, hydroxyl groups and double 
bonds. 
We remarked several advantages related to its use, giving 
clean and fast reactions and increasing the productivity defined as 
the amount of compound synthesized in a certain reference time. 
Furthermore, we considered chemoselectivity and 
regioselectivity of the methylation reactions with diazomethane. The 
more acid is the functional group, the faster the methylation, while 
Pd (II) catalyzed cyclopropanation occurs preferentially on terminal 
and electron poor alkenes. Thus, diazomethane reactions display 
good to high chemoselectivity and regioselectivity, which can also be 
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